UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 1 of 209 PROTOCOL PS0013  AMENDMENT 3  
A PHASE 3, MULTICENT ER, DOUBLE -BLIND, 
PLACEBO -CONTROLLED S TUDY WITH AN INITIAL  
TREATMENT PERIOD FOL LOWED BY A RANDOMIZED -
WITHDRAWAL PERIOD TO  EVALUATE THE EFFICA CY AND 
SAFETY OF BIMEKIZUMA B IN ADULT SUBJECTS WITH 
MODERATE TO SEVERE C HRONIC PLAQUE PSORIA SIS 
PHASE 3  
EudraCT Number: 2016 -003426 -16 
IND Number: 128707  
Sponsor:  
UCB Biopharma SPRL  
Allée de la Recherche 6 0 
1070 Brussels  
BELGIUM  
Protocol/Amendment number  Date  Type of 
amendment  
Final Protocol  15 Aug 2017  Not applicable  
Protocol Amendment 1  15 Oct 2017  Not applicable  
Protocol Amendment 2  06 Apr 2018  Substantial  
Protocol Amendment 3  21 May 2019  Nonsubstantial  
Confidential Material  
Confidential  
This document is the property of UCB and may not – in full or in part – be passed on, 
reproduced, published, or otherwise used without the express permission of UCB.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 2 of 209 STUDY CONTACT INFORMATION  
Sponsor  
UCB B iopharma SPRL  
Allée de la Recherche 60  
1070 Brussels, BELGIUM  
Sponsor Study Physician  
Name:  , MD  
Address:  UCB Biosciences, 8010 Arco Corporate Drive, Raleigh, NC 27617  
Phone:   
Fax:  
Clinical Project Manager  
Name:   
Address:  UCB Biosciences GmbH, Alfred Nobel Strasse, Monheim am Rhein, 
40789, Germany  
Phone:   
Fax:  
Clinical Trial Biostatistician  
Name:   
Address:  208 Bath Road, Slough, SL1 3WE, UK  
Phone:   
Fax:  
Clinical Monitoring Contract Research Organization  
Name:  PAREXEL International (IRL) Limited -Ireland  
Address:  Ireland Limited at 70 Sir John Rogerson’s Quay, Dublin 2, Ireland  
Phone:  +353 (1) 477 3171  
Fax: +353 (1) 477 3308  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 3 of 209 SERIOUS ADVERSE EVENT REPORTING  
Serious adverse event reporting (24h)  
Fax Europe and Rest of the World: +32 2 386 24 21  
USA and Canada:  +1 800 880 6949  
 or +1 866 890 3175  
Email  Global:  DS_ICT@ucb.com  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 4 of 209 TABLE OF CONTENTS  
LIST OF ABBREVIATION S ................................ ................................ ................................ .. 10 
1 SUMMARY  ................................ ................................ ................................ .....................  14 
2 INTRODUCTION  ................................ ................................ ................................ ...........  15 
2.1 Psoriasis  ................................ ................................ ................................ .......................  15 
2.1.1  Global epidemiology of psoriasis  ................................ ................................ ........  16 
2.1.2  Current treatments for psoriasis  ................................ ................................ ...........  16 
2.2 Bimekizumab  ................................ ................................ ................................ ...............  18 
2.2.1  Clinical  ................................ ................................ ................................ .................  18 
2.2.1.1  Completed studie s ................................ ................................ .....................  18 
2.2.1.2  Ongoing studies  ................................ ................................ .........................  20 
2.2.2  Nonclinical  ................................ ................................ ................................ ...........  20 
3 STUDY OBJECTIVE(S)  ................................ ................................ ................................ . 21 
3.1 Primary objective  ................................ ................................ ................................ .........  21 
3.2 Secondary objectives  ................................ ................................ ................................ ... 21 
3.3 Other objectives  ................................ ................................ ................................ ...........  22 
4 STUDY VARIABLES  ................................ ................................ ................................ ..... 23 
4.1 Primary efficacy variables  ................................ ................................ ...........................  23 
4.2 Secondary variables  ................................ ................................ ................................ ..... 23 
4.2.1  Secondary efficacy variables  ................................ ................................ ...............  23 
4.2.2  Secondary safety variables  ................................ ................................ ..................  23 
4.3 Other variables  ................................ ................................ ................................ .............  23 
4.3.1  Other efficacy variable(s)  ................................ ................................ ....................  23 
4.3.2  Other safety variables  ................................ ................................ ..........................  25 
4.3.3  Pharmacokinetic variable  ................................ ................................ .....................  25 
4.3.4  Pharmacogenomic variables  ................................ ................................ ................  25 
4.3.5  Immunological variable  ................................ ................................ .......................  25 
5 STUDY DESIGN  ................................ ................................ ................................ .............  25 
5.1 Study description  ................................ ................................ ................................ .........  25 
5.2 Study periods  ................................ ................................ ................................ ...............  26 
5.2.1  Screening Period  ................................ ................................ ................................ .. 26 
5.2.2  Initial Treatment Period  ................................ ................................ .......................  26 
5.2.3  Randomized -Withdrawal Period  ................................ ................................ .........  27 
5.2.4  Safety Follow -Up ................................ ................................ ................................ . 27 
5.2.5  Escape Treatment  ................................ ................................ ................................ . 27 
5.2.6  Premature End of Treatment  ................................ ................................ ................  28 
5.3 Study duration per subject  ................................ ................................ ...........................  28 
5.4 Planned number of subjects and site(s)  ................................ ................................ ........  28 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 5 of 209 5.5 Anticipated regions and countries  ................................ ................................ ................  28 
5.6 Schedule of study assessments ................................ ................................ .....................  29 
5.7 Schematic diagram  ................................ ................................ ................................ ....... 37 
5.8 Rationale for study design and selection of dose  ................................ .........................  38 
5.8.1  Study design  ................................ ................................ ................................ .........  38 
5.8.2  Selection of d ose ................................ ................................ ................................ .. 38 
6 SELECTION AND WITHDR AWAL OF SUBJECTS  ................................ ...................  38 
6.1 Inclusion criteria  ................................ ................................ ................................ ..........  38 
6.2 Exclusion criteria  ................................ ................................ ................................ .........  39 
6.3 Withdrawal c riteria  ................................ ................................ ................................ ...... 42 
6.3.1  Potential drug -induced liver injury IMP discontinuation criteria  ........................  44 
7 STUDY TREATMENT(S)  ................................ ................................ ..............................  45 
7.1 Description of investigational medicinal product(s)  ................................ ....................  45 
7.2 Treatment(s) to be administered  ................................ ................................ ..................  46 
7.3 Packaging  ................................ ................................ ................................ .....................  47 
7.4 Labeling  ................................ ................................ ................................ .......................  47 
7.5 Handling and storage requirements  ................................ ................................ .............  47 
7.6 Drug accountability  ................................ ................................ ................................ ...... 48 
7.7 Procedures for monitoring subject compliance  ................................ ............................  48 
7.8 Concomitant medication(s)/treatment(s)  ................................ ................................ ..... 48 
7.8.1  Permitted concomitant treatments (medications and therapies)  ..........................  49 
7.8.1.1  Topical medications  ................................ ................................ ..................  49 
7.8.1.2  Other medications  ................................ ................................ ......................  49 
7.8.2  Prohibited concomitant treatments (medications and therapies)  .........................  49 
7.8.2.1  Vaccines  ................................ ................................ ................................ .... 50 
7.9 Blinding ................................ ................................ ................................ ........................  50 
7.9.1  Procedures for maintaining and breaking the treatment blind  .............................  51 
7.9.1.1  Maintenance of IMP blind  ................................ ................................ .........  51 
7.9.1.2  Breaking the treatment blind in an emergency situation  ...........................  51 
7.10  Randomization and numbering of subjects  ................................ ................................ .. 51 
8 STUDY PROCEDURES BY VISIT  ................................ ................................ ...............  52 
8.1 Screening Visit (2 to 5 weeks)  ................................ ................................ .....................  52 
8.2 Initial Treatment Period  ................................ ................................ ...............................  54 
8.2.1  Baseline Visit  ................................ ................................ ................................ ....... 54 
8.2.2  Weeks 1 and 2 (±3 days relative to Baseline)  ................................ ......................  55 
8.2.3  Weeks 4 and 8 (±3 days relative to Baseline)  ................................ ......................  55 
8.2.4  Week  12 (±3 days relative to Baseline)  ................................ ...............................  56 
8.2.5  Week 16 (±3 days relative to Baseline)  ................................ ...............................  58 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 6 of 209 8.3 Randomized -Withdrawal Period  ................................ ................................ ..................  59 
8.3.1  Weeks 20 and 24 (±3 days relative to Baseline) and Weeks 28, 32, 36, 40, 44, 
48, and 52 (±7 days relative to Baseline) ................................ .............................  59 
8.3.2  Week  56 (±3  days relative to Baseline)  ................................ ...............................  60 
8.4 Escape Treatment Period  ................................ ................................ .............................  61 
8.4.1  Esca pe Baseline Visit  ................................ ................................ ..........................  61 
8.4.2  Escape Weeks 4 and 8 (±3 days)  ................................ ................................ .........  62 
8.4.3  Escape Visit -Week  12/Premature End of Treatment (±3  days relative to 
Baseline)  ................................ ................................ ................................ ..............  63 
8.5 Premature End of Treatment Visit  ................................ ................................ ...............  64 
8.6 Safety Follow -Up Visit (20 weeks after final d ose, ±7  days)  ................................ ...... 64 
8.7 Unscheduled Visit  ................................ ................................ ................................ ........  65 
9 ASSESSMENT OF EFFICACY  ................................ ................................ ......................  65 
9.1 Psoriasis Area and Severity Index  ................................ ................................ ...............  65 
9.2 Investigator’s Global Assessment  ................................ ................................ ................  66 
9.3 Dermatology Life Quality Index  ................................ ................................ ..................  67 
9.4 Patient Health Questionnaire 9  ................................ ................................ ....................  67 
9.5 Scalp IGA ................................ ................................ ................................ .....................  67 
9.6 mNAPSI  ................................ ................................ ................................ .......................  68 
9.7 pp-IGA ................................ ................................ ................................ .........................  68 
9.8 Euro Quality of Life 5 -Dimensions, 3 -Level  ................................ ...............................  69 
9.9 36-Item Short Form Health Survey ................................ ................................ ..............  69 
9.10  Patient Global Assessment of psoriasis  ................................ ................................ ....... 70 
9.11  Patient Symptom Diary responses  ................................ ................................ ...............  70 
9.12  PASE questionnaire  ................................ ................................ ................................ ..... 70 
9.13  PGADA for arthritis visual analog scale  ................................ ................................ ..... 71 
10 ASSESSMENT OF PHARMA COKINETIC AND PHARMA COGENOMIC 
VARIABLE(S)  ................................ ................................ ................................ ................  71 
10.1  Pharmacokinetic variables  ................................ ................................ ...........................  71 
10.2  Pharmacogenomic variables  ................................ ................................ ........................  71 
11 ASSESSMENT OF IMMUNO LOGICAL VARIABLE(S)  ................................ ............  72 
12 ASSESSMENT OF SAFETY  ................................ ................................ ..........................  72 
12.1  Adverse events  ................................ ................................ ................................ .............  72 
12.1.1  Definitions  ................................ ................................ ................................ ...........  72 
12.1.1.1  Adverse event  ................................ ................................ ............................  72 
12.1.1.2  Serious adverse event  ................................ ................................ ................  73 
12.1.1.3  Adverse events of special interest  ................................ .............................  74 
12.1.1.4  Other safety topics of interest  ................................ ................................ .... 74 
12.1.2  Procedures for reporting and recording adverse events  ................................ ....... 74 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 7 of 209 12.1.2.1  Description of adverse events  ................................ ................................ .... 74 
12.1.2.2  Rule for repetition of an adverse event ................................ ......................  75 
12.1.2.3  Additional procedures for reporting serious adverse events  .....................  75 
12.1.3  Follow up of adverse events  ................................ ................................ ................  76 
12.1.4  Pregnancy  ................................ ................................ ................................ ............  76 
12.1.5  Suspected transmission of an infectious agent via a medicinal product  ..............  77 
12.1.6  Overdose of investigational medicinal product  ................................ ...................  77 
12.1.7  Safety signal detection  ................................ ................................ .........................  77 
12.2  Laboratory measurements  ................................ ................................ ............................  78 
12.2.1  Evaluation of PDILI  ................................ ................................ ............................  79 
12.2.1.1  Consultation with Medical Monitor and local hepatologist  ......................  84 
12.2.1.2  Immediate action: determination of IMP discontinuation  .........................  84 
12.2.1.3  Testing: identification/exclusion of alternative etiology  ...........................  84 
12.2.1.4  Follow -up evaluation  ................................ ................................ .................  86 
12.3  Other safety measurements  ................................ ................................ ..........................  87 
12.3.1  Assessment and management of TB and TB risk factors  ................................ .... 87 
12.3.1.1  Tuberculosis assessment by IGRA  ................................ ............................  90 
12.3.1.2  Chest x -ray for tuberculosis  ................................ ................................ ...... 90 
12.3.1.3  Tuberculosis questionnaire  ................................ ................................ ........  90 
12.3.1.4  Tuberculosis management  ................................ ................................ .........  90 
12.3.2  Pregnancy testing  ................................ ................................ ................................ . 91 
12.3.3  Vital signs  ................................ ................................ ................................ ............  91 
12.3.4  12-lead electrocardiograms  ................................ ................................ ..................  91 
12.3.5 Physical examination  ................................ ................................ ...........................  91 
12.3.6  Height and body weight  ................................ ................................ .......................  92 
12.3.7  Assessment of suicidal ideation and behavior  ................................ .....................  92 
12.4  Other study measurements  ................................ ................................ ...........................  92 
12.4.1  Demographic information  ................................ ................................ ....................  92 
12.4.2  Medical history  ................................ ................................ ................................ .... 92 
12.4.3  Psoriasis  history  ................................ ................................ ................................ ... 92 
12.4.4  Data Monitoring and Adjudication Committees  ................................ ..................  92 
13 STUDY MANAGEMENT AND  ADMINISTRATION  ................................ .................  93 
13.1  Adherence to protocol  ................................ ................................ ................................ .. 93 
13.2  Monitor ing ................................ ................................ ................................ ...................  93 
13.2.1  Definition of source data  ................................ ................................ .....................  93 
13.2.2  Source data verification  ................................ ................................ .......................  94 
13.3  Data handling  ................................ ................................ ................................ ...............  94 
13.3.1  Case Report Form completion  ................................ ................................ .............  94 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 8 of 209 13.3.2  Database entry and reconciliation  ................................ ................................ ........  94 
13.3.3  Subject Screening and Enrollment log/Subject Identification Code list ..............  95 
13.4  Termination of the study  ................................ ................................ ..............................  95 
13.5  Archiving and data retention  ................................ ................................ ........................  95 
13.6  Audit and inspection  ................................ ................................ ................................ .... 95 
13.7  Good Clinical Practice  ................................ ................................ ................................ . 96 
14 STATISTICS  ................................ ................................ ................................ ...................  96 
14.1  Definition of analysis sets  ................................ ................................ ............................  96 
14.2  General statistical considerations  ................................ ................................ .................  97 
14.3  Planned efficacy analyses  ................................ ................................ ............................  98 
14.3.1  Analysis of the primary efficacy variable  ................................ ............................  98 
14.3.1.1  Sensitivity analyses  ................................ ................................ ...................  98 
14.3.2  Other efficacy analyses  ................................ ................................ ........................  99 
14.3.2.1  Analysis of the secondary efficacy variables  ................................ ............  99 
14.3.2.2  Analysis of the other efficacy variables  ................................ ..................  100 
14.4  Subgroup analyses  ................................ ................................ ................................ ..... 101 
14.5  Planned safety and other analyses ................................ ................................ ..............  101 
14.5.1  Safety analyses  ................................ ................................ ................................ ... 101 
14.5.2  Pharmac okinetic analyses  ................................ ................................ ..................  102 
14.5.3  Immunogenicity analyses  ................................ ................................ ..................  102 
14.6  Handling of protocol deviations ................................ ................................ .................  102 
14.7  Handling of dropouts or missing data  ................................ ................................ ........  102 
14.8  Planned interim analysis and data monitoring  ................................ ...........................  104 
14.9  Determination of sample size  ................................ ................................ .....................  104 
15 ETHICS AND REGULATOR Y REQUIREMENTS  ................................ ....................  104 
15.1  Informed consent  ................................ ................................ ................................ ....... 104 
15.2  Subject identification cards  ................................ ................................ ........................  105 
15.3  Institutional Review Boards and Independent Ethics Committees  ............................  105 
15.4  Subject privacy ................................ ................................ ................................ ...........  106 
15.5  Protocol amendments  ................................ ................................ ................................ . 106 
16 FINANCE, INSURANCE, AND PUBLICATION  ................................ .......................  106 
17 REFERENCES  ................................ ................................ ................................ ..............  106 
18 APPENDICES  ................................ ................................ ................................ ...............  109 
18.1  Protocol Amendment 1  ................................ ................................ ..............................  109 
18.2  Protocol Amendment 2  ................................ ................................ ..............................  162 
18.3  Protoco l Amendment 3  ................................ ................................ ..............................  205 
19 DECLARATION AND SIGN ATURE OF INVESTIGATO R ................................ ..... 208 
20 SPONSOR DECLARATION  ................................ ................................ ........................  209 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 9 of 209  
LIST OF TABLES  
Table  5‒1:  Schedule of study assessments ................................ ................................ .........  30 
Table  5‒2:  Schedule of study assessments for subjects allocate d to escape treatment  ...... 35 
Table  7‒1:  Dosing Scheme  ................................ ................................ ................................  47 
Table  7‒2:  Prohibited PSO medications  ................................ ................................ ............  49 
Table  9‒1:  Body areas for calculation of percent BSA for PASI  ................................ ...... 66 
Table  9‒2:  Five-point Investigator’s Global Assessment  ................................ ..................  66 
Table  9‒3:  Scalp IGA ................................ ................................ ................................ .........  68 
Table  9‒4:  pp-IGA ................................ ................................ ................................ .............  69 
Table  12‒1:  Anticipated serious adverse events for the population of subjects with 
moderate to severe chronic plaque psoriasis  ................................ ....................  74 
Table  12‒2:  Laboratory measurements  ................................ ................................ ................  78 
Table  12‒3:  Required investigations and follow up for PDILI ................................ ............  80 
Table  12‒4:  PDILI laboratory measurements  ................................ ................................ ...... 85 
Table  12‒5:  PDILI information to be collected  ................................ ................................ ... 86 
 
LIST OF FIGURES  
Figure  5‒1:  Schematic diagram  ................................ ................................ ...........................  37 
Figure  12-1: Schematic diagram of TB test result s and study eligibility  .............................  89 
Figure  14-1: Sequence of testing  ................................ ................................ ..........................  97 
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 10 of 209 LIST OF ABBREVIATION S 
AE adverse event  
AESI  adverse event of special interest  
ALP  alkaline phosphatase  
ALT  alanine aminotransferase  
AMS  Active Medication Set  
ANCOVA  analysis of covariance  
AST  aspartate aminotransferase  
axSpA  axial sponyloarthritis  
BA bioavailability  
BP blood pressure  
BSA  body surface area  
cAMP  cyclic adenosine monophosphate  
CDC  Centers for Disease Control  
CDMS  clinical data management system  
CI confidence interval  
CMH  Cochran -Mantel -Haenszel  
CPM  Clinical Project Manager  
CPMP  Committee for Proprietary Medicinal Products  
CRO  contract research organization  
CSR  Clinical Study Report  
CTCAE  Common Terminology Criteria for Adverse Events  
CV cardiovascular  
DLQI  Dermatology Life Quality Index  
DMC  Data Monitoring Committee  
ECG  electrocardiogram  
eCRF  electronic Case Report Form  
eC-SSRS  electronic Columbia Suicide Severity Rating Scale  
EHR  Electronic Healthcare Record  
ePRO  electronic Patient -Reported Outcome  
EQ-5D-3L Euro -Quality of Life 5-Dimensions, 3 levels  
ESS Escape Subject Set  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 11 of 209 FAS Full Analysis Set  
GCP  Good Clinical Practice  
GI gastrointestinal  
GMP  Good Manufacturing Practice  
HBcAb  anti-hepatitis B core antibody  
HBsAg  anti-hepatitis B surface antigen  
HCP  healthcare practitioner  
HCV  hepatitis C virus  
HCV Ab  hepatitis C antibody  
HIV human immunodeficiency virus  
HLT  High Level Term  
IB Investigator’s Brochure  
IBD inflammatory bowel disease  
ICF Informed Consent Form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
Ig immunoglobulin  
IGA Investigator’s Global Assessment  
IGRA  interferon -gamma release assay  
IL interleukin  
IMP investigational medicinal product  
IRB Institutional Review Board  
IRT interactive response technology  
iv intravenous  
LOCF  last observation carried forward  
LTB  latent tuberculosis  
LTBI  latent tuberculosis infection  
mAb  monoclonal antibody  
mNAPSI  Modified Nail Psoriasis Severity Index Score  
MAR  missing at random  
MCMC  Markov -Chain Monte Carlo  
MCS  Mental  Component Summary  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 12 of 209 MedDRA  Medical Dictionary for Regulatory Activities  
MI multiple imputation  
NRI nonresponder imputation  
NSAID  nonsteroidal anti -inflammatory drugs  
NTMB  nontuberculous mycobacterium  
PASE  Psoriatic Arthritis Screening and Evaluation  
PASI  Psoriasis Area Severity Index  
PCS Physical Component Summary  
PD pharmacodynamics  
PDE4  phosphodiesterase 4  
PDILI  potential drug -induced liver injury  
PEOT  Premature End of Treatment  
PFS prefilled syringe  
PGA  Physician’s Global Assessment  
PGADA  Patient’s Global Assessment of Disease Activity  
PHQ -9 Patient Health Questionnaire 9  
PK pharmacokinetics  
PK-PPS Pharmacokinetics Per -Protocol Set  
pp-IGA palmoplantar Investigator’s Global Assessment  
PPS Per-Protocol Set  
PRO  patient -reported outcome  
PS Patient Safety  
PsA psoriatic arthritis  
PSO psoriasis  
Q4W  every 4 weeks  
Q8W  every 8 weeks  
QOL  quality of life  
RS Randomized Set  
SAE  serious adverse event  
SAP Statistical Analysis Plan  
sc subcutaneous  
scalp IGA  scalp -specific IGA  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 13 of 209 SD standard deviation  
SF-36 Short Form 36 -item Health Survey  
SFU Safety Follow -Up 
SOP Standard Operating Procedure  
SS Safety Set  
TB tuberculosis  
TEAE  treatment -emergent adverse event  
TNF  tumor necrosis factor  
ULN  upper limit of normal  
VAS  visual analog scale  
WBC  white blood cell  
WK16ResS  Week  16 Responder Set  
  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 14 of 209 1 SUMMARY  
This is a Phase 3, multicenter, randomized, double -blind, placebo -controlled study consisting of 
a 16-week Initial Treatment Period followed by a 40 -week Randomized -Withdrawal Period to 
evaluate the efficacy, safety, and pharmacokinetics (PK) of bimekizumab compared with placebo 
in adult subjects with moderate to severe chronic plaque psoriasis (PSO).  
The study population consists of adult subjects (≥18 years of age) with a diagnosis of moder ate 
to severe chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score  ≥3 
[on a 5 -point scale]) who are a candidate for systemic PSO therapy and/or phototherapy.  
Approximately 535 subjects will be screened in order to have 400 subjects randomized in the 
study. There will be approximately 320 subjects in the bimekizumab treatment arm and 80 
subjects in the placebo treatment arm. For each subject, the study will last a maximum of 
77 weeks and will consist of 4 periods: a Screening Period (2 to 5 weeks), a double -blind, 
placebo -controlled Initial Treatment Period (16 weeks), a double -blind,  placebo -controlled 
Randomized -Withdrawal Period (4 0 weeks) Period, and a Safety Follow -Up (SFU) Period (20 
weeks after the final dose of investigational medicinal product [IMP]). After completing the 
study, eligible subjects will be allowed to enroll in an open -label study.  
Eligible subjects will be rando mized 4:1 to receive the following blinded IMP regimens:  
 Bimekizumab 320mg administered sc every 4 weeks (Q4W)  
 Placebo administered sc Q4W  
Investigational medicinal product will be administered in the clinic at Baseline, Week  4, Week  8, 
and Week 12. At the  Week  16 study visit, bimekizumab and placebo subjects who have achieved 
a PASI90 response will enter the 40 -week Randomized -Withdrawal Period. Dosing will be based 
on treatment group assignment at initial randomization as follows:  
 Subjects initially rando mized to bimekizumab 320mg Q4W will be re -randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg every 8 weeks (Q8W) or placebo 
(ie, treatment withdrawal)  
 Subjects initially randomized to placebo will continue to receive placebo (Q4W) provid ed the 
subject is a PASI90 responder  
Subjects who do not achieve a PASI90 response at Week  16 of the Initial Treatment Period will 
be allocated to an escape arm and receive open -label bimekizumab 320mg Q4W for 12  weeks. 
Subjects who achieve a PASI50 respon se at Week  12 of the open -label escape arm will be 
allowed to enroll in the open -label study.  
All subjects who relapse at Week  20 or later during the Randomized -Withdrawal Period (up to 
Week  56) will be allocated to an escape arm and receive open -label bim ekizumab 320mg Q4W 
for 12  weeks. Relapse is defined as not achieving a PASI75 response. Subjects who achieve a 
PASI50 response at Week  12 of the open -label escape arm will be allowed to enroll in the open -
label study.   
Subjects who complete the Randomized Withdrawal Period (after a Week  16 response 
[≥PASI90] on bimekizumab during the Initial Treatment Period ) will be allowed to enroll in an 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 15 of 209 open -label study. Placebo -randomized subjects, who receive placebo during the entire Initial and 
Randomized -Withdrawal  periods, that complete Week 56 without relapse into the open -label 
escape arm will not be eligible for the open -label study.  
At Week  56, all subjects enrolling in the open -label study will undergo the Week  56 study 
assessments before receiving their first  dose of IMP in the open -label study. All subjects not 
enrolling in the open -label study will have their Week  56 study assessments and enter the SFU 
Period.  
Subjects withdrawing early from the study will undergo the Premature End of Treatment (PEOT) 
Visit assessments and will enter the SFU Period.  
The primary objective of the study is to compare the efficacy of bimekizumab administered sc 
for 16  weeks versus placebo in the treatment of subjects with moderate to severe chronic plaque 
PSO. The secondary objec tives of the study are listed in Section  3.2. 
The co -primary efficacy variables are the PASI90 response (defined as a subject that achieves 
90% redu ction from Baseline in the PASI score) at Week  16 and the IGA response (defined as 
Clear or Almost Clear with at least a 2 category improvement relative to Baseline) at Week  16. 
The secondary efficacy variables are listed in Section  4.2.1 . 
Pharmacokinetic variables are listed in Section  4.3.3 . Pharmacogenomic variables are listed in 
Section  4.3.4 . Immunological variables are listed in Section  4.3.5 . 
Pharmacokinetic, genomic, genetic, proteomic, and immunological variables will be evaluated to 
assess their relationship to treatment response.  
Safety variables to be assessed are adverse even ts (AEs), vital signs, electrocardiograms (ECGs), 
and measurements of laboratory parameters.  
2 INTRODUCTION  
2.1 Psoriasis  
Psoriasis is a common, chronic inflammatory disease characterized by a series of linked cellular 
changes in the skin: hyperplasia of epidermal keratinocytes, vascular hyperplasia and ectasia, and 
infiltration of T lymphocytes, neutrophils, and other types of leukocytes in affected skin. Though 
the pathophysiology of PSO is not fully understood, the importance of T -cells and inflammatory  
cytokines has been demonstrated by the clinical benefit provided by therapies directed at these 
targets (Krueger and Ellis, 2005).  
There are a variety of forms including plaque, guttate, inverse, pustular, and erythrodermic. 
Plaque PSO is the most common,  comprising approximately 80% to 90% of all cases. 
Approximately 17% of those with PSO have moderate to severe disease (Kurd et al, 2008).  
In addition to the impact on skin, PSO has a multitude of psychosocial and emotional effects on 
patients, including i ncreased self -consciousness, frustration, fatigue, depression, and suicidal 
ideation. As a result, patients frequently report sleeping problems, difficulties at work, problems 
interacting with family members, disrupted leisure activities, and sexual diffic ulties 
(Dowlatshahi et al, 2014; Gottlieb, 2005; Mukhtar et al, 2004; Ortonne, 2004; Krueger et al, 
2001).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 16 of 209 A number of comorbidities have been associated with PSO, especially with more severe PSO. 
Psoriatic arthritis (PsA), cardiovascular (CV) disease, met abolic syndrome, chronic pulmonary 
disease, peptic ulcer disease, renal disease, and diabetes have all been demonstrated to have an 
increased prevalence in PSO patients (Yeung et al, 2013; Christophers et al, 2010; Gisondi et al, 
2007; Gelfand et al, 2006) . 
2.1.1  Global epidemiology of psoriasis  
Psoriasis affects approximately 3% of the  US adult population (Rachakonda et al, 2014; Kurd 
and Gelfand, 2009) and its onset can begin at any age (Augustin et al, 2010; Icen et al, 2009). 
The reported worldwide incidence and prevalence of PSO varies greatly depending on age, 
gender, ethnicity, and geography primarily due to genetic and environmental factors. Estimates 
of incidence and prevalence include all types of PSO. Plaque PSO is the most common form of 
the disease th erefore reported estimates of the magnitude of this condition are likely weighted 
heavily by this subtype. Both the incidence and prevalence of PSO are higher among Caucasians 
and those living in higher latitudes. Psoriasis affects approximately 2% to 4% o f the population 
of western countries. Geographical differences are also influenced by case definition, study 
design, and the definition of prevalence (Parisi et al, 2013; Langley et al, 2005; Raychaudhuri 
and Gross, 2000).  
2.1.2  Current treatments for psoriasis  
Therapy for patients with PSO varies according to the severity of disease. Limited or mild 
disease is often treated with topical therapies such as corticosteroids and vitamin D analogs. 
Patients with more severe disease are often treated with phototherapy , methotrexate, 
cyclosporine, the oral phosphodiesterase 4 (PDE4) inhibitor apremilast, or biologic agents, such 
as tumor necrosis factor (TNF) antagonists, interleukin (IL) -12/23 inhibitors, IL -23p19 inhibitors 
and IL -17A inhibitors. The effectiveness of TNF inhibitors in the treatment of PSO has been 
demonstrated in many Phase 3 clinical studies and has led to the approval of multiple TNF 
inhibitors for use in patients with moderate to severe PSO. Interleukin inhibitors approved for 
this indication includ e the IL -12/23 antagonist ustekinumab, the IL -23p19 antagonist 
guselkumab, the IL -17A inhibitors secukinumab and ixekizumab, and the IL -17 receptor 
antagonist brodalumab.  
Standard therapies for PSO are listed below:  
 Topical steroids (eg, triamcinolone, mometasone, clobetasol, betamethasone, hydrocortisone) 
are generally used as first -line treatment of PSO. High -strength steroids are typically 
reserved for use on the arms and legs. Areas such as the face and skin folds (axillary, 
inguinal regions, etc) ar e usually treated with a low potency steroid. Chronic use of topical 
steroids can lead to corticosteroid -related side effects and is generally discouraged.  
 Vitamin D analogs (eg, calcipotriol and tacalcitol) are commonly used to treat mild to 
moderate PSO,  and work best within the mild patients. They are safe but lack efficacy for 
more severe disease.  
 Phototherapy is a frequent option for moderate to severe patients, but the inconvenience of 
multiple treatment visits and varying efficacy limits its use in t he market.  
 Methotrexate is a systemic immunosuppressant and is used in moderate to severe PSO 
patients. Toxicity concerns, particularly in older patients, are a major drawback.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 17 of 209  Cyclosporine is a systemic immunosuppressant used in patients with severe, reca lcitrant, 
PSO who have failed at least one systemic therapy or in whom other systemic therapies are 
contraindicated. In recommended dosages cyclosporine can cause systemic hypertension and 
nephrotoxicity, therefore, renal function must be monitored during therapy.  
 Apremilast is an oral small -molecule inhibitor of PDE4 that is also approved for treatment of 
adults with moderate to severe plaque PSO. Phosphodiesterase 4 inhibitors work 
intracellularly to modulate a network of proinflammatory and anti -inflamma tory mediators. 
Phosphodiesterase 4 is a cyclic adenosine monophosphate (cAMP) -specific PDE and the 
dominant PDE in inflammatory cells. Phosphodiesterase 4 inhibition elevates intracellular 
cAMP levels, which in turn down -regulates the inflammatory respons e by modulating the 
expression of TNFα, IL -23, IL -17, and other inflammatory cytokines.  
 Biologics, including TNFα inhibitors (adalimumab, etanercept, and infliximab), 
IL-12/23  inhibitors (ustekinumab), the IL -23p19 antagonist (guselkumab), the IL -17A 
inhib itors (secukinumab and ixekizumab), and the IL -17 receptor antagonist brodalumab are 
the treatment options of choice for patients with moderate to severe plaque PSO who are 
candidates for systemic therapy or phototherapy. These products are injected sc or delivered 
via intravenous (iv) infusion. Different from the traditional systemic drugs that impact the 
entire immune system, biologics target specific parts of the immune system and offer reduced 
multi -organ toxicity and adverse effects associated with tra ditional treatments.  
 TNFα inhibitors, while effective, come with boxed warnings including the risk of serious 
infections and reports of lymphoma and malignancy in children and adolescent patients. 
The efficacy of TNFα inhibitors in treating PSO is attribut ed to their inhibition of 
Th17 -T cells.  
 Ustekinumab has been approved in the US and the EU for the treatment of patients with 
moderate to severe plaque PSO who are candidates for phototherapy or systemic therapy. 
Ustekinumab is a human immunoglobulin (Ig)  G1κ monoclonal antibody that binds with 
specificity to the p40 protein subunit used by both the IL -12 and IL -23 cytokines, 
naturally occurring cytokines that are involved in inflammatory and immune responses, 
such as natural killer cell activation and CD4 + T-cell differentiation and activation.  
 Secukinumab and ixekizumab have been approved in the US and the EU for the treatment 
of moderate to severe plaque PSO in adult patients who are candidates for systemic 
therapy or phototherapy. Secukinumab is a huma n IgG1 monoclonal antibody that 
selectively binds to the interleukin -17A (IL -17A) cytokine and inhibits its interaction 
with the IL -17 receptor. Ixekizumab is a humanized IgG4 monoclonal antibody that 
selectively binds with the interleukin 17A (IL -17A) cyt okine and inhibits its interaction 
with the IL -17 receptor. IL -17A is a naturally occurring cytokine that is involved in 
normal inflammatory and immune responses. Both drugs inhibit the release of 
proinflammatory cytokines and chemokines.  
 Guselkumab has be en approved in the US and EU for the treatment of adult patients with 
moderate to severe plaque PSO who are candidates for systemic therapy or phototherapy. 
It is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of 
interleukin 23  (IL-23) and inhibits its interaction with the IL -23 receptor. IL -23 is a 
naturally occurring cytokine that is involved in normal inflammatory and immune 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 18 of 209 responses. Guselkumab inhibits the release of proinflammatory cytokines and 
chemokines.  
 Brodalumab has  been approved in the US for the treatment of moderate to severe plaque 
PSO in adult patients who are candidates for systemic therapy or phototherapy and have 
failed to respond or have lost response to other systemic therapies. In the EU, brodalumab 
is ind icated for the treatment of moderate to severe plaque PSO in adult patients who are 
candidates for systemic therapy. Brodalumab is a human monoclonal IgG2 antibody that 
selectively binds to human IL -17RA and inhibits its interactions with cytokines IL -17A,  
IL-17F, IL -17C, IL -17A/F heterodimer and IL -25. Blocking IL- 17RA inhibits IL -17 
cytokine -induced responses including the release of proinflammatory cytokines and 
chemokines. Brodalumab has a black box warning regarding suicidal ideation and 
behavior.  
2.2 Bimekizumab  
Bimekizumab (UCB4940) is an engineered, humanized full length monoclonal antibody (mAb) 
of immunoglobulin (Ig) G1 sub -class of approximately 150,000 Daltons which is expressed in a 
genetically engineered Chinese Hamster Ovary cell line. Bimekizuma b has high affinity for 
human IL -17A and human IL -17F and selectively and potently inhibits the activity of both 
isoforms in vitro. Interleukin -17A and IL -17F are key proinflammatory cytokines believed to 
play important roles in autoimmune and inflammatory  diseases. Bimekizumab is being 
developed for the treatment of patients with inflammatory diseases such as PsA, PSO, and axial 
spondyloarthritis (axSpA).  
While anti -IL-17A antibodies have demonstrated efficacy in patients with PSO, PsA, and 
ankylosing spon dylitis, as yet, no therapeutic approach selectively and potently inhibits the 
activity of both IL -17A and IL -17F isoforms in vitro. Bimekizumab is an engineered, 
humanized, full -length IgG1 mAb which has been designed to inhibit the activity of IL -17A and  
IL-17F subtypes of IL -17. This property makes bimekizumab distinct from the other IL -17-
targeting agents like secukinumab and ixekizumab (selective anti -IL-17-A mAb), or brodalumab 
(anti-IL-17 receptor mAb).  
Overexpression of IL -17A, IL -17C, and IL -17F in  lesion tissue suggests that broader IL -17 
blockade may be more beneficial in the treatment of plaque PSO. However, blocking all IL -17 
isoforms (including the IL 17E isoform, also known as IL -25) may not be the optimal approach. 
The role of IL -25 in PSO an d other IL -17 mediated diseases has not been well established, 
however it has been suggested that IL -25 may play a beneficial role in inflammatory conditions 
associated with type 1 T helper (Th -1) mediated immune responses, such as PSO (as opposed to 
type 2 T helper [Th -2] mediated) (Valizadeh et al, 2015). Thus, it can be hypothesized that 
inhibition of both IL -17A and IL -17F is associated with additional benefits in PSO compared to 
the selective IL -17A inhibition or a broader IL -17 blockade.  
2.2.1  Clinical  
2.2.1.1  Comp leted studies  
Five clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, 
UP0031 in 12 healthy volunteers, and UP0042 in 48 healthy volun teers.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 19 of 209 UP0008 was a Phase 1, single ascending dose study in adults with mild to moderate PSO 
affecting ≤5% BSA. In this blinded study, single doses of up to 640mg (approximately 8mg/kg 
in an 80kg adult) were evaluated without any safety concerns. A total of 26 subjects with PSO 
with less than 5% of body surface involvement were treated with a range of single iv doses from 
8 to 640mg. There were no clinically relevant safety findings identified at any dose and all doses 
were well tolerated. The pre -specifie d exploratory assessment of disease activity showed 
clinically relevant and statistically significant improvements at the higher doses studied.  
RA0124 was a Phase 1, open -label, parallel -group, single -dose study in healthy subjects. The 
primary objective o f this study was to determine the absolute bioavailability (BA) of single sc 
doses of bimekizumab (80mg and 160mg). The secondary objectives were to evaluate the dose 
proportionality of bimekizumab 80mg and 160mg sc, and to evaluate the safety and tolerabi lity 
of these sc doses and 160mg given by iv infusion. In RA0124, the absolute BA was similar for 
the 2 doses tested (0.656 and 0.631 for the bimekizumab 80mg and 160mg sc doses, 
respectively). The PK of bimekizumab was linear in the tested dose range and the median t1/2 
following sc administration was similar to that following iv administration (27.81 days and 28.25 
days for bimekizumab 160mg sc and 160mg iv, respectively).  
Bimekizumab has also been investigated in a Phase 1b, proof of concept, randomized,  placebo 
controlled, multiple dose study (PA0007). The primary objective of PA0007 was to assess the 
safety and PK of multiple dose administration of iv bimekizumab in subjects with PsA. Four 
active doses and a placebo were tested. Drug was administered as  a loading dose at Week  0, and 
2 additional doses were administered at Week  3 and Week  6. In each treatment group, subjects 
received a total of 3 doses of bimekizumab, administered every 3 weeks as shown below:  
 80mg loading dose followed by 40mg at Weeks 3  and 6  
 160mg loading dose followed by 80mg at Weeks 3 and 6  
 240mg loading dose followed by 160 mg at Weeks 3 and 6  
 560mg loading dose followed by 320mg at Weeks 3 and 6  
The results of this study demonstrated that all doses of bimekizumab were well tolerated and 
there were no unexpected clinically relevant safety findings.  
Infections (mostly nasopharyngitis) were the most commonly reported events in both the active 
treatment and the placebo group. None of the infections were considered serious or req uired 
treatment with antibiotics. Two subjects in the active treatment group experienced 1  local 
candida infection each (oropharhyngitis and vulvovaginitis, respectively) that were non -serious 
and resolved with topical therapy. There was a potential reduct ion in mean neutrophil count in 
the active treatment group, although this drop was not clinically relevant and a clear relationship 
with dose or time was not evident. Some increases in liver function tests were reported, but none 
had a convincing relations hip to exposure to IMP. The exploratory analysis showed clinically 
relevant improvement in activity of PsA and in skin involvement in those subjects with 
concomitant active psoriatic lesions.  
UP0031 was a Phase 1, open -label, parallel -group, randomized, single -dose study to evaluate the 
BA, PK, and tolerability of 2 different formulations of bimekizumab in healthy subjects. Subjects 
receiving Formulation  A ( ) were administered two  1mL injections of 80mg each 
of bimekizumab and subjects rece iving Formulation  B were administered a 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 20 of 209 single injection of bimekizumab 160mg given as a 1mL injection. Six subjects were randomized 
to each bimekizumab formulation. The geometric means (GeoMeans) for area under the curve 
(AUC) were similar  between bimekizumab 2x80mg and 1x160mg groups and the relative BA for 
Formulation  B vs Formulation  A was 96.1% (95% confidence interval [CI]: 72.7%, 127.0%). 
Administration of the 2 formulations of bimekizumab used in this study identified no new safety 
issues. There were no treatment -emergent adverse events (TEAEs) leading to discontinuation, 
and no serious adverse events (SAEs) or fatalities were reported. The only preferred term 
experienced by more than 1 subject in either treatment group was injection site pain (5  subjects 
[83.3%] and 3 subjects [50.0%] in the 2x80mg and 1x160mg groups, respectively). The most 
frequently reported TEAE considered related to the IMP was injection site pain, experienced by 
5 subjects [83.3%] and 3 subjects [50.0%] in the 2 x80mg and 1x160mg groups, respectively. 
There were no clinically significant laboratory values reported in the study.  
UP0042 was a randomized double -blind, placebo -controlled, single -dose, parallel -group study to 
evaluate the safety, tolerability, and PK o f bimekizumab administered as an sc injection to 
Japanese and Caucasian healthy subjects. This study demonstrated that the PK profiles following 
single administration of 80mg, 160mg, and 320mg with an sc injection were dose proportional 
with a linear elimi nation in both Japanese and Caucasian subjects and that the PK profiles of 
Japanese and Caucasian subjects were considered to be generally similar. A single dose of 
bimekizumab (80mg, 160mg, or 320mg) administered as an sc injection was generally safe and 
well tolerated in healthy Japanese and Caucasian subjects and no major differences in safety 
findings were observed between Japanese and Caucasian subjects.  
2.2.1.2  Ongoing studies  
Four additional studies of bimekizumab in the treatment of PSO are ongoing . 
 PS0010 is a Phase 2b, double -blind, placebo -controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and pharmacodynamics (PD) of bimekizumab in adult subjects with 
moderate to severe chronic plaque PSO.  
 PS0011 is a long -term extension study for subje cts who completed PS0010 to assess the 
long-term safety, tolerability, and efficacy of bimekizumab.  
 PS0016 is a Phase 2a, subject -blind, investigator -blind study to evaluate the time course of 
PD response, safety, and PK of bimekizumab in adult subjects wi th moderate to severe 
chronic plaque PSO.  
 PS0018 is a long -term extension study for eligible subjects from PS0016 to assess the safety, 
tolerability, and efficacy of bimekizumab.  
Bimekizumab is also being evaluated in the treatment of other indications (eg , PsA, axSpA, 
hidradenitis suppurativa). Additional information on the clinical data for bimekizumab is 
available in the current version of the Investigator’s Brochure (IB).  
2.2.2  Nonclinical  
Parallel inhibition of IL -17A and IL -17F has been shown to be efficaci ous in a variety of animal 
models of inflammatory disease. Intravenously administered bimekizumab was well tolerated in 
repeat dose toxicology studies in Cynomolgus monkeys with a no adverse effect level of 
200mg/kg/week. The findings of note in toxicity s tudies were diarrhea related to infectious 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 21 of 209 enteritis (observed in the single dose study) and asymptomatic mild colonic ulceration in a 
proportion of animals (in the repeat dose study); this latter finding was not associated with 
hematology abnormalities. D ata suggest that bimekizumab has induced primary lesions to the 
mucosa associated lymphoid tissue via a pharmacologically -related mechanism. In a second 
repeat -dose study, none of the minor apoptosis/necrosis findings observed in gut associated 
lymph nodes  were revealed. In animals given the highest dose of bimekizumab in the study 
(20mg/kg/week), a slightly higher number of protozoa ( Balantidium coli ) was observed in the 
cecum and colon as compared to the control animals and low dose animals. Therefore, gu t 
associated lymph node lesions observed in the first study are considered to be accidental and/or 
linked to exaggerated pharmacology and proliferation of Balantidium coli  and is considered the 
consequence of a change in local mucosal immunity. To date, si milar findings have not been 
seen in studies in humans.  
Additional information on the nonclinical data for bimekizumab is available in the current 
version of the IB.  
3 STUDY OBJECTIVE(S)  
3.1 Primary objective  
The primary objective of the study is to compare the efficacy of bimekizumab administered sc 
for 16  weeks versus placebo in the treatment of subjects with moderate to severe chronic plaque 
PSO.  
3.2 Secondary objectives  
The secondary objectives of the study are to:  
 Evaluate the efficacy of bimekizumab compared to  placebo at achieving complete clearance 
(PASI100) after 16 weeks of treatment  
 Evaluate the efficacy of bimekizumab compared to placebo after 4 weeks of treatment  
 Evaluate the change in itch, pain, and scaling of bimekizumab compared to placebo after 
16 weeks of treatment as reported by subjects using the Patient Symptom Diary  
 Evaluate the change in psoriatic scalp disease of bimekizumab compared to placebo after 
16 weeks of treatment in subjects with scalp PSO at Baseline  
 Evaluate the efficacy of continuou s treatment with bimekizumab versus treatment withdrawal 
(placebo) as defined by PASI90 at Week 56 for subjects who responded to bimekizumab 
treatment at Week  16 
 Assess the maintenance of efficacy of bimekizumab dosing Q4W versus Q8W at Week 56  
 Assess TEAE s, SAEs, and TEAEs leading to withdrawal adjusted by duration of subject 
exposure to study treatment  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 22 of 209 3.3 Other objectives  
The other objectives of the study are to demonstrate the effects of bimekizumab on aspects of the 
disease:  
 Assess the time to relapse amon g subjects who responded to bimekizumab treatment at 
Week  16 
 Assess the efficacy of 12 weeks of escape treatment with bimekizumab in subjects who 
relapse (defined as not achieving a PASI75 response) during the Randomized -Withdrawal 
Period  
 Assess the efficacy of 12 weeks of escape treatment with bimekizumab for subjects who do 
not achieve a PASI90 response (defined as a subject that does not achieve 90%  reduction in 
the PASI score ) at Week  16 
 Assess the efficacy of bimekizumab over time  
 Assess the efficacy of bimekizumab dosing Q4W versus Q8W during the Randomized -
Withdrawal Period  
 Assess the change of skin -related quality of life (QOL)  
 Assess the change of general health -related QOL  
 Assess the change in nail PSO over time in subjects wit h nail PSO at Baseline  
 Assess the change in scalp PSO over time in subjects with scalp PSO at Baseline  
 Assess the change in palmoplantar PSO over time in subjects with palmoplantar PSO at 
Baseline  
 Assess the symptoms of PsA as measured by the Psoriatic Art hritis Screening and Evaluation 
(PASE) questionnaire  
 Assess the change of patient -reported joint symptoms in subjects with PsA at Baseline  
 Assess the change in symptoms of PSO as reported by subjects using the Patient Symptom 
Diary (all items) through Week  16 
 Assess depression  
 Assess the PK of bimekizumab  
 Assess the immunogenicity of bimekizumab  
 Assess the effect of bimekizumab on gene and protein expression, and explore the 
relationship between genomic, genetic, and proteomic biomarkers and disease biolog y, drug 
treatment and inflammatory and immune responses (from consenting subjects who agree to 
participate in the biomarker substudy)  
 Assess the safety and tolerability of bimekizumab  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 23 of 209 4 STUDY VARIABLES  
4.1 Primary efficacy variables  
The co -primary efficacy varia bles are the PASI90 response (defined as a subject that achieves 
90% reduction from Baseline in the PASI score) at Week  16 and the IGA response (defined as 
Clear or Almost Clear with at least a 2 category improvement relative to Baseline) at Week  16. 
4.2 Secon dary variables  
4.2.1  Secondary efficacy variables  
The secondary efficacy variables are:  
 PASI100 response at Week  16 
 PASI75 response at Week  4 
 Patient Symptom Diary responses for itch, pain, and scaling at Week  16 
 Scalp IGA response (Clear or Almost Clear with at  least a 2 -category improvement from 
Baseline ) at Week  16 for subjects with scalp PSO at Baseline  
 PASI90 response at Week 56 among Week 16 PASI90 responders  
4.2.2  Secondary safety variables  
 TEAEs adjusted by duration of subject exposure to study treatment  
 SAEs a djusted by duration of subject exposure to study treatment  
 TEAEs leading to withdrawal adjusted by duration of subject exposure to study treatment  
4.3 Other variables  
The other variables are listed below and will be evaluated according to the planned assessmen ts 
in Table  5‒1. 
4.3.1  Other efficacy variable(s)  
The other efficacy variables are listed below and will be evaluated at all scheduled visits in 
accordance with the Schedule of Study Assessments in  Table  5‒1. This excludes the timepoints 
for the primary and secondary variables specified above in Section  4.1 and Section  4.2.1 , 
respectively . 
Change from Baseline variables evaluated during the Initial Treatment Period are relative to the 
Baseline Visit (f irst dose). For subjects who are re -randomized at the Week 16 Visit, change 
from Baseline variables during the Randomized -Withdrawal Period may be evaluated relative to 
both the Baseline Visit (first dose) and the Week 16 Visit. Similarly, for subjects who  initiate 
escape treatment with bimekizumab (either due to lack of response at Week 16 or loss of 
response [relapse] during the Randomized -Withdrawal Period), these variables during the 
12-week escape treatment period may be evaluated relative to both the Baseline Visit (first dose) 
and the visit at which escape treatment was initiated.  
For simplicity, “change from Baseline” is used below for all such variables and applies to all 
scheduled visits where the assessments were performed (whether during the Init ial Period, 
Randomized -Withdrawal Period, or Escape Treatment Period). Greater detail on the definition of 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 24 of 209 Baseline for different summaries will be provided in the Statistical Analysis Plan (SAP). Unless 
otherwise stated PASI responder rates will be calcul ated relative to the Baseline Visit (first 
dose).  
The other efficacy variables are:  
 PASI50, PASI75, PASI90, and PASI100 response  
 Time to PASI50, PASI75, PASI90, and PASI100 response during the Initial Treatment 
Period  
 Time to relapse during the Randomized -Withdrawal Period  
 Percentage of subjects who relapse during the Randomized -Withdrawal Period  
 Absolute and percent change from Baseline in PASI score  
 IGA response (Clear with at least a 2 -category improvement from Baseline)  
 IGA response (Clear or Almost Cle ar with at least 2 -category improvement from Baseline)  
 Shift from Baseline in IGA score  
 Absolute and percent change from Baseline in the BSA affected by PSO  
 Absolute and percent change from Baseline in the product of IGA and BSA (IGAxBSA)  
 Change from Basel ine in Dermatology Life Quality Index (DLQI)  
 Percentage of subjects achieving a DLQI total score of 0 or 1  
 Percentage of subjects achieving a minimal clinically important difference (improvement 
from Baseline of 4 or more) in the DLQI  
 Change from Baseline in the Patient’s Global Assessment of Disease Activity (PGADA) for 
the arthritis visual analog scale (VAS) in the subgroups of subjects with PsA as defined by 
PASE score at Baseline  
 Change from Baseline in Patient Global Assessment (PGA) of PSO score  
 Patie nt Symptom Diary responses  
 Scalp -specific Investigator’s Global Assessment (scalp IGA) response (Clear or Almost 
Clear  with at least a 2 -category improvement relative to Baseline ) for subjects with scalp 
PSO at Baseline  
 Change from Baseline in Modified Nai l Psoriasis Severity Index (mNAPSI) score for 
subjects with nail PSO at Baseline  
 Palmoplantar Investigator’s Global Assessment (pp -IGA) response (Clear or Almost Clear) 
for subjects with palmoplantar PSO at Baseline  
 Change from Baseline in the PASE questionnaire scores (function score, symptom score, and 
total score)  
 Shift from Baseline in PASE score suggestive of PsA (<47 versus ≥47)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 25 of 209  Change from Baseline in Short Form 36 -item Health Survey (SF -36) Physical Component 
Summary (PCS) score, and Mental C omponent Summary (MCS) score, and individual 
domains  
 Responses to Euro -Quality of Life 5 -Dimensions, 3 levels (EQ -5D-3L), absolute and changes 
from Baseline in EQ -5D-3L VAS scores  
 Change from Baseline in Patient Health Questionnaire (PHQ) -9 scores  
4.3.2  Other sa fety variables  
Safety variables to be assessed are:  
 Severity and frequency of AEs  
 Change from Baseline in vital signs  
 ECG results  
 Change from Baseline in clinical laboratory values (chemistry, hematology, and urinalysis)  
Physical examination findings consi dered clinically significant changes since the physical 
examination at the Screening Visit will be recorded as AEs.  
4.3.3  Pharmacokinetic variable  
The PK variable is the plasma concentration of bimekizumab.  
4.3.4  Pharmacogenomic variables  
Additional blood samples will  be collected from subjects who consent to participate in the 
substudy at specific time points and stored at -80°C for up to 20 years.  
Genomic, genetic, epigenetic, proteins, and metabolite biomarkers may be measured to evaluate 
the relationship with respo nse to treatment with bimekizumab, PSO disease biology, and 
inflammatory and immune response processes. The nature and format of these tentative substudy 
analyses will be determined when the results of the main study are made available.  
The candidate explo ratory variables are the blood or blood derivative (eg, serum) concentrations 
of cytokines and chemokines of relevance to IL -17A/F signaling pathway and PSO biology. 
Additional variables may include but will not be limited to serum complement concentration s. 
4.3.5  Immunological variable  
The immunological variable is the anti -bimekizumab antibody level prior to and following IMP.  
5 STUDY DESIGN  
5.1 Study description  
PS0013 is a Phase 3, multicenter, randomized, double -blind placebo -controlled study consisting 
of a 16-week Initial Treatment Period followed by a 40 -week Randomized -Withdrawal Period to 
evaluate the efficacy and safety of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO. To be eligible to participate in this study, subjects must be adults with a 
diagnosis of moderate to severe PSO (Baseline PASI ≥12 and BSA affected by PSO ≥10% and 
IGA score ≥3 [on a 5 -point scale]) who are a candidate for systemic PSO therapy and/or 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 26 of 209 phototherapy. Subjects may have been previously exposed to a bio logic therapy (see Exclusion 
Criterion # 23, Section  6.2). 
5.2 Study periods  
This study will include 4 periods, a Screening Period (2 to 5 weeks), a place bo-controlled Initial 
Treatment Period (16  weeks), a placebo -controlled Randomized -Withdrawal Period (40  weeks), 
and a SFU Period (20 weeks after the final dose of IMP). After completing the study, eligible 
subjects will be allowed to enroll in an open -label study. Subjects enrolling into the open -label 
study will not have the PS0013 SFU Visit.  
Subjects who do not achieve a PASI90 response at Week  16 of the Initial Treatment Period will 
be allocated to escape treatment (see Section  5.2.5 ). All subjects who relapse at Week  20 or later 
during the Randomized -Withdrawal Period (up to Week  56) will be allocated to escape treatment 
(see Section  5.2.5 ). Relapse is defined as not achieving a PASI75 response . Subjects who 
achieve a PASI50 response at Week  12 of the open -label escape arm will be  allowed to enroll in 
the open -label study.  
Subjects who complete the Randomized Withdrawal Period (after a Week  16 response 
[≥PASI90] on bimekizumab during the Initial Treatment Period ) will be allowed to enroll in an 
open -label study. Placebo -randomized  subjects, who receive placebo during the entire Initial and 
Randomized -Withdrawal periods, that complete Week 56 without relapse into the open -label 
escape arm will not be eligible for the open -label study.  
5.2.1  Screening Period  
The Screening Period will last 2 weeks, but can be extended up to a total of 5 weeks in cases 
where a laboratory assessment needs to be repeated or to allow washout of prohibited 
medications. During this time, eligible subjects will be informed about the study and sign the 
Informed Cons ent Form (ICF), laboratory data (hematology, urine, and biochemistry tests) will 
be obtained, and the doses of medications used to treat PsA, will be verified as stable. The 
Screening Period will also enable washout of any medications not permitted for use  during the 
study. Subjects who require prophylaxis for latent tuberculosis (LTB) infection must be on 
treatment for at least 8 weeks prior to their first dose of IMP. These subjects may be rescreened 
once they have completed the first 8 weeks of prophylax is treatment.  
One rescreening may be allowed after consultation with the Medical Monitor.  
The assessments to be performed at the Screening Visit are presented in  Table  5‒1. 
5.2.2  Initial Treatment Period  
During the placebo -controlled Initial Treatment Period, approximately 400 subjects will be 
randomized 4:1 to receive the following blinded IMP regimens:  
 Bimekizumab 320mg administered Q4W (320 subjects)  
 Placeb o administered Q4W (80 subjects)  
Investigational medicinal product will be administered in the clinic by sc injection at the time 
points specified in the schedule of assessments ( Table  5‒1). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 27 of 209 Subjects will be followed in a double -blind fashion. Subjects may receive placebo injections at 
certain visits in order to blind the IMP. The assessments to be performed at each Initial 
Treatment Period visit are pres ented in Table  5‒1. 
Subjects withdrawing early from the study will undergo the PEOT Visit assessments and will 
enter the SFU Period. Subjects withdrawing early from the study will not be eligible for 
inclusion in the open -label study.  
5.2.3  Randomized -Withdrawal Period  
At the Week  16 study visit, bimekizumab subjects who have achieved a PASI90 response will 
enter into a double -blind, placebo -controlle d Randomized -Withdrawal Period lasting 40  weeks. 
Subjects who do not achieve a PASI90 response at the Week  16 study visit will be allocated to 
the escape arm (see Section  5.2.5 ). 
During the Randomized -Withdrawal Period, dosing will be based on treatment group assignment 
at initial randomization as follows:  
 Subjects initially randomized to bimekizumab 320mg Q4W will be re -randomized 1:1:1 to 
either bim ekizumab 320mg Q4W or bimekizumab 320mg Q8W or placebo (ie, treatment 
withdrawal)  
 All subjects initially randomized to placebo who achieve a PASI90 response at Week 16 will 
continue to receive placebo (Q4W)  
Investigational medicinal product will be adminis tered in the clinic at Week  16 and Q4W 
thereafter through Week  52. The assessments to be performed at each visit of the Randomized -
Withdrawal Period are presented in  Table  5‒1. 
All subjects who relapse at Week  20 or later during the Randomized -Withdrawal Period (up to 
Week  56) will be allocated to the escape arm (see Section  5.2.5 ). Relapse is defined as not 
achieving a PASI75 response.  
At the end of the Randomized -Withdrawal Period, all subjects enrolling in the open -label study 
(after signing a new ICF) will undergo the Week  56 study assessments be fore receiving their first 
dose of IMP in the open -label study. All subjects not enrolling in the open -label study will have 
the Week  56 study assessments and will enter the SFU Period.  
5.2.4  Safety Follow -Up 
All subjects not continuing in the open -label study, including those withdrawn from IMP, will 
have a SFU Visit 20 weeks after their final dose of IMP.  
The assessments for the SFU are presented in  Table  5‒1. 
5.2.5  Escape Treatment  
As described above, subjects who do not achieve a PASI90 response at Week  16 of the Initial 
Treatment Period and all subjects who relapse at Week  20 or later during the Randomized -
Withdrawal Period (up to Week  56) will receive open -label  bimekizumab 320mg Q4W for 
12 weeks (ie, escape treatment).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 28 of 209 For subjects who relapse during the Randomized -Withdrawal Period, the subject should 
complete the 12 -week escape treatment period even if this extends to a time point beyond what 
would have been t he Week 56 visit (if the subject had not escaped).  
Subjects who achieve a PASI50 response by the end of the 12 weeks of escape treatment are 
eligible to enroll in the open -label study. The Schedule of Study Assessments for subjects 
receiving escape treatme nt is provided in Table  5‒2. 
5.2.6  Premature End of Treatment  
Subjects withdrawing early from the study will undergo PEOT Visit assessments ( see 
Section  8.5) and will enter the SFU Period.  
5.3 Study duration per subject  
For each subject, the study will last a maximum of up to 77 weeks, as follows:  
 Screening P eriod: 2 to 5 weeks  
 Double -blind, placebo -controlled Initial Treatment Period: 16 weeks  
 Double -blind, placebo -controlled Randomized -Withdrawal Period: 40 weeks  
 Escape treatment (if required): 12 weeks  
 Safety Follow -Up Period: a SFU Visit is planned 20 week s after the final dose of IMP (for 
subjects not enrolling in the open -label study)  
After the 40 -week Randomized -Withdrawal Period, subjects will be allowed to enroll in an open -
label study,  in which case subjects will undergo the Week  56 study assessments before receiving 
their first open -label IMP dose . Subjects who achieve a PASI50 response in the open -label 
escape arm will also be allowed to enroll in the open -label study. Subjects who complete the 
Randomized Withdrawal Period (after a Week  16 response [ ≥PASI90] on bimekizumab during 
the Initial Treatment Period ) will be allowed to enroll in an open -label study. Placebo -
randomized subjects, who receive placebo during the entire Initial and Randomized -Withdrawal 
periods, that complete Week 56 without relap se into the open -label escape arm will not be 
eligible for the open -label study.   
The SFU Visit will not be required for subjects who enroll in the open -label study.  
The end of the study is defined as the date of the last visit of the last subject in the s tudy.  
5.4 Planned number of subjects and site(s)  
Approximately 535  subjects will be screened in order to have 400 subjects randomized in the 
study. There will be approximately 320 subjects in the bimekizumab treatment arm and 80 
subjects in the placebo treatme nt arm. The planned number of study sites is approximately 100. 
Every eligible subject who signs an ICF will be randomized.  
5.5 Anticipated regions and countries  
The regions planned for study conduct are North America, Western Europe, Central/Eastern 
Europe, and Asia/Australia , with possible extension to other regions and countries.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 29 of 209 5.6 Schedule of study assessments  
The Schedule of Study Assessments for all subjects enrolled in the study is presented in  
Table  5‒1. The Schedule of Study Assessments for subjects allocated to escape treatment is 
presented in  Table  5‒2. At each visit, all study assessments should be performed prior to 
administration of IMP.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 30 of 209 Table  5‒1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEO
T SFU
b Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Informed consentc X                Xd   
Inclusion/exclusion  X X                  
Urine drug screen  X                 X  
Demographic data  X                   
Psoriasis history  X                   
Significant past medical 
history and concomitant 
diseases  X Xe                  
Physical examf, g X X     X   X   X   X  X X 
Height   X                  
Body weight   X     X   X   X   X  X  
Vital signsh X X X X X X X X X X X X X X X X X X X 
Hematology and 
biochemistry  X X X X X X X X X X  X  X  X  X X 
Urinalysis  X X      X  X  X  X  X  X X 
ECG  X      X     X    X  X  
Pregnancy testingi X X   X X X X X X X X X X X X X X X 
Hepatitis B and C testingj X                   
HIV testingk X                   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 31 of 209 Table  5‒1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEO
T SFU
b Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Chest x -rayl X                   
IGRA Tuberculosis test  X                X   
Tuberculosis 
questionnaire  X X     X   X   X   X  X X 
Blood sample for 
bimekizumab plasma 
concentrationsm  X X X X X X X X X   X   X  X X 
Blood sample for 
anti-bimekizumab 
antibodiesm  X   X X X X X X   X   X  X X 
Blood sample for 
genomic, proteomic, 
metabolomics, and 
candidate biomarker 
analysesc,m  X X   X X X          X  
Blood sample for 
genetic/ epigenetic 
analysesc,m  X                X  
PASI  X X X X X X X X X X X X X X X X X X X 
IGA  X X X X X X X X X X X X X X X X X X X 
Percentage of BSA  X X X X X X X X X X X X X X X X X X X 
DLQI   X  X X  X X X X X X  X  X  X  X  
PHQ -9 X X   X X X X X X X X X  X X X X X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 32 of 209 Table  5‒1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEO
T SFU
b Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
eC-SSRS  X X X X X X X X X X X X X X X X X X X 
Patient Symptom Diary 
(daily)  X X X X X X X X            
Scalp IGA   X Xn Xn Xn Xn Xn Xn Xn Xn  Xn  Xn  Xn  Xn  
mNAPSI   X   Xo Xo Xo Xo Xo Xo  Xo  Xo  Xo  Xo  
pp-IGA  X   Xp Xp Xp Xp Xp Xp  Xp  Xp  Xp  Xp  
EQ-5D-3L  X   X X X X  X  X  X  X  X  
SF-36  X   X X X X  X  X  X  X  X  
Patient Global 
Assessment of PSOq          X  X  X  X  X  
PASE   X                X  
PGADAr  X   X  X X  X  X  X  X  X  
Concomitant medication  X X X X X X X X X X X X X X X X X X X 
Adverse  events  X X X X X X X X X X X X X X X X X X X 
IRTs,t X X X X X X X X X X X X X X X X X X X 
Bimekiz umab or placebo 
administrations,t  X   X X X Xu X X X X X X X X X   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 33 of 209 Table  5‒1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEO
T SFU
b Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
BSA=body s urface area; CRF=Case Report Form; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC -SSRS=electronic 
Columbia -Suicide Severity Rating Scale; EQ -5D-3L= Euro -Quality of Life 5 -Dimensions, 3 levels; GI=gastrointestinal; HCV=hep atitis C virus; HIV=human 
immunodeficiency virus; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal product; 
IRT=interactive response technology; mNAPSI=Modified Nail Psoriasis Severity Index Score; PA SE=Psoriatic Arthritis Screening and Evaluation; 
PASI=Psoriasis Area and Severity Index;; PEOT=Premature End of Treatment Visit;  PGADA=Patient’s Global Assessment of Disease Activity; PHQ -9=Patient 
Health Questionnaire 9; pp -IGA=palmoplantar Investigator’s  Global Assessment; PsA=psoriatic arthritis; PSO=psoriasis; SF -36=Short Form 36 item Health 
Survey; SFU=Safety Follow -Up; scalp IGA=scalp -specific Investigator’s Global Assessment; TB=tuberculosis;  
a Visit windows of ±3 days from the first dose to the We ek 24 visit. Visit windows of ±7 days from the Week 28 visit to the Week 52 visit. The SFU Visit 
window is ±7 days from final dose.  
b The SFU Visit will occur 20 weeks after the final dose for subjects who do not enroll in the open -label study.  
c All genom ic, proteomic, and metabolomics samples will be stored at -80°C at the central biorepository for up to 20 years.  
d A separate ICF will be required to be completed for the open -label study.  
e Ensure no significant changes in medical history.  
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB.  
g The physical examination will be performed as per Section  12.3.5 . 
h Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blo od sampling, and prior to dosing, 
where applicable.  
i Pregnancy testing will consist of serum testing at the Screening. The pregnan cy test will be urine at all other visits  
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2)  positive 
for anti -hepatitis B core antibody (HBcAb+) and n egative for anti -hepatitis B surface antibody (HBsAb−) are excluded. A positive test for HCV is defined as: 1) 
positive for hepatitis C antibody (anti -HCV Ab), and 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are  also 
excluded. Subjects will also be tested for anti -hepatitis  B surface antibody.  
k The HIV test results will not be recorded in the eCRF.  
l Screening chest x -ray must occur within 3 months prior to the Screening Visit.  
m All blood samples taken prior to  dosing.  
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline.  
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 34 of 209 Table  5‒1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEO
T SFU
b Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
p The pp -IGA will only be assesse d in subjects with palmoplantar involvement (pp -IGA score >0) at Baseline.  
q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from Scr eening through the Initial 
Treatment Period. During th e Randomized -Withdrawal Period this assessment will be completed at the specified clinic visits .  
r The PGADA is assessed only for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47).  
s IMP administration is based on random ization.  
t The dosing window is ±3 days relative to the scheduled dosing visit through Week 24. The dosing window is ±7 days from Week 2 8 through the end of the 
study.  
u At Week 16, subjects initially randomized to BKZ 320mg Q4W who achieve PASI90 response  will be re -randomized 1:1:1 to either BKZ 320mg Q4W, BKZ 
320mg Q8W or placebo; subjects initially randomized to placebo who achieve PASI90 response at Week 16 will continue to receiv e placebo; and subjects who 
do not achieve PASI90 response at Week 16 wil l be allocated to the escape arm.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 35 of 209 Table  5‒2: Schedule of study assessments for subjects allocated to escape treatment  
Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
eC-SSRS  X X X X X 
Urine drug screen     X  
Physical exam     X X 
Body Weight  X   X  
Vital signsc X X X X X 
Hematology and biochemistry  X X X X X 
Urinalysis  X   X X 
ECG     X  
Pregnancy testingd X X X X X 
IGRA Tuberculosis test     X  
Tuberculosis questionnaire     X X 
Blood sample for bimekizumab plasma concentrationse X X X X X 
Blood sample for anti -bimekizumab antibodiese X X X X X 
Blood sample for genomic, proteomic, metabolomics, and candidate 
biomarker  analysese X   X  
Blood sample for genetic/epigenetic analysese    X  
PASI  X X X X X 
IGA X X X X X 
Percentage of BSA  X X X X X 
DLQI  X X X X  
PHQ -9 X X X X  
scalp IGAf X X X X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 36 of 209 Table  5‒2: Schedule of study assessments for subjects allocated to escape treatment  
Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
mNAPSIg X X X X  
pp-IGAh X X X X  
EQ-5D-3L X   X  
SF-36 X   X  
Patient Global Assessment of PSOi X   X  
PASE  X   X  
PGADAj X X X X  
Concomitant medication  X X X X X 
Adverse events  X X X X X 
IRT X X X X X 
Bimekizumab administrationk X X X   
BL=baseline; BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; EQ -5D-3L=Euro -Quality of Life 5 -Dimensions, 
3 levels; ET=Early Termination; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IRT=inter active response technology ; 
mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area and Severity Index; PEOT=Premature End of Treatment Visit;  PGADA=Patient’s Global 
Assessment of Disease Activity; PHQ -9=Patient Health Questionnaire 9; SF -36=Sh ort Form 36 -item Health Survey; SFU=Safety Follow -Up; TB=tuberculosis  
a Visit windows of ±7 days from the first dose at all visits except SFU. SFU Visit window is ±7 days from final dose.  
b The SFU Visit will occur 20 weeks after the final dose for subject s who do not enroll in the open -label study.  
c Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blo od sampling, and prior to dosing, 
where applicable.  
d A urine pregnancy test will be  performed at every study dosing visit. Pregnancy test results must be negative prior to administering study drug.  
e All blood samples taken prior to dosing.  
f The scalp IGA will only be assessed for those subjects with scalp involvement at Baseline.  
g The mNAPSI will be assessed only in subjects with nail involvement at Baseline.  
h The pp -IGA will only be assessed in subjects with palmoplantar involvement at Baseline.  
i During escape treatment, this assessment will be completed at each clinic visit specifi ed. 
j The PGADA is assessed only for subjects with PsA at Baseline.  
k The dosing window is ±7 days relative to the scheduled dosing visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 37 of 209 5.7 Schematic diagram  
Figure  5‒1: Schematic diagram  
          Bimekizumab 320mg Q8WBimekizumab 
320mg Q4WScreening
N=320Initial Treatment Period
Bimekizumab extension 
study
to evaluate response to 
treatment and long-term 
safety
SFU Visit
20 Weeks after last dose for 
subjects not enrolling in 
extension study          Bimekizumab 320mg Q4WRandomized - Withdrawal Period
<PASI90          Placebo Q4W  PASI90
Randomize 
1:1:1
relapse
Week 16
Co-Primary 
Endpoint: PASI90 ResponseIGA responseRandomization56 BaselineN=400Relapse: <PASI75 at Week 20 or later
Placebo  PASI90N=80
12-week, open-label escape arm: 
Bimekizumab 320mg Q4W
20          Placebo
28<PASI90relapseRelapse: <PASI75 at 
Week 20 or later
IGA=Investigator’s Global Assessment; PASI=Psoriasis Area and Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeks; SFU=Safet y Follow -Up 
Note: Subjects who do not achieve a PASI90 response at Week  16 will be allocated to an escape arm and receive open -label bimekizumab 320mg Q4W for 
12 weeks.  
Note: Relapse is defined as not achieving a PASI75 response. All subjects who relapse at Week 20 or later will be allocated t o an escape arm and receive open -
label bimeki zumab 320mg Q4Wfor 12 weeks.  
Note: Subjects in the placebo treatment arm in the Initial Treatment Period will continue to receive placebo Q4W at Week 16 a nd later visits provided a PASI90 
response was achieved at Week 16.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 38 of 209 5.8 Rationale for study design and selection of dose  
5.8.1  Study design  
A randomized, double -blind, placebo -controlled study design has been selected in order to 
demonstrate efficacy and safety of bimekizumab for regulatory approval. The study populati on 
will include adults with moderate to severe chronic plaque PSO and allow subjects who have 
received previous biologic treatment as well as those who are biologic treatment naïve. The 
primary efficacy outcome measures (based on PASI and IGA) and other ef ficacy assessments 
included in this study are consistent with those used for other PSO studies and are considered 
appropriate for establishing efficacy of bimekizumab. An initial treatment period of 16 weeks 
will be used to demonstrate the efficacy of bime kizumab over placebo. The study duration 
extends beyond the initial treatment period (to 56 weeks) to collect information on dosing 
beyond initial treatment, including the impact on efficacy and safety of withdrawing 
bimekizumab treatment from those who re sponded at Week 16.  
The results of the Phase 2b study PS0010 indicate that approximately 80% of subjects in the 
bimekizumab 320mg Q4W treatment arm achieved a high level of response (PASI90). Subjects 
who do not achieve a PASI90 response at Week 16 in PS0013 are allocated to a 12-week escape 
treatment with bimekizumab 320mg Q4W. Allocating subjects who do not achieve a PASI90 on 
placebo to the bimekizumab 320mg Q4W escape arm provides them with the opportunity to 
potentially achieve a higher level of efficacy. Beyond just achi eving a higher level of skin 
clearance, there is evidence that PASI90 is associated with higher levels of patient satisfaction 
(as measured by DLQI) compared with a lower PASI75 threshold (Puig et al, 2017). All subjects 
who relapse at Week 20 or later wil l be allocated to an escape arm and receive open -label 
bimekizumab 320mg Q4W for 12 weeks. Subjects in the placebo treatment arm in the Initial 
Treatment Period who are ≥PASI90 at Week 16 and ≥PASI  75 at Week 20 or later will continue 
to receive placebo Q4 W at Week 16 and later visits.  
5.8.2  Selection of dose  
Bimekizumab doses ranging from 64mg to 480mg were evaluated in the Phase 2b multicenter, 
randomized, double -blind, placebo -controlled, parallel -group, dose -ranging study PS0010. 
Bimekizumab 320mg was found to have an acceptable safety profile, only required 2 injections 
per treatment administration, and achieved significant PASI responses at Week 12 (summarized 
in the IB). Furthermore, data from the Phase 2a multicenter, randomized, subject -blind, 
Investigat or-blind study PS0016 and PK/PD modeling in this PSO population indicates improved 
responses through Week 16. Therefore, a bimekizumab dose of 320mg (Q4W initial and Q4W or 
Q8W maintenance) was selected for this study.  
6 SELECTION AND WITHDR AWAL OF SUBJECTS  
6.1 Inclusion criteria  
To be eligible to participate in this study, all of the following criteria must be met at Screening 
and at the Baseline Visit:  
1. Subject has provided informed consent.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 39 of 209 2. Subject is considered reliable and capable of adhering to the protocol (eg, able to understand 
and complete diaries), visit schedule, or medication intake according to the judgment of the 
Investigator.  
3. Male or female at least 18 years of age.  
4. Chronic plaque PSO for at least 6 months prior to the Screening Visit.  
5. PASI ≥12 and BSA affected by PSO ≥10% and IGA score ≥3 on a 5 -point scale.  
6a. Subject is a candidate for systemic PSO therapy and/or phototherapy.  
7. Criterion deleted.  
8. Female subjects must be:  
 Postmenopausal. Menopause is defined as 12 consecutive months of amenorrhea, for 
which there is no other obvious pathological or physiological cause.  
 Permanently sterilized (eg, tubal occlusion, hysterectomy, bilateral salpingectomy)  
 Or, if of childbearing potential (and engaged in sexual activity that could result in 
procreation),  must be willing to use a highly effective method of contraception 
throughout the duration of the study until 20 weeks after last administration of IMP, and 
have a negative pregnancy test at Visit 1 (Screening) and immediately prior to first dose. 
The foll owing methods are considered highly effective when used consistently and 
correctly:  
◦ Combined (estrogen and progestogen) hormonal contraception associated with 
inhibition of ovulation (oral, intravaginal, or transdermal)  
◦ Progestogen -only hormonal contracept ion associated with inhibition of ovulation 
(oral, injectable, implantable)  
◦ Intrauterine device  
◦ Intrauterine hormone -releasing system  
◦ Vasectomised partner  
◦ Abstinence as a form of birth control is generally not allowed in the study unless 
abstinence is in a ccordance with a subject’s preferred and common lifestyle. Study 
personnel must confirm the continued use of abstinence is still in accordance with the 
subject’s lifestyle at regular intervals during the study.  
9. Subject agrees not to change their usual sun exposure during the course of the study and to 
use ultraviolet A/ultraviolet B sunscreens if unavoidable exposure occurs.  
6.2 Exclusion criteria  
Subjects are not permitted to enroll in the study if any of the following criteria are met:  
1. Female subject who is breastfeeding, pregnant, or plans to become pregnant during the study 
or within 20 weeks following the final dose of IMP.  
2. Subject previously participated in a bimekizumab clinical study who received at least 1 dose 
of the IMP (including placebo).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 40 of 209 3a. Subje ct is currently participating in another study of a medication (systemic) under 
investigation. Subject must be washed out of the medication for 12 weeks or at least 5 half -
lives prior to the Baseline Visit, whichever is greater.  
4a. Subject is currently pa rticipating in another study of a topical medication under investigation. 
Subject must be washed out of the medication for 4 weeks prior to the Baseline Visit.  
5a. Subject is currently, or was within the 4 weeks prior to the Baseline Visit, participating i n 
another study of a medical device under investigation.  
6. Subject has a known hypersensitivity to any excipients of bimekizumab.  
7. Subject has a form of PSO other than chronic plaque -type (eg, pustular, erythrodermic and 
guttate PSO, or drug -induced PSO).  
8. Subject has an active infection or history of infection(s) as follows:  
 Any active infection (except common cold) within 14 days prior to Baseline.  
 A serious infection, defined as requiring hospitalization or iv anti -infective(s) within 
2 months prior to the B aseline visit.  
 A history of opportunistic, recurrent, or chronic infections that, in the opinion of the 
Investigator, might cause this study to be detrimental to the subject. Opportunistic 
infections are infections caused by uncommon pathogens (eg, pneumoc ystis jirovicii, 
cryptococcosis) or unusually severe infections caused by common pathogens (eg, 
cytomegalovirus, herpes zoster)  
9. Subject has concurrent acute or chronic viral hepatitis B or C or human immunodeficiency 
virus (HIV) infection. Subjects who hav e evidence of, or tested positive for hepatitis B or 
hepatitis C are excluded. A positive test for the hepatitis B virus is defined as: 1)  positive for 
hepatitis B surface antigen (HBsAg+) or 2) positive for anti -hepatitis B core antibody 
(HBcAb+). A posit ive test for the hepatitis C virus (HCV) is defined as: 1) positive for 
hepatitis C antibody (anti -HCV Ab) and 2) positive via a confirmatory test for HCV (for 
example, HCV polymerase chain reaction).  
10. Subject has received any live (includes attenuated) vac cination within the 8 weeks prior to 
the Baseline visit (eg, inactivated influenza and pneumococcal vaccines are allowed but nasal 
influenza vaccination is not permitted).  
11. Subject has received Bacillus Calmette -Guerin vaccinations within 1 year prior to th e 
Baseline visit.  
12. Subject has known tuberculosis (TB) infection, is at high risk of acquiring TB infection, or 
has current or history of nontuberculous mycobacterium (NTMB) infection. A subject with 
LTB (a positive interferon -gamma release assay [IGRA] and  diagnosis confirmed by TB 
specialist) may be rescreened once and enrolled after receiving at least 8  weeks of 
appropriate LTB infection therapy and if no evidence of therapy -related hepatotoxicity has 
occurred prior to the first injection (alanine aminotr ansferase [ALT]/aspartate 
aminotransferase [AST] remain ≤3 times upper limit of normal [ULN]).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 41 of 209 Subject has a past history of active TB involving any organ system unless adequately treated 
according to World Health Organization/Centers for Disease Control ( CDC) therapeutic 
guidance and proven to be fully recovered upon consult with a TB specialist.  
Refer to Section  12.3.1  for details on determining full  TB exclusion criteria.  
13. Subject has a history of a lymphoproliferative disorder including lymphoma or current signs 
and symptoms suggestive of lymphoproliferative disease.  
14a.Subject has any active malignancy or history of malignancy within 5 years prior to the 
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell 
carcinoma, or in situ cervical cancer.  
15. Subject has a diagnosis of inflammatory conditions other than PSO or PsA, including but not 
limited to rheumatoid arthritis, sarcoidosis, or systemic lupus erythematosus. Subjects with a 
diagnosis of Crohn’s disease or ulcerative colitis are allowed as long as they have no active 
symptomatic disease at Screening or Baseline.  
16. Subject has had major surgery (including joint surgery) within the 3 months prior to the 
Baseline Visit, or has planned major surgery within 6 months after entering the study.  
17a.Subject has any systemic disease (ie, cardiovascular, neurological, renal, liver, metabolic, 
gastrointestinal, hematologica l, immunological, etc.) considered by the Investigator to be 
uncontrolled, unstable, or likely to progress to a clinically significant degree during the 
course of the study.  
18. Subject has had myocardial infarction or stroke within the 6 months prior to the Screening 
Visit.  
19. Subject has laboratory abnormalities at Screening, including any of the following:  
a. ≥3.0x ULN of any of the following: ALT, AST, alkaline phosphatase (ALP); or >ULN 
total bilirubin (≥1.5xULN total bilirubin if known Gilbert’s syndrome)  
b. Whit e blood cell (WBC) count <3.00x103/μL 
c. Absolute neutrophil count <1.5x103/μL 
d. Lymphocyte count <500 cells/μL  
e. Hemoglobin <8.5g/dL  
f. Any other laboratory abnormality, which, in the opinion of the Investigator, will prevent 
the subject from completing the study o r will interfere with the interpretation of the study 
results  
Individual screening tests for which the results are in error, borderline, or indeterminate 
for inclusion in the study can be repeated once for confirmation during the Screening 
Period. Upon ret esting, subjects whose results remain outside this threshold should not be 
randomized.  
20. Subject has any other condition, including medical or psychiatric, which, in the Investigator's 
judgment, would make the subject unsuitable for inclusion in the study.  
21. Criterion deleted.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 42 of 209 22. Criterion deleted.  
23. Subject has experienced primary failure (no response within 12 weeks) to 1 or more IL -17 
biologic response modifier (eg, brodalumab, ixekizumab, secukinumab) OR more than 1 
biologic response modifier other than an IL -17. 
24. Subject is taking PsA medications other than stable doses (ie, stable for at least 1 week prior 
to the Screening Visit) of nonsteroidal anti -inflammatory drugs (NSAIDs) or analgesics (see 
Section  7.8.1.2 ). 
25. Subject has a history of chronic alcohol or drug abuse within 6 months prior to Screening as 
evaluated by the Investigator based on medical history, site interview, and/or results of the 
specified urine drug screen.  
26. Presence of active suicidal ideation, or positive suicide behavior using the "Screening" 
version of the electronic Columbia Suicide Severity Rating Scale (eC -SSRS) and with either 
of the following criteria:  
 History of a suicide attempt w ithin the 5 years prior to the Screening Visit. Subjects with 
a history of a suicide attempt more than 5 years ago should be evaluated by a mental 
healthcare practitioner (HCP) before enrolling into the study.  
 Suicidal ideation in the past month prior to t he Screening Visit as indicated by a positive 
response ("Yes") to either Question 4 or Question 5 of the "Screening" version of the eC -
SSRS.  
27a.Subject has presence of moderately severe major depression or severe major depression, 
indicated by a score of ≥15using the screening PHQ -9. Medication used to treat depression 
should be stable for 8 weeks prior to Baseline.  
28. Subject is a member of Investigator site personnel directly affiliated with this study and/or 
their immediate families. Immediate family is de fined as a spouse, parent, child, or sibling, 
whether biological or legally adopted.  
29. Subject is a UCB employee or employee of third -party organizations involved in the study.  
30. Subject is taking or has taken prohibited psoriasis medications without meeting t he 
mandatory washout period relative to the Baseline Visit ( Table  7‒2). 
6.3 Withdrawal criteria  
Subjects are free to withdraw from the study at any time, without prejudice to their continued 
care. Subjects who withdraw from the study should complete the PEOT Visit (see Section  8.5). 
Subjects should be withdrawn from the study and will be encouraged to come back for the SFU 
visit 20  weeks after final dose of IMP if the subject withdraws his/her consent or the Sponsor or 
a regulatory agency request s withdrawal of the subject.  
A subject should be withdrawn from IMP and will be asked to come back for the SFU visit 
20 weeks after final dose of IMP if any of the following events occur:   
1. Subject develops an illness that in the opinion of the Investigator  would interfere with his/her 
continued participation if the risk of continuing participation outweighs the potential benefit.  
2. Subject develops erythrodermic, guttate, or pustular form of PSO.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 43 of 209 3. Criterion deleted.  
4. Subject is noncompliant with the study proce dures or medications in the opinion of the 
Investigator.  
5. Subject uses prohibited concomitant medications, with the exception of topicals, as defined 
in this protocol ( Section  7.8.2 ), that may present a risk to the safety of the subject or the 
integrity of the study data, in the opinion of the Investigator and/or the Medical Monitor.  
6. Subject has a clinical laboratory value meeting any of the following criteria:  
a. Hepatotoxicity as described in Section  6.3.1   
b. A laboratory value meeting any of the following criteria:  
◦ Absolute neutrophil count <1.0x103/μL 
◦ Absolute lymphocyte count <0.2x103/μL 
Subjects may remain in the study if the result is transient. A retest is required within 1 to 
2 weeks at a scheduled or unscheduled visit. If the repeat absolute neutrophil count or 
absolute lymphocyte count is sti ll below the allowable values, the subject must be 
withdrawn. If the repeat absolute neutrophil count or absolute lymphocyte count is above 
the allowable values, the subject may continue in the study.  
7. The subject experiences a severe AE, an SAE, or a clini cally significant change in a 
laboratory value that, in the opinion of the Investigator, merits the discontinuation of the 
investigational product and appropriate measures being taken.  
8. Criterion deleted.  
9. There is confirmation of a pregnancy during the stud y, as evidenced by a positive pregnancy 
test (see Section  12.1.4  for more information regarding pregnancies).  
10. A subject considered as having either a suspected new LTB infection or who develops active 
TB or NTMB infection during the study (including but no t limited to, conversion 
demonstrated by IGRAs or other diagnostic means) must be immediately discontinued from 
IMP and a PEOT Visit must be scheduled as soon as possible, but not later than the next 
regular visit.  
The subject must be permanently withdrawn  if further examinations result in a diagnosis of 
active TB, or if the subject is diagnosed with latent TB infection (LTBI) with no initiation of 
prophylactic treatment, prematurely discontinues prophylactic treatment, or, in the opinion of 
the Investigato r or Sponsor, is noncompliant with prophylactic TB therapy.  
Confirmed active TB is an SAE and must be captured on an SAE Report Form and provided 
to the Sponsor in accordance with SAE reporting requirements. As with all SAEs, periodic 
follow -up reports sho uld be completed as per protocol requirements until such time as the TB 
infection resolves.  
Additional information on TB policies is provided in Section  12.3.1 . 
11. Subjects with newly diagnosed IBD or with IBD flares during the study must:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 44 of 209  Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist  
 Discontinue IMP and be followed -up until resolution of active IBD symptoms  
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
the Medical Monitor and UCB study physician to confirm the su bject’s suitability for 
continued participation in the study.  
12. Subjects must be referred  immediately to a mental health care professional and may be 
withdrawn from the study based upon the Investigator’s judgment of benefit/risk for:  
 Active suicidal ideatio n as indicated by a positive response (“Yes”) to Question 4 of the 
“Since Last Visit” version of the eC -SSRS  
 Moderately severe major depression as indicated by a PHQ -9 score of 15 to 19 if this 
represents an increase of 3 points compared to last visit.  
13. Subjects must be referred immediately to a mental healthcare professional and must be 
withdrawn in case of:  
 Active suicidal ideation as indicated by a positive response (“Yes”) to Question 5 of the 
“Since Last Visit” version of the eC -SSRS  
 Any suicidal behavi or since last visit.  
 Severe major dep ression as indicated by a PHQ -9 score ≥20  
The mental health consultation must be recorded in source documentation.  
Investigators should attempt to obtain information on subjects in the case of withdrawal or 
discontinuat ion. For subjects considered as lost to follow -up, the Investigator should make an 
effort (at least 1 phone call and 1 written message to the subject), and document his/her effort 
(date and summary of the phone call and copy of the written message in the s ource documents), 
to complete the final evaluation. All results of these evaluations and observations, together with a 
narrative description of the reason(s) for removing the subject, must be recorded in the source 
documents. The electronic Case Report For m (eCRF) must document the primary reason for 
withdrawal or discontinuation.  
Investigators should contact the Medical Monitor, whenever possible, to discuss the withdrawal 
of a subject in advance.  
6.3.1  Potential drug -induced liver injury IMP discontinuation cri teria  
Subjects with potential drug -induced liver injury (PDILI) must be assessed to determine if IMP 
must be discontinued. In addition, all concomitant medications and herbal supplements that are 
not medically necessary should also be discontinued.  
The PDI LI criteria below require immediate and permanent discontinuation of IMP for subjects 
with either of the following:  
 ALT or AST ≥ 8xULN  
 ALT or AST ≥3xULN and coexisting total bilirubin ≥2xULN  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 45 of 209 The PDILI criterion below requires immediate discontinuation of I MP for:  
 Subjects with ALT or AST ≥3xULN who exhibit temporally associated symptoms of 
hepatitis or hypersensitivity. Hepatitis symptoms include fatigue, nausea, vomiting, right 
upper quadrant pain or tenderness. Hypersensitivity symptoms include fever (wit hout clear 
alternative cause), rash, or eosinophilia (ie, >5%).  
If a nondrug -related cause for the symptoms can be confirmed, these subjects may resume 
IMP administration after discussion with the responsible UCB physician, but only when the 
requirements for rechallenge with IMP as provided in Section  12.2.1.2.1  are followed.  
The PDILI criterion below allows for subjects to continue on IMP at the discretion of the 
Investigator.  
 Subjects with ALT or AST ≥5xULN and < 8xULN, total bilirubin <2xULN, and no 
eosinophilia (ie, ≤5%), with no fever, rash, or symptoms of hepatitis (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness).  
Evaluation of PDILI must be initiated as described in Section  12.2.1  with repeat tests 
performed in 2 weeks. Upon re -test, if ALT or AST values have reduced to <5xULN, the 
subject can continue with the study. However, if A LT or AST remains ≥5xULN and 
<8xULN after re -test, IMP should be temporarily withheld and subject should undergo a 
repeat test in two weeks. If ALT or AST values remain ≥5xULN even after the second re -
test, then the subject should be permanently withdrawn from the study and should be 
followed for possible drug -induced liver injury.  
If subjects are unable to comply with the applicable monitoring schedule, IMP must be 
discontinued immediately.  
Investigators should attempt to obtain information on subjects in the case of IMP discontinuation 
to complete the final evaluation. Subjects with PDILI should not be withdrawn from the study 
until investigation and monitoring are complete. All results of these evaluations and 
observations, as well as the reason(s) for IM P discontinuation and subject withdrawal (if 
applicable), must be recorded in the source documents. The eCRF must document the primary 
reason for IMP discontinuation.  
7 STUDY TREATMENT(S)  
7.1 Description of investigational medicinal product(s)  
The IMPs used in this study are bimekizumab and placebo.  
 Bimekizumab will be supplied in a  
 for sc 
injection.  
 Placebo will be supplied as 0.9% sod ium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 1mL PFS for sc injection.  
Further details of the IMPs and their specifications are provided in the IMP Handling Manual . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 46 of 209 7.2 Treatment(s) to be ad ministered  
Unblinded study staff will be responsible for preparation of the clinical trial material, including 
recording the administration information on source documents, and administration of the IMP as 
sc injections. The unblinded personnel will not be  involved in the study in any way other than 
assuring the medication is taken from the correct kit and administering the drug to the subjects.  
Suitable areas for sc injections are the lateral abdominal wall, upper outer thigh, or upper arm. 
During each dos ing visit, each of the injections should be administered at a separate injection 
site. Injection sites should be rotated at each visit and injections should not be given into a PSO 
plaque or areas where the skin is tender, bruised, erythematous, or indurat ed. The injection 
should last approximately 10 to 15 seconds.  
An IMP Handling Manual will be provided to each site containing instructions regarding drug 
preparation and dosing.  
Double -blind Initial Treatment Period dosing  
 Subjects randomized to receive bi mekizumab 320mg Q4W will receive 2 bimekizumab 
160mg injections sc Q4W.  
 Subjects randomized to receive placebo will receive 2 placebo injections sc Q4W.  
Randomized -Withdrawal Period dosing  
Investigational medicinal product treatment during the Randomized -Withdrawal Period will be 
based on treatment group assignment at randomization (see Section  5.2.3 ). 
 Subjects who are re -randomized to receive bimekizumab 320mg Q4W will receive 2 
bimekizumab 160mg injections sc Q4W.  
 Subjects re -randomized to receive bimekizumab 320mg Q8W will alternate between 
receiving bimekizumab (2 bimekizumab 160mg injections sc) followed 4 weeks later by 
placebo (2 placebo injections sc).  
 Subjects re -randomized to receive placebo will receive 2 placebo injections Q4W.  
 Subjects in the placebo treatment arm in the Initial Treatment Period who are ≥PASI90 at 
Week 16 and ≥PASI 75 at Week 20 or later will continue to receive plac ebo Q4W at 
Week  16 and later visits.  
Subjects who do not achieve a PASI90 response at Week  16 and all subjects who relapse at 
Week  20 or later during the Randomized -Withdrawal Period (up to Week  56) will receive open -
label bimekizumab 320mg Q4W for 12  week s (escape treatment, see Section  5.2.5 ). 
The dosing scheme is depicted in Table  7‒1.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 47 of 209 Table  7‒1: Dosing Scheme  
Week  
Dose Assignment  0 4 8 12 16 20 24 28 32 36 40 44 48 52 
Bimekizumab 320mg 
Q4W/Q4W  ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Bimekizumab 320mg 
Q4W/Q8W  ●● ●● ●● ●● ●● ○○ ●● ○○ ●● ○○ ●● ○○ ●● ○○ 
Bimekizumab 320mg 
Q4W/placebo  ●● ●● ●● ●● ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ 
Placebo  ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ 
n/a=not applicable; Q4W=every 4 weeks; Q8W=every 8 weeks  
Note: A bimekizumab 160mg injection is depicted by a black circle (●). A placebo injection is depicted by an open 
circle (○).  
Note: Subjects who do not achieve a ≥PASI90 response at Week  16 and all subjects who relapse (defined no t 
achieving a ≥PASI75 response at Week  20 or later) during the Randomized -Withdrawal Period (up to Week 52) 
will receive open -label bimekizumab 320mg Q4W for 12 weeks (ie, escape treatment). Subjects in the placebo 
treatment arm in the Initial Treatment Pe riod that are >PASI90 at Week 16 and >PASI 75 at Week 20 or later will 
continue to receive placebo Q4W at Week 16 and later visits.  
7.3 Packaging  
Bimekizumab and placebo will be packaged and labeled according to Good Manufacturing 
Practice (GMP) guidelines and  applicable laws or regulations. They will be suitably packaged in 
such a way as to protect the product from deterioration during transport and storage. Further 
information regarding storage and transport conditions are provided in the IMP Handling 
Manual.  
7.4 Labeling  
Bimekizumab and placebo will be labeled in accordance with the current International Council 
for Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and GMP and will include 
any locally required statements. If necessary, labels will be  translated into the local language.  
7.5 Handling and storage requirements  
Refer to the IMP Handling Manual for the storage conditions of the IMP.  
The Investigator (or designee) is responsible for the safe and proper storage of IMP at the site. 
Investigational  medicinal product stored by the Investigator is to be kept in a secured area with 
limited access according to the storage conditions mentioned on the label.  
Appropriate storage conditions must be ensured either by controlling the temperature (eg, room, 
refrigeration unit) or by completion of a temperature log in accordance with local requirements 
on a regular basis (eg, once a week), showing actual and minimum/maximum temperatures 
reached over the time interval.  
In case an out of range temperature is noted , it must be immediately reported as per instructions 
contained in the IMP Handling Manual.  
The IMP will be shipped to the study sites in temperature controlled containers. Out -of-range 
shipping or storage conditions must be brought to the attention of the  sponsor or designee, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 48 of 209 immediately. Authorization to use any out -of-range IMP must be documented and received prior 
to dispensing or administering the IMP at the study site.  
7.6 Drug accountability  
A Drug Accountability Form will be used to record IMP dispensin g and return information on a 
by subject basis and will serve as source documentation during the course of the study. Details of 
any IMP lost, damaged (eg, due to breakage or wastage), not used, partially used, disposed of at 
the study site, or returned to  the sponsor or designee must also be recorded on the appropriate 
forms. All supplies and pharmacy documentation must be made available throughout the study 
for UCB (or designee) to review.  
In order to maintain the blind, all IMP documentation (eg, shippin g receipts, drug accountability 
logs, Interactive Response Technology [IRT] randomization materials) must be maintained and 
accessed by unblinded, trained site personnel only. Designated, unblinded site personnel must be 
appropriately trained and licensed (per country guidelines) to administer injections.  
Blinded study staff may be delegated the responsibility to receive, inventory, and destroy the 
used kits. The packaging identifies each kit by a unique number that does not correlate to the 
contents and th erefore, does not unblind study site staff. Unblinded study staff will be 
responsible for preparation (breaking tamper proof sticker on kit, etc) of the clinical trial 
material, including recording the administration information on source document.  
The Investigator (or designee) is responsible for retaining all used, unused, and partially used 
containers of IMP until returned or destroyed.  
The Investigator may assign some of the Investigator’s duties for drug accountability at the study 
site to an approp riate pharmacist/designee.  
The Investigator must ensure that the IMP is used only in accordance with the protocol.  
Periodically, and/or after completion of the clinical phase of the study, all used (including empty 
containers)/partially used, unused, damag ed, and/or expired IMP must be reconciled and either 
destroyed at the site according to local laws, regulations, and UCB Standard Operating 
Procedures (SOPs) or returned to UCB (or designee). Investigational medicinal product intended 
for the study cannot be used for any other purpose than that described in this protocol.  
7.7 Procedures for monitoring subject compliance  
Investigational medicinal product will be administered in the clinic and compliance will be 
determined at the visit by study personnel. Drug ac countability must be recorded on the Drug 
Accountability Form.  
7.8 Concomitant medication(s)/treatment(s)  
Any treatment administered from the time of informed consent to the final study visit will be 
considered concomitant medication. This includes medications  that were started before the study 
and are ongoing during the study.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 49 of 209 7.8.1  Permitted concomitant treatments (medications and therapies)  
7.8.1.1  Topical medications  
Subjects may continue to use topical moisturizers or emollients, bath oils, or oatmeal bath 
preparations for skin conditions during the study, as needed. Over -the-counter shampoos for the 
treatment of PSO of the scalp are also permitted.  
Mild and low potency topical steroids will be permitted for use limited to the face, axilla, and/or 
genitalia, as needed. T hese topical medications should not be used within approximately 24 
hours prior to study visits requiring IGA and PASI measures.  
7.8.1.2  Other medications  
Subjects who are already receiving an established NSAID regimen for PsA or symptoms of 
arthritis and have bee n on a stable dose for at least 1 week prior to the Screening Visit may 
continue their use during the study. However, initiation of, or increase in dosage of NSAIDs 
during the study (especially in subjects with a history of gastrointestinal [GI] intoleranc e to 
NSAIDs or a history of GI ulceration) should not occur prior to Week  12 and should not happen 
within 2 weeks of the Week  56 Visit.  
Subjects may take mild pain relievers (acetaminophen/paracetamol, mild opiates) as needed for 
arthritis pain but prefera bly not within 24 hours of the Baseline and Week  56 Visits.  
Intra -articular steroid injections of any joint and hyaluronic acid injections are allowed after 
Week  12. 
Subjects who are receiving an established  regimen for depression should remain on stable d osing 
prior to Baseline and throughout the study.  
7.8.2  Prohibited concomitant treatments (medications and therapies)  
Table  7‒2 presents the list of prohibited PSO medications.  
Table  7‒2: Prohibited PSO medications  
Drug  Washout period relative to Baseline Visit  
Topicals except for those permitted ( Section  7.8.1.1 ) 2 weeks  
Systemic retinoids  3 months  
Systemic treatment (non -biological):  
systemic immunosuppressant agents (eg, 
methotrexate, cyclosporine, azathioprine, 
thioguanine)  
fumaric acid esters specifically used for the treatment 
of PSO  
systemic corticosteroids  
phototherapy  1 month  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 50 of 209 Table  7‒2: Prohibited PSO medications  
Drug  Washout period relative to Baseline Visit  
Anti-TNFs:  
etanercept (including biosimilar)  
infliximab (including biosimilar), golimumab,  
certolizumab pegol, adalimumab (including 
biosimilar)   
1 month for etanercept  
3 months for everything other than etanercept  
Other biologics and other systemic therapies, eg:  
ustekinumab  Any exposure for ustekinumab  
apremilast, tofacitinib  2 weeks for  apremilast and tofacitinib  
alefacept, efalizumab, guselkumab  3 months for alefacept, efalizumab, and 
guselkumab  
tildrakizumab, risankizumab  5 months for tildrakizumab and risankizumab  
briakinumab  6 months for briakinumab  
rituximab  12 months for rituxi mab 
Anti-IL-17 therapy:  
brodalumab  
ixekizumab  
secukinumab  3 months  
(bimekizumab is excluded per exclusion 
criteria)  
Any other antipsoriatic agent (systemic) under 
investigation (or approved after the protocol is approved)  3 months or 5 half -lives, whichever is greater  
Any other antipsoriatic agent (topical) under investigation  1 month  
IL-17=interleukin 17; PSO=psoriasis; TNF=tumor necrosis factor  
Subjects who take prohibited medications may be withdrawn from IMP but followed until the 
SFU Visit. T he decision to withdraw a subject for taking prohibited medications should be made 
in consultation with the Medical Monitor.  
7.8.2.1  Vaccines  
Administration of live (including attenuated) vaccines is not allowed during the conduct of the 
study and for 20 weeks aft er the final dose of IMP (see Exclusion Criterion # 10, Section  6.2). 
Administration of inactivated vaccines is allowed during the study at the discretion of the 
Investigator.  
7.9 Blinding  
All Sponsor and Investigator site personnel involved in the study will be blinded to the 
randomized IMP assignment with the following exceptions:  
 Unblinded study staff will be responsible for preparation (breaking t amper proof sticker on 
kit, etc) of the clinical trial material, including recording the administration information on 
source documents, and administration of the IMP as sc injections. The unblinded personnel 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 51 of 209 will not be involved in the study in any way ot her than assuring the medication is taken from 
the correct kit and administering the drug to the subjects.  
 Bioanalytical staff analyzing blood samples for bimekizumab and anti -bimekizumab 
antibody determination.  
During the study the Sponsor will provide bl inded and unblinded site monitors for the purposes 
of verifying safety, efficacy, and drug administration and documentation records. Unblinded 
study site personnel need to be available in order to resolve queries. Study monitors and study 
site personnel, b linded to treatment assignment, will not discuss or have access to any drug 
related information.  
Study sites will be required to have a written blinding plan in place, signed by the Principal 
Investigator, which will detail the site’s steps for ensuring th at the double -blind nature of the 
study is maintained. Sites will be instructed to keep study subjects blind to the IMP as detailed in 
the site blinding plan.  
Further details are provided in the study manual and site blinding plan.  
7.9.1  Procedures for maintaini ng and breaking the treatment blind  
7.9.1.1  Maintenance of IMP blind  
All subject treatment details (bimekizumab  or placebo) will be allocated and maintained by the 
IRT system.  
7.9.1.2  Breaking the treatment blind in an emergency situation  
The integrity of this clinical study must be maintained by observing the treatment blind. In the 
event of an emergency for which the appropriate treatment for a subject cannot be made without 
knowing the treatment assignment, it will be possible to determine to which treatment arm and 
dose the subject has been allocated by contacting the IRT. All sites will be provided with details 
of how to contact the system for code breaking at the start of the study. The Medical Monitor or 
equivalent should be consulted prior to unblinding, whenever possible.  
The Clinical Project Manager (CPM) will be informed immediately via the IRT when a code is 
broken, but will remain blinded to specific treatment information. Any unblinding of the IMP 
performed by the Investigator must be recorded in the source d ocuments and on the Study 
Termination eCRF page.  
7.10 Randomization and numbering of subjects  
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region ( North America, Western 
Europe, Central/Eastern Europe, and Asia/Australia) and prior biologic exposure (yes/no). The 
IRT will generate individual assignments for subject kits of IMP, as appropriate, according to the 
visit schedule.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 52 of 209 At Screening, each subj ect will be assigned a 5 -digit number that serves as the subject identifier 
throughout the study. The subject number will be required in all communication between the 
Investigator or designee and the IRT regarding a particular subject.  
At the Baseline Visi t, a subject will be randomized into the study. The Investigator or designee 
will use the IRT for randomization. The IRT will automatically inform the Investigator or 
designee of the subject’s identification number. The IRT will allocate kit numbers to the  subject 
based on the subject number during the course of the study. The kits are blinded.  
At Week  16, subjects who received bimekizumab Q4W during the Initial Treatment Period may 
be re -randomized to a new treatment group based on their PASI response.  
Subject numbers and kit numbers will be tracked via the IRT.  
8 STUDY PROCEDURES BY VISIT  
Table  5‒1 (Schedule of Study Assessments) provides a general overvi ew of study assessments. A 
list of procedures to be completed at each visit is described below.  
 From the Week 1 Visit to the Week 24 Visit, visit windows of ±3 days on either side of the 
scheduled dosing are permitted; however, the Investigator should try to keep the subjects on 
the original dosing schedule. From the Week 28 Visit to the Week 52 Visit, visit windows are 
±7 days. Changes to the dosing schedule outside of the visit window must be discussed with 
the Medical Monitor.  
 The dosing window is ±3 day s relative to the scheduled dosing visit through Week 24. The 
dosing window is ±7 days relative to the scheduled dosing visit from Week 28 through the 
end of the study.  
 For the SFU Visit (20 weeks after the final dose), the visit window is ±7  days relative  to the 
scheduled visit date.  
8.1 Screening Visit (2 to 5 weeks)  
Prior to any study specific activities, subjects will be asked to read, sign, and date an ICF that has 
been approved by the Sponsor and an Institutional Review Board (IRB)/Independent Ethics 
Comm ittee (IEC), and that complies with regulatory requirements. Subjects will be given 
adequate time to consider any information concerning the study given to them by the Investigator 
or designee. As part of the informed consent procedure, subjects will be gi ven the opportunity to 
ask the Investigator any questions regarding potential risks and benefits of participation in the 
study.  
Where local regulations permit, subjects will also be given the option to participate in the 
genomics, genetics, and proteomics substudy. Subjects agreeing to participate in the substudy 
will be required to complete a separate ICF. The ICF must be signed prior to collecting any 
samples for the substudy. The substudy will only be conducted where ethically accepted and 
authorized by the regulatory agencies. Refusal to participate in the substudy will not affect a 
subject’s ability to participate in the main PS0013 study.  
The following procedures/assessments will be performed at the Screening Visit:  
 Informed consent  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 53 of 209  Inclusion/exclusion  
 Urine drug screen  
 Demographic data (age, gender, race and ethnicity [ according to local regulations ]) 
 Psoriasis history including the date of onset and past treatments  
 Significant past medical history including clinically relevant past or coexisting medic al 
conditions and surgeries  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Vital signs (sitting systolic and diastolic blood pressure [BP), pulse rate, and body 
temperature) should be obtained prior to blo od sampling  
 Collection of blood and urine samples for the following clinical laboratory tests:  
 Hematology and biochemistry  
 Urinalysis  
 Serum pregnancy test  
 Hepatitis B and Hepatitis C  
 HIV 
 IGRA Tuberculosis test  
 Record 12 -lead ECG  
 Chest x -ray (not necessary if performed within 3 months prior to Screening Visit and report 
is available)  
 Tuberculosis questionnaire  
 PASI  
 IGA 
 Percentage of BSA  
 PHQ -9 
 eC-SSRS  
 Patient Symptom Diary (daily)  
 Concomitant medication  
 AEs 
 Confirm subject eligibility and contact IRT  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 54 of 209 8.2 Initial Treatment Period  
8.2.1  Baseline Visit  
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:  
 Inclusion/exclusion  
 Significant past medical history and concomitant diseases to ensure no significant changes 
since screening  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Height  
 Body weight  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of b lood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 Genetic/epigenetic analysis (participating subjects only)  
 Tuberculosis questionnaire  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 Patient Symptom Diary (daily ) 
 Scalp IGA  
 mNAPSI  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 55 of 209  pp-IGA 
 EQ-5D-3L 
 SF-36 
 PASE  
 PGADA  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab or placebo 
will occur.  
8.2.2  Weeks 1 and 2 ( ±3 days relative to Baseline)  
The following p rocedures/assessments will be performed/recorded:  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests  should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Bimekizumab plasma concentrations  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (Week  1 only) 
(participating subjects only)  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 eC-SSRS  
 Patient Symptom Diary (daily)  
 Scalp IGA for subjects with scalp involvement at Baseline  
 Concomitant medication  
 AEs 
 IRT 
8.2.3  Weeks 4 and 8 ( ±3 days relative to Baseline)  
The following procedures/assessments will be performed/recorded:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 56 of 209  Vital signs (sitting systo lic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urine pregn ancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (Week 8 only) 
(participating subjects only)  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 Patient Symptom Diary (daily)  
 Scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 PGADA (Week 4 only)  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab or placebo 
will occur.  
8.2.4  Week  12 (±3 days relative to Baseline)  
The following procedures/assessments will be performed/recorded:  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Body weight  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 57 of 209  Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood  and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidat e biomarker  analyses (participating 
subjects only)  
 Record 12 -lead ECG  
 Tuberculosis questionnaire  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 Patient Symptom Diary (daily)  
 Scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 PGADA for subjects with PsA at Baseline  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administratio n of bimekizumab or placebo.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 58 of 209 8.2.5  Week 16 ( ±3 days relative to Baseline)  
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 Patient Symptom Diary (daily)  
 Scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 PGADA for subjects with PsA at Baseline  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, the Randomized -Withdrawal Period will 
begin with administration of bimekizumab or placebo.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 59 of 209 8.3 Randomized -Withdrawal Period  
8.3.1  Weeks 20 and 24 ( ±3 days relative to Baseline) and Weeks 28, 32, 36,  
40, 44, 48, and 52 ( ±7 days relative to Baseline)  
The following procedures/assessments will be performed/recorded prior to administration of 
IMP:  
 Informed consent (to be completed for the open -label study, if applicable) (Week  52 only)  
 Physical exam inclu ding evaluation of signs and symptoms of active TB and risk for 
exposure to TB (Weeks 24, 36, and 48 only)  
 Body weight (Weeks 24, 36 , and 48  only)  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to  blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry (Weeks 20, 24, 32, 40, and 48 only)  
 Urinalysis (Weeks 24, 32 40, and 48 only)  
 Urine pregnancy test   
 Bimekizumab plasma concentrations (Weeks 20, 24, 36 , and 48  only)  
 Anti-bimekizumab antibodies (Weeks 20, 24, 36 , and 48  only)  
 Record 12 -lead ECG (Weeks 32  and 48 only)  
 IGRA Tuberculosis test (Week  52 only)  
 Tuberculosis questionnaire (Weeks 24, 36, and 48 only)  
 PASI  
 Percentage of BSA  
 IGA 
 DLQI (Weeks 20, 24, 32, 40, and 48 only)  
 PHQ -9 
 eC-SSRS  
 Scalp IGA for subjects with scalp involvement at Baseline (Weeks 20, 24, 32, 40, and 48 
only)  
 mNAPSI for subjects with nail involvement at Baselin e (Weeks 20, 24, 32, 40, and 48 only)  
 pp-IGA for subjects with palmoplantar involvement at Baseline (Weeks 20, 24, 32, 40, and 
48 only)  
 EQ-5D-3L (Weeks 24, 32, 40, and 48 only only)  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 60 of 209  SF-36 (Weeks 24, 32, 40, and 48 only only)  
 Patient Global Assessment of P SO (Weeks 24, 32, 40, and 48 only)  
 PGADA for subjects with PsA at Baseline (Weeks 24, 32, 40, and 48 only)  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab or placebo 
will occur.  
8.3.2  Week  56 (±3 days relative to Baseline)  
The following procedures/assessments will be performed/recorded:  
 Urine drug screen  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Body weight  
 Vital signs (sitting systolic  and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 Genetic/epigenetic analysis (participating subjects only)  
 Record 12 -lead ECG  
 Tuberculosis questionnaire  
 PASI  
 Percentage of BSA  
 IGA 
 DLQI  
 PHQ -9 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 61 of 209  eC-SSRS  
 Scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 Patient Global Assessment of PSO  
 PASE  
 PGADA for subjects with PsA at Baseline  
 Concomitant medication  
 AEs 
 Contact IRT  
8.4 Escape Treatment Period  
As described in Section  5.2.3 , subjects who do not achieve a PASI90 response at Week  16 and 
all subjects who relapse at Week 20 or later will be allocated to an escape arm and receive 
open -label bimekizumab 320mg Q4W for 12 weeks. (ie, escape treatment). Su bjects should 
complete all visit procedures for their scheduled treatment visit and then only complete unique 
procedures for the escape baseline visit. No duplicate assessments should be performed when a 
subject enters the escape arm.  
8.4.1  Escape Baseline Visit  
The following procedures/assessments will be performed/recorded:  
 Body weight  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 PASI  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 62 of 209  IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 Scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 Patient Global Assessment of PSO  
 PASE  
 PGADA for subjects with PsA at Baseline  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion of the above -mentioned procedures, administration of bimekizumab will occur.  
8.4.2  Escape Weeks 4 and 8 ( ±3 days)  
The following procedures or assessments will be performed/recorded prior to administration of 
IMP:  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine sa mples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 PASI  
 IGA 
 Percentage of BSA  
 DLQI  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 63 of 209  PHQ -9 
 eC-SSRS  
 Scalp IGA for  subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 PGADA for subjects with PsA at Baseline  
 Concomitant medication  
 AEs 
 Contact IRT  
After completion  of the above -mentioned procedures, administration of bimekizumab will occur.  
8.4.3  Escape Visit -Week  12/Premature End of Treatment ( ±3 days relative 
to Baseline)  
The following procedures or assessments will be performed/recorded:  
 Urine drug screen  
 Physical exam  including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Body weight  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samp les for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
 Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 Genetic/epigenetic analysis (participating subjects only)  
 Record 12 -lead ECG  
 IGRA Tuberculosis test  
 Tuberculosis questionnaire  
 PASI  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 64 of 209  IGA 
 Percentage of BSA  
 DLQI  
 PHQ -9 
 eC-SSRS  
 Scalp IGA for subjects with scalp involvement at Baseline  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline  
 EQ-5D-3L 
 SF-36 
 Patient Global Assessment of PSO  
 PASE  
 PGADA for subjects with PsA at Baseline  
 Concomitant medication  
 AEs 
 Contact IRT  
8.5 Premature End of Treatment Visit  
If a subject is withdrawn from the study:  
 The subject will be  withdrawn from IMP, will undergo the same assessments as the 
Week  56 visit ( see Section  8.3.2 ), and will enter the SFU Period.  
 The subject  will be encouraged to return for the SFU Visit (20 weeks after the last 
received dose; see Section  8.6). 
8.6 Safety Follow -Up Visit (20 weeks after fi nal dose, ±7 days)  
All subjects not continuing in the open -label study, including those withdrawn from IMP, will 
have a SFU Visit 20 weeks after their final dose of IMP.  
The following procedures/assessments will be performed/recorded:  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Vital signs (sitting systolic and diastolic BP, pulse rate, and body temperature) should be 
obtained prior to blood sampling  
 Collection of blood and urine samples for the f ollowing clinical laboratory tests should be 
obtained prior to dosing:  
 Hematology and biochemistry  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 65 of 209  Urinalysis  
 Urine pregnancy test  
 Bimekizumab plasma concentrations  
 Anti-bimekizumab antibodies  
 Tuberculosis questionnaire  
 PASI  
 IGA 
 Percentage of BSA  
 eC-SSRS  
 Concomitant medication  
 AEs 
 Contact IRT  
8.7 Unscheduled Visit  
At the Investigator’s discretion, an Unscheduled Visit may be completed at any time during the 
study but prior to the SFU Visit, if deemed necessary for the subject’s safety and well -being.  
If an Unsc heduled Visit is conducted due to safety or efficacy reasons, an eC -SSRS assessment 
will be performed with the subject during the visit. If an Unscheduled Visit is conducted for 
reasons other than safety or efficacy concerns (eg, repeated collection of a l aboratory specimen 
due to collection or analysis issues), an eC -SSRS will not be required at these visits.  
At this visit, any assessment may be performed, as needed, depending on the reason for the visit.  
9 ASSESSMENT OF EFFICA CY 
The PASI, BSA, IGA, scalp IG A, mNAPSI, and pp -IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training on how to perform these 
assessments correctly. The same assessor should evaluate the subject at each assessment.  
9.1 Psoriasis Area and Severity Index  
The PASI is the most commonly used and validated assessment for grading the severity of PSO 
in clinical studies (Feldman, 2004). The PASI quantifies the severity and extent of the disease 
and weighs these with the percentage of BSA involvement.  
The percent area of involvement (BSA%) is estimated across 4 body areas; head, upper 
extremities, trunk, and lower extremities. Assessors will enter the degree of i nvolvement for a 
given region on a scale of 0 to 6 (0=none; 1=1% to <10% affected, 2=10% to <30% affected, 
3=30% to <50% affected, 4=50% to <70% affected, 5=70% to <90% affected, 6=90% to 100% 
affected) (Table  9‒1). 
The Investigator assesses the average redness, thickness, and scaliness of lesions in each body 
area (each on a 5 -point scale); 0=none, 1=slight, 2=moderate, 3=marked, and 4=very marked.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 66 of 209 The PASI score ranges from 0 to 72 with a higher score indicating increased disease severity.  
Table  9‒1: Body areas for calculation of percent BSA for PASI  
Body area  Detail s of area  BSA  Degree of 
involvement of 
body areaa 
Head  Face, back of head  10%  0 to 6  
Upper extremities  Left, right, upper lower, flexor 
surface, extensor surface  20%  0 to 6  
Trunk  Front, back, groin  30%  0 to 6 
Lower extremities  Left, right, upper lower, flexor 
surface, extensor surface, including 
buttocks  40%  0 to 6  
Total   100%   
BSA=body surface area; PASI=Psoriasis Area and Severity Index  
a Where 0=none; 1=1% to <10% affected; 2=10% to <30% affected; 3=30% to <50% affected; 4=50% to <70% 
affected; 5=70% to <90% affected; 6=90% to 100% affected  
The PASI50, PASI75, PASI90, and PASI100 responses are based on at least 50%, 75%, 90%, 
and 100% impr ovement in the PASI score, respectively.  
The total BSA affected by PSO will be entered as a percentage from 0 to 100.  
The PASI will be completed at the visits specified in Table  5‒1 and Table  5‒2. 
9.2 Investigator’s Global Assessment  
A static IGA for PSO will be used to assess disease severity in all subjects during the study. The 
IGA will be completed at the visits specified in in Table  5‒1 and Table  5‒2. 
The Investigator will assess  the overall severity of PSO using the following 5 -point scale 
presented in Table 9 -2. 
Table  9‒2: Five-point Investigator’s Global Assessment  
Score  Short descriptor  Detailed descriptor  
0 Clear  No signs of psoriasis; post -inflammatory hyperpigmentation may be present  
1 Almost clear  No thickening; normal to pink coloration; no to minimal focal scaling  
2 Mild  Just detectable to mild thickening; pink to light red coloration; 
predominately fine scaling  
3 Moderate  Clearly distinguishable to moderate thickening; dull to bright red; moderate 
scaling  
4 Severe  Severe thickening with hard edges; bright to deep dark red coloration; 
severe/coarse scaling covering almost all or all lesions  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 67 of 209 9.3 Dermatology Life Quality Index  
The DLQI is a questionnaire designed for use in adult subjects with PSO. The DLQI is a skin 
disease -specific questionnaire aimed at the evaluation of how symptoms and treatment affect 
subjects’ health rela ted QOL. This instrument asks subjects about symptoms and feelings, daily 
activities, leisure, work and school, personal relationships and treatment. It has been shown to be 
valid and reproducible in subjects with PSO. The DLQI score ranges from 0 to 30 wi th higher 
scores indicating lower health related QOL. A 4 -point change in the DLQI score (DLQI 
response) has been reported to be meaningful for the subject (within -subject minimal important 
difference); while a DLQI absolute score of 0 or 1 indicates no or  small impact of the disease on 
health related QOL. Subjects will be asked to complete the DLQI as outlined in the Schedule of 
Study Assessments in Table  5‒1 and Table  5‒2. 
9.4 Patient Health Questionnaire 9  
The PHQ -9 is a multipurpose instrument for screening, diagnosing, monitoring, and measuring 
the sev erity of depression (Kroenke et al, 2001). The PHQ -9 scores for depression range from 0 
to 27, with higher scores indicating worse state. A score of 5 to 9 is considered to be minimal 
symptoms of depression. A score of 10 to 14 is considered to be minor de pression, dysthymia, or 
mild major depression. A score of 15 to 19 is considered to indicate moderately severe major 
depression, and a score ≥20 is considered to be severe major depression.  
The PHQ -9 will be assessed at the visits specified in Table  5‒1 and Table  5‒2. 
Refer to Section  6.3 for PHQ -9-related withdrawal criteria.  
9.5 Scalp IGA  
A static IGA for scalp PSO will be used to assess disease severity on the scalp.  
All subjects will complete the scalp IGA at Baseline. Only subjects with scalp involvement at 
Baseline will complete the scalp IGA at the other visits specified in in Table  5‒1 and Table  5‒2. 
Subjects with scalp involvement at Baseline are defined as those with a scalp IGA score >0 at 
Baseline.  
Scalp le sions will be assessed in terms of clinical signs of redness, thickness, and scaliness using 
a 5-point scale Table  9‒3. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 68 of 209 Table  9‒3: Scalp IGA  
Score  Short Descriptor  Detailed Descriptor  
0 Clear  Scalp has no signs of PSO; post -inflammatory hyperpigmentation may 
be present  
1 Almost clear  Scalp has no thickening; normal to pink coloration; no to minimal focal 
scaling  
2 Mild  Scalp has just detectable to mild thickening; pink to light red coloration; 
predominately fine scaling  
3 Moderate  Scalp has clearly distinguishable to moderate thickening; dull to bright 
red, moderate s caling  
4 Severe  Scalp has severe thickening with hard edges; bright to deep dark red 
coloration; severe/coarse scaling covering almost all or all lesions  
PSO=psoriasis; scalp IGA=scalp -specific Investigator’s Global Assessment  
9.6 mNAPSI  
Psoriatic nail disease will be evaluated using the mNAPSI. All affected nails will be scored 
(0 to 3) for onycholysis/oil drop dyschromia, nail plate crumbling, and pitting and will be scored 
(0 for “no” or 1 for “yes”) for leukonychia, nail bed hyperkeratosis, splinter hemorrhages and red 
spots in the lunula. The score for an individual nail ranges from 0 to 13 with higher scores 
indicative of more severe nail disease. The total mNAPSI score is the sum of the scores for each 
individual nail. If a nail is unaffected, it w ill be recorded as such and will not contribute to the 
total mNAPSI score. Subjects with nail disease at Baseline are defined as those with a mNAPSI 
score >0 at Baseline.  
The mNAPSI will be assessed at the visits specified in Table  5‒1 and Table  5‒2. 
9.7 pp-IGA 
A static IGA for palmoplantar PSO will be use d to assess palmoplantar disease severity.  
All subjects will complete the pp -IGA at Baseline. Only subjects with palmoplantar involvement 
at Baseline will complete the pp -IGA at the other visits specified in in Table  5‒1 and Table  5‒2. 
Subjects with palmoplantar involvement at Baseline are defined as those with a pp -IGA score >0 
at Baseline.  
Palmoplantar disease will be assessed in terms of clinical signs of redness, thickness, and 
scaliness using a 5 -point scale ( Table  9‒4). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 69 of 209 Table  9‒4: pp-IGA 
Score  Short Descriptor  Detailed Descriptor  
0 Clear  Palmoplantar areas have no signs of PSO; post -inflammatory 
hyperpigmentation may be present  
1 Almost clear  Palmoplantar areas have no thickening; normal to pink coloration; no to 
minimal focal scaling  
2 Mild  Palmoplantar areas have just detectable to mild thickening; pink to light 
red coloration; predominately fine scaling  
3 Moderate  Palmoplantar areas have clearly distinguishable to moderate thickening; 
dull to bright red and clearly distinguishable coloration; moderate 
scaling  
4 Severe  Palmoplantar  areas have severe thickening with hard edges; bright to 
deep dark red coloration; severe/coarse scaling covering almost all or 
all lesions; numerous fissures  
PSO=psoriasis; pp -IGA=palmoplantar -specific Investigator’s Global Assessment  
9.8 Euro Quality of Life 5 -Dimensions, 3 -Level  
The Euro Quality of Life 5 -Dimensions 3 -Level (EQ -5D-3L) health questionnaire provides a 
descriptive profile and a single index value for health status. The instrument is comprised of a 
5-item health status measure and a VAS. The  EQ-5D-3L VAS records the respondent’s self -rated 
health status on a vertical 20cm scale, graduated from 0 to 100 (0=worst imaginable health 
status, 100=best imaginable health status).  
The EQ -5D-3L will be assessed at the visits specified in Table  5‒1 and Table  5‒2. 
9.9 36-Item Short Form Health Survey  
The SF -36 (Version 2, standard recall) is a 36 -item generic health related QOL instrument that 
uses a recall period of 4 weeks. Items are grouped into 8 doma ins as follows: Physical 
Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), 
Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 
items), and 1 item for perceived stabili ty or change in health (Health Transition) during the last 
year. The concepts represented by these domains contribute to physical, mental, and social 
aspects of health -related QOL. In addition to domain scores, the PCS and MCS scores are 
calculated from th e 8 domains (excluding the Health Transition item). Component scores 
appreciate the impact of each domain on physical and mental health status (Maruish, 2011). Each 
of the 8 domain scores and the component summary scores range from 0 to 100, with a higher 
score indicating a better health status. The domains and the 2 component summary scores are 
standardized with a mean of 50 and a standard deviation (SD) of 10 in the general USA 
population. The minimally important differences (MIDs), in terms of T -score po ints at a group 
level, for SF -36 domains and component summaries are the following: PCS, 2; MCS, 3; Physical 
Functioning, 3; Role Physical, 3; Bodily Pain, 3; General Health, 2; Vitality, 2; Social 
Functioning, 3; Role Emotional, 4; and Mental Health, 3.  
The SF -36 will be completed by the subject at the visits specified in Table  5‒1 and Table  5‒2. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 70 of 209 9.10 Patient Global Assessment of psoriasis  
The Patient Global Assessment of PSO is a PSO -specific item in which the patient responds to 
the multiple -choice question, “How severe are your psoriasis -related symptoms right now?” 
Possible responses to the question are “no symptoms,” “mild symptoms,” “moderate symptoms,” 
“severe symptoms,” or “very severe symptoms.”  
The Patient Global Assessment of PSO will be performed as part of the patient symptoms diary 
from Screenin g through the Initial Treatment Period.  
During the Randomized -Withdrawal Period, this assessment will be completed at the visits 
specified in Table  5‒1. 
During escape treatment, this assessment will be completed at the visits specified in Table  5‒2. 
9.11 Patient Symptom Diary responses  
UCB developed a new PRO measure that will be used to assess key symptoms relevant to 
patients with moderate to severe chronic plaque PSO. PS0010 used the draft PRO measure in 
selected countries to enable psychometric validation of the PRO. Site staff will train the 
participat ing subjects on the use of the electronic PRO (ePRO) diary at the Screening Visit, 
following which the device will be dispensed to the subject for home use until the Week  16 Visit. 
The ePRO diary will be administered on a daily basis from Screening to the Week  16 Visit.  
The ePRO diary will also administer the patient global assessment of psoriasis as noted above 
appropriate anchor items at the end of every study week. The ePRO diary software will be 
programmed such that the subjects will be given a window of opportunity to complete the ePRO 
diary. The data collected on the ePRO diary will be uploaded to a central server database and 
will be 21 CFR Part 11 compliant. Appropriate GCP procedures (including subject/site training 
and testing) will be performed a t the study sites.  
The Patient Symptom Diary responses for itch, pain, and scaling at Week 16 will be computed 
based on the responder definition as well as the absolute and percent change from Baseline. Each 
of the Patient Symptom Diary response scores inc luded in the statistical testing procedure (itch, 
pain, and scaling) will be characterized in terms of the cumulative percent of subjects 
demonstrating a pre -specified point improvement at Week 16. The threshold for the Patient 
Symptom Diary response score  of itch, pain, and scaling is 2.39, 1.98, and 2.86, respectively. 
The responder analysis will be limited to the subjects with a Baseline Patient Symptom Diary 
response score at or above the applicable threshold score (ie, at least 2.39, 1.98, and 2.86 for  itch, 
pain, and scaling, respectively).  
9.12 PASE questionnaire  
The PASE questionnaire is a self -administered tool to screen for active PsA in patients with PSO 
(Husni et al, 2014). The questionnaire consists of 15 items that are divided into a 7 -item 
symptoms  subscale and an 8 -item functions subscale. Standardized responses are based on 5 
categories relating to agreement (strongly agree [5], agree [4], no idea [3], disagree [2], and 
strongly disagree [1]). The total maximum score is 75 points (symptom score: 3 5 points and 
function score: 40 points). Psoriatic Arthritis Screening and Evaluation questionnaire scores ≥47 
points are indicative of active PsA.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 71 of 209 If a subject with a PASE score ≥47 points is referred to a rheumatologist, the referral will be 
recorded in the eCRF. Subjects with PsA, defined as a past medical history of PsA or PASE ≥47, 
are required to receive the additional PsA assessments as noted in Section  9.13. 
The PASE questionnaire will be completed at the visits specified in Table  5‒1 and Table  5‒2. 
9.13 PGADA for arthritis visual analog scale  
The PGADA for the arthritis VAS will be used to provide an overall evaluation of arthritis 
disease symptoms. Subjects will respond to the question, “Consi dering all the ways your arthritis 
affects you, please mark a vertical line on the scale below to show how you are feeling today,” 
“using a VAS where 0 is “very good, no symptoms” and 100 is “very poor, severe symptoms.”  
All subjects will complete the PGAD A at Baseline. Subjects with PsA at Baseline (defined as a 
past medical history of PsA or PASE ≥47) will complete the PGADA at the visits specified in 
Table  5‒1 and Table  5‒2. 
10 ASSESSMENT OF PHARMA COKINETIC AND 
PHARMACOGENOMIC VARI ABLE(S)  
10.1 Pharmacokinetic variables  
Blood samples for measurement of PK assessments ( Section  4.3.3 ) will be collected at the time 
points specified in the schedule of study assessments ( Table  5‒1 and Table  5‒2). 
At dosing visits, blood samples will be drawn prior to dosing, and will be drawn at the same time 
of the sampling for clini cal laboratory tests. The time and date of collection will be recorded in 
the eCRF.  
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. Detailed information on samp le analysis will be 
provided in a bioanalytical report.  
10.2 Pharmacogenomic variables  
A separate ICF will be required for those subjects who agree to participate in the genomics, 
genetics, and proteomics substudy, and must be signed prior to collection of any samples for the 
substudy. The substudy will only be conducted where ethically accepted and authorized by the 
regulatory agencies. Refusal to participate in the substudy will not affect a subject’s ability to 
participate in the main study.  
These analyses wi ll enable evaluation of biomarkers relative to disease biology and progression, 
drug treatment, and inflammatory and immune response processes. The nature and format of 
these tentative analyses will be determined at a later date.  
For individuals consenting  to the genomics, genetics, and proteomics substudy, blood samples 
will be drawn for exploratory genetic/epigenetic, genomic, proteomic, and metabolomics 
analysis and for candidate exploratory biomarker analyses. Candidate exploratory biomarker 
evaluations  may include, but are not limited to, IL -17A/IL17 -F pathway signaling and PSO 
biology (eg, IL -17A, IL -17F, IL -23, IL -6, tumor necrosis factor, dendritic cell -specific 
transmembrane protein, and circulating osteoclast precursors).  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 72 of 209 Collection of these sample s will occur at the time points specified in the schedule of study 
assessments ( Table  5‒1 and Table  5‒2). At dosing visits, blood samples will be drawn prior to 
dosing, and will be drawn at the same time of the sampling for clinical laboratory tests. The time 
and date of collection will be reco rded in the eCRF. The samples will be stored at -80°C at the 
central biorepository for up to 20 years.  
Instructions pertaining to sample collection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. Detailed information on sample analysis will be 
provided in a bioanalytical report.  
11 ASSESSMENT OF IMMUNO LOGICAL VARIABLE(S)  
Blood samples for measurement of antibodies to bimekizumab will be collected at the visits 
specified in Table  5‒1 and Table  5‒2. The threshold for antibody positivity will be defined prior 
to analysis.  
At dosing visits, blood samples will be drawn prior to dosing, and will be drawn at the same time 
of the sampling for clinical laboratory tests. The time and date of collection will be recorded in 
the eCRF.  
Instructions pertaining to sample co llection, processing, storage, labeling, and shipping are 
provided in the laboratory manual for this study. The presence of antibodies to bimekizumab will 
be determined using a validated bioanalytical method. Detailed information on sample analysis 
will be  provided in a bioanalytical report.  
12 ASSESSMENT OF SAFETY  
12.1 Adverse events  
12.1.1  Definitions  
12.1.1.1  Adverse event  
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product that does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
medicinal (investigational) product, whether or no t related to the medicinal (investigational) 
product.  
In order to ensure complete safety data collection, all AEs occurring during the study (ie,  after 
the signing of the ICF), including any pretreatment and posttreatment periods required by the 
protocol, must be reported in the eCRF even if no IMP was taken but specific study procedures 
were conducted. This includes all AEs not present prior to the initial visit and all AEs that 
recurred or worsened after the initial visit.  
Signs or symptoms of the conditi on/disease for which the IMP is being studied should be 
recorded as AEs only if their nature changes considerably or their frequency or intensity 
increases in a clinically significant manner as compared to the clinical profile known to the 
Investigator fro m the subject’s history or the Baseline Period.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 73 of 209 12.1.1.2  Serious adverse event  
Once it is determined that a subject experienced an AE, the seriousness of the AE must be 
determined. An SAE must meet 1 or more of the following criteria:  
 Death  
 Life-threatening  
(Life -threatening does not include a reaction that might have caused death had it occurred in 
a more severe form.)  
 Significant or persistent disability/incapacity  
 Congenital anomaly/birth defect (including that occurring in a fetus)  
 Important medical event that, based upon appropriate medical judgment, may jeopardize the 
patient or subject and may require medical or surgical intervention to prevent 1 of the other 
outcomes listed in the definition of serious  
(Important medical events may include, but are not limite d to, potential Hy’s Law [see 
Section  12.1.1.3 ], allergic bronchospasm requiring intensive treatment in an emergency room 
or at home, blood dyscrasias that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse.)  
 Initial inpatient hospitalization or prolongation of hospitalization  
(A patient admitted to a hospital, even if he/she is released on the same day, meets the 
criteria for the initial inpatient hospitalization. An emergency room visit that r esults in 
admission to the hospital would also qualify for the initial inpatient hospitalization criteria. 
However, emergency room visits that do not result in admission to the hospital would not 
qualify for this criteria and, instead, should be evaluated for 1 of the other criteria in the 
definition of serious [eg,  life-threatening adverse experience, important medical event].  
Hospitalizations for reasons not associated with the occurrence of an AE [eg,  preplanned 
surgery or elective surgery for a pre -existing condition that has not worsened or manifested 
in an unusual or uncharacteristic manner] do not qualify for reporting. For example, if a 
subject has a condition recorded on his/her medical history and later has a preplanned surgery 
for this condition, it is not appropriate to record the surgery or hospitalization as an SAE, 
since there is no AE upon which to assess the serious criteria. Please note that, if the 
pre-existing condition has worsened or manifested in an unusual or uncharacteristic manner, 
this would then qualify as an AE and, if necessary, the seriousness of the event would need to 
be determined.)  
Confirmed active TB must be reported as an SAE. The Investigator is to complete and submit the 
TB Follow -Up Form provided.  
12.1.1.2.1  Anticipated serious adv erse events  
The following Anticipated SAEs are anticipated to occur in the population studied in this 
protocol at some frequency that is independent of drug exposure.  
This list does not change the Investigator’s obligation to report all SAEs (including Ant icipated 
SAEs) as detailed in Section  12.1. 2.3. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 74 of 209 Table  12‒1: Anticipated serious adverse events for the population of subjects 
with moderate to severe chronic plaque psoriasis  
MedDRA® system order class  MedDRA preferred term  
Skin and subcutaneous tissue disorders  Any psoriatic condition HLT  
Musculoskeletal and connective tissue disorders  Psoriatic arthropathy  
HLT=High Level Term; MedDRA=Medical Dictionary for Regulatory Activities; SAE=serious adverse event  
Note: Exception: Listed events will not be regarded as anticipated SAEs if they are life threatening or if they result 
in the death of the study subject.  
12.1.1.3  Adverse events of special interest  
An AE of special interest (AESI) is any AE that a regulatory authority has mandated be reported 
on an expedited basis, regardless of the seriousness, expectedness, or relatedness of the AE to the 
administration of a UCB product/compound.  
Potential Hy’s Law, defined as ≥3xULN ALT or AST with coexisting ≥2xULN total bilirubin in 
the absence of ≥2xULN ALP, with no alternative explanation for the biochemical abnormality, 
must ALWAYS be reported to UCB as an AESI (ie, without waiting for any additional etiologic 
investigations to have been concluded). Follow -up information should then be reported if an 
alternative etiology is identified during investigation and monitoring of the subject.  
12.1.1.4  Other safety topics of interest  
Pre-specified safety topics of interest for the study are: infections (serious, opportunistic, fungal, 
and TB), neutropenia, hypersensitivity, suicidal ideation and behavior, depression, major 
cardiovascular eve nts, liver function test changes/enzyme elevations, malignancies, and 
inflammatory bowel diseases (with gastroenterology referral, as appropriate) . This is based on 
findings from the IMP clinical program to date, potential risks generally associated with biologic 
immunomodulators, or findings from other medicines with a related mechanism of action.gs. 
There are no specific AE reporting requirements for these topics, however special monitoring, 
additional data collection activities, and/or enhanced signal d etection activities (within UCB) are 
in place.  
12.1.2  Procedures for reporting and recording adverse events  
The subject will be given the opportunity to report AEs spontaneously. A general prompt will 
also be given at each study visit to detect AEs. For example:  
“Did you notice anything unusual about your health (since your last visit)?”  
In addition, the Investigator should review any self -assessment procedures (eg,  diary cards) 
employed in the study.  
12.1.2.1  Description of adverse events  
When recording an AE, the Investi gator should use the overall diagnosis or syndrome using 
standard medical terminology, rather than recording individual symptoms or signs. The eCRF 
and source documents should be consistent. Any discrepancies between the subject’s own words 
on his/her own records (eg,  diary card) and the corresponding medical terminology should be 
clarified in the source documentation.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 75 of 209 When recording the severity of an AE in the eCRF (ie, mild, moderate, or severe), the 
Investigator may refer to the Common Terminology Crite ria for Adverse Events (CTCAE) 
Version 4 (http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm) for 
additional guidance as needed. Details for completion of the Adverse Event eCRF (including 
judgment of relationship to IMP) are descri bed in the eCRF Completion Guidelines.  
12.1.2.2  Rule for repetition of an adverse event  
An increase in the intensity of an AE should lead to the repetition of the AE being reported with:  
 The outcome date of the first AE that is not related to the natural course of the disease being 
the same as the start date of the repeated AE, and the outcome of “worsening”  
 The AE verbatim term being the same for the first and repeated AE, so that the repeated AE 
can be easily identified as the worsening of the first one  
12.1.2.3  Additional  procedures for reporting serious adverse events  
If an SAE is reported, UCB must be informed within 24 hours of receipt of this information by 
the site (see contact information for SAE reporting listed in the Serious Adverse Event Reporting 
section at the front of the protocol). The Investigator must forward to UCB (or its representative) 
a duly completed “Investigator SAE Report Form for Development Drug” (SAE Report Form) 
provided by UCB, even if the data are incomplete, or if it is obvious that more data  will be 
needed in order to draw any conclusions. Information recorded on this form will be entered into 
the global safety database.  
An Investigator SAE Report Form will be provided to the Investigator. The Investigator SAE 
Report Form must be completed in  English.  
It is important for the Investigator, when completing the SAE Report Form, to include the 
assessment as to a causal relationship between the SAE and the IMP administration. This insight 
from the Investigator is very important for UCB to consider in assessing the safety of the IMP 
and in determining whether the SAE requires reporting to the regulatory authorities in an 
expedited manner.  
Additional information (eg,  autopsy or laboratory reports) received by the Investigator must be 
provided within 2 4 hours. All documents in the local language must be accompanied by a 
translation in English, or the relevant information included in the same document must be 
summarized in the Investigator SAE Report Form.  
The Investigator is specifically requested to co llect and report to UCB (or its representative) any 
SAEs (even if the Investigator is certain that they are in no way associated with the IMP), up to 
30 days from the end of the study for each subject, and to also inform participating subjects of 
the need to inform the Investigator of any SAE within this period. Serious AEs that the 
Investigator thinks may be associated with the IMP must be reported to UCB regardless of the 
time between the event and the end of the study.  
Upon receipt of the SAE Report Form , UCB will perform an assessment of expectedness of the 
reported SAE. The assessment of the expectedness of the SAE is based on the IB.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 76 of 209 12.1.3  Follow up of adverse events  
An AE should be followed until it has resolved, has a stable sequelae, the Investigator 
determines that it is no longer clinically significant, or the subject is lost to follow up. This 
follow -up requirement applies to AEs, SAEs, and AEs of special interest; further details 
regarding follow up of PDILI events is provided in Section  12.2.1.4 . 
If an AE is ongoing at the end of the study for a subject, follow up should be provided until 
resolution/stable level of sequelae is achieved, or until the Investigator no longer deems that it is 
clinically significant, or until the subject is lost to follow up. If no follow up is provided, the 
Investigator must provide a justification. The follow up will usually be continued for 20  weeks 
after the subjec t has discontinued his/her IMP.  
Information on SAEs obtained after clinical database lock will be captured through the Patient 
Safety (PS) database without limitation of time.  
12.1.4  Pregnancy  
If an Investigator is notified that a subject has become pregnant after the first intake of any IMP, 
the Investigator must immediately notify UCB’s PS department by providing the completed 
Pregnancy Report and Outcome Form (for contact details see Serious Adverse Event reporting 
information at the beginning of this proto col). The subject should be withdrawn from the study 
as soon as pregnancy is known (by positive pregnancy test), and the following should be 
completed:  
 The subject should return for an early discontinuation visit.  
 The subject should immediately stop the intake of the IMP.  
 A SFU Visit should be scheduled 20 weeks after the subject has discontinued her IMP.  
The Investigator must inform the subject of information currently known about potential risks 
and about available treatment alternatives.  
The pregnancy will be documented on the Pregnancy Report and Outcome Form provided to the 
Investigator. The progression of the pregnancy and the eventual birth (if applicable) must be 
followed up using the Pregnancy Report and Outcome Form in which the Investigator has to 
report on the health of the mother and of the child. Every reasonable attempt should be made to 
follow the health of the child for 30 days after birth for any significant medical issues. In certain 
circumstances, UCB may request that follow up is contin ued for a period longer than 30 days. If 
the subject is lost to follow up and/or refuses to give information, written documentation of 
attempts to contact the subject needs to be provided by the Investigator and filed at the site. 
UCB’s PS department is th e primary contact for any questions related to the data collection for 
the pregnancy, eventual birth, and follow up.  
In cases where the partner of a male subject enrolled in a clinical study becomes pregnant, the 
Investigator or designee is asked to contac t the subject to request consent of the partner via the 
Partner Pregnancy Consent Form that has been approved by the responsible IRB/IEC and should 
be available in the Investigator site file. In case of questions about the consent process, the 
Investigator  may contact the UCB/contract research organization (CRO) contract monitor for the 
study. The Investigator will complete the Pregnancy Report and Outcome Form and send it to 
UCB’s PS department (for contact details see Serious Adverse Event reporting infor mation at the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 77 of 209 beginning of this protocol) only after the partner has agreed that additional information can be 
captured and has provided the signed Partner Pregnancy Consent form. UCB’s PS department is 
also the primary contact for any questions related to  the data collection for the partner pregnancy, 
eventual birth, and follow up.  
A pregnancy becomes an SAE in the following circumstances: miscarriage, elective abortion 
when medically indicated (e.g. when pregnancy is endangering life or health of woman or  when 
fetus will be born with severe abnormalities), unintended pregnancy after hormonal 
contraceptive failure (if the hormonal contraceptive was correctly used), ectopic pregnancy, fetal 
demise, or any congenital anomaly/birth defect of the baby. Those SA Es must be additionally 
reported using the Investigator SAE Report Form.  
Should a subject become pregnant while participating in the study, the subject may be offered the 
option to enroll in a separate observational pregnancy follow -up study sponsored by U CB and 
conducted independently from study PS0013. If the study is available locally, the PS0013 PI will 
be provided with the locally approved information about the observational pregnancy follow -up 
study to inform the subject at the time the pregnancy is r eported. Participation in this separate 
study will be voluntary and will not impact therapeutic management of the subject nor interfere 
with termination and follow -up procedures as described in study protocol PS0013.  
12.1.5  Suspected transmission of an infectious  agent via a medicinal 
product  
For the purposes of reporting, any suspected transmission of an infectious agent via a medicinal 
product should be considered as an SAE; such cases must be reported immediately, recorded in 
the AE module of the eCRF, and foll owed as any other SAE. Any organism, virus, or infectious 
particle (eg, prion protein transmitting transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infectious agent.  
12.1.6  Overdose of investigational medicinal product  
Exces sive dosing (beyond that prescribed in the protocol and including overdose) should be 
recorded in the eCRF. Any SAE or nonserious AE associated with excessive dosing must be 
followed as any other SAE or nonserious AE. These events are only considered AEs o r SAEs if 
there are associated clinical signs and symptoms or if the act of taking the excess medicine itself 
is an AE or SAE (eg,  suicide attempt).  
12.1.7  Safety signal detection  
Selected data from this study will be reviewed periodically to detect as early as p ossible any 
safety concern(s) related to the IMP so that Investigators, clinical study subjects, regulatory 
authorities, and IRBs/IECs will be informed appropriately and as early as possible.  
In addition, an independent Data Monitoring Committee (DMC) will  periodically review and 
monitor safety data from this study and advise UCB. Details are provided in the DMC Charter.  
Cardiovascular and Neuropsychiatric Adjudication Committees will also periodically review and 
monitor safety data from this study and advi se UCB. Details are provided in the Adjudication 
Committee Charters.  
The Study Physician or medically qualified designee/equivalent will conduct an ongoing review 
of SAEs and perform ongoing SAE reconciliations in collaboration with the PS representative.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 78 of 209 As appropriate for the stage of development and accumulated experience with the IMP, 
medically qualified personnel at UCB may identify additional safety measures (eg,  AEs, vital 
signs, laboratory or ECG results) for which data will be periodically reviewed  during the course 
of the study.  
12.2 Laboratory measurements  
Clinical laboratory assessments consist of serum chemistry, hematology, urinalysis, and urine 
drug screen. A centralized laboratory will be used to supply all laboratory test supplies and 
analyze all  blood and urine samples for hematology, biochemistry, and urinalysis measurements. 
Any unscheduled laboratory testing should also be collected using the central laboratory. Testing 
to rule out hepatitis B, hepatitis C, and HIV (see Exclusion Criterion # 9, Section  6.2) will be 
performed at Screening in addition to those measurements listed in Table  12‒2. 
Specific details regarding the handling and processing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals.  
The following laboratory parameters will b e measured:  
Table  12‒2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Basophils  Calcium  pH 
Eosinophils  Chloride  Albumin (protein)  
Lymphocytes  Magnesium  Glucose  
Monocytes  Potassium  Blood  
Neutrophils  Sodium  Leukocyte esterase  
Hematocrit  Glucose  Nitrite  
Hemoglobin  BUN   
MCH  Creatinine  Urine dipstick for pregnancy testingb 
MCHC  ALP  Urine drug screenc 
MCV  AST   
Platelet count  ALT   
RBC count  GGT   
WBC count  Total bilirubin   
 Serum pregnancy testingb  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; GGT=gamma glutamyltransferase; MCH=mean corpuscular hemoglobin; MCHC=mean corpuscular 
hemoglobin concentration; MCV=mean corpuscular volume; PEOT=Premature End of Treatment; RBC=red blood 
cell; WBC=white blood cell  
a A urine microscopic examination will be performed if the result for albumin (protein), leukocyte esterase, blood  or 
nitrite is abnormal. A urine microscopic examination will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), hyaline casts, WBC casts, RBC casts, waxy casts, granular casts, calcium oxalate 
crystals, uric acid crystals, tri phosphate crystals, yeast, bacteria, amorphous urates, and amorphous phosphates.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 79 of 209 b Pregnancy testing will consist of serum testing at the Screening Visit. The pregnancy test will be urine at all other 
visits.  
c Urine drug screen will be performed at Screen ing Visit, and Week 56 or PEOT Visit. 
12.2.1  Evaluation of PDILI  
The PDILI IMP discontinuation criteria for this study are provided in Section  6.3.1  with the 
accompanying required follow -up investigation and monitoring detailed below. All PDILI events 
must be reported as an AE and reported to the study site and Sponsor within 24 hours of learning 
of their occurrence. Any PDILI event that meets the cri terion for potential Hy’s Law must be 
reported as an AE of special interest (see Section  12.1.1.3 ), and, if applicable, also reported as an 
SAE (see Section  12.1.1.2 ). 
Evaluation of PDILI consists of the diagnostic testing and continued monitoring included in 
Table  12‒3 (specific tests dependent on laboratory results and corresponding symptoms) and 
consultation with a local hepatologist (if applicable; discussed in Section  12.2.1.1 ). The local 
hepatologist is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually  be a hepatologist, but may be a 
gastroenterologist. Additional investigation and monitoring may be required and adapted based 
on the diagnosis after the cause of the liver injury/abnormality is confirmed (details in 
Section  12.2.1.4 ). 
The results of all monitoring, including laboratory testing and other testing, should be made 
available to the study site and Sponsor.  
All initial tests resulting in abn ormal hepatic laboratory values need to be repeated, but 
appropriate medical action must not be delayed waiting for the repeat result.  
If tests are done locally for more rapid results, a concurrent sample should also be sent to the 
central laboratory whene ver possible. Medical care decisions are to be made initially using the 
most rapidly available results and a conservative approach must be taken if the results from the 
2 laboratory tests are significantly different. Data from the local and central laborat ory are to be 
recorded on the applicable eCRF pages.  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. In these cases, the Investigator should also 
consider dose reduc tion for medically necessary concomitant medication and consider changing 
any medically required concomitant medication known to be hepatotoxic to a suitable 
alternative.  
When IMP is stopped due to PDILI (as described in Section  6.3.1 ), IMP must be permanently 
discontinued unless a subsequent alternative diagnosis fully explains the hepatic findings. If a 
subsequent alternative diagnosis fully explains the hepatic findings, and the requirements 
provided in Section  12.2.1.2.1  are met, rechallenge with IMP may be appropriate.  
Table  12‒3 summarizes the approach to investigate PDILI.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 80 of 209 Table  12‒3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis of 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥3xULN  ≥2xULNb NA Hepatology  consultc 
Medical Monitor must 
be notified within 
24 hours (eg,  by 
laboratory alert) and 
subject discussed with 
Medical Monitor 
ASAP.  Immediate, 
permanent IMP 
discontinuation.  
 Essential: Must have 
repeat liver 
chemi stry values 
and additional 
testing completed 
ASAP (see 
Section  12.2.1.3 ); 
recommended to 
occur at the site with 
HCP.  Monitoring of liver 
chemistry values at least 
twice per week until 
values normalize, 
stabilize, or return to 
within baseline values.d ≥3xULN  NA Yes 
≥8xULN  NA NA Need for hepatology 
consult to be 
discussed.(required if 
ALT or AST 
≥8xULN)  
Medical Monitor must 
be notified within 
24 hours (eg,  by 
laboratory alert) and 
subject discussed with 
Medical Monitor 
ASAP.  Immediate, 
permanent IMP 
discontinuation  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 81 of 209 Table  12‒3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis of 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
≥5xULN 
(and ≥2x 
baseline) 
and 
<8xULN  <2xULN  No Discussion with 
Medical Monitor 
required.  
Consider need for 
hepatology consult if 
there is no evidence of 
resolution (see Follow 
up requirements).c Further investigation 
– immediate IMP 
discontinuation not 
required (see 
Section  12.2.1.2 ). 
 
IMP discontinuation 
required if any of the 
following occur:  
 Subject cannot 
comply with 
monitoring 
schedule.  
 Liver chemistry 
values continue 
to increase.  
 Liver chemistry 
values remain 
≥5xULN (and 
≥2x baseline) 
after 4 weeks of 
monitoring 
without  evidence 
of resolution.  Essential: Every 
attempt must be 
made to have repeat 
liver chemistry 
values and 
additional testing 
completed within 
48 hours at the site 
with HCP (see 
Section  12.2.1.3 ). Monitoring of liver 
chemistry values at least 
twice per week for 
2 weeks.d 
 Immediate IMP 
discontinuation 
required if liver 
chemistry values 
continue to increase.  
After 2 weeks of 
monitoring liver 
chemistry values:  
 ALT or AST 
remains ≥5xULN 
<8xULN, IMP 
should be 
temporarily 
withheld and 
subject should 
undergo repeat test 
in 2 weeks.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 82 of 209 Table  12‒3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis of 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
       Continue IMP if 
ALT or AST values 
<5xULN; continue 
to monitor at least 
twice per week until 
values normalize, 
stabilize,  or return 
to within baseline 
values.  
 If ALT or AST 
remains ≥5xULN 
after second re -test, 
immediate, 
permanent IMP 
discontinuation 
required.  
Continue to monitor 
until values normalize, 
stabilize, or return to 
within baseline values.d 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 83 of 209 Table  12‒3: Required investigations and follow up for PDILI  
Laboratory value   Immediate  Follow up  
ALT or 
AST  Total 
bilirubin  Symptomsa of 
hepatitis of 
hypersensitivity  Consultation 
requirements  Actions  Testing  Evaluation  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; ASAP=as soon as possible; AST=aspartate aminotransferase; HCP=healthcare practitio ner; 
IMP=investigational medicinal product; NA=not applicable; PDILI=potential drug -induced liver injury; ULN=upper limit of normal  
a Hepatitis symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or tenderness; hypersensitivity symptoms include eosinophilia (>5%), 
rash, and fever (without clear alternat ive cause).  
b If the subject also has ≥2xULN ALP, the possibility of an indication of biliary obstruction should be discussed with the Medi cal Monitor.  
c Details provided in Section  12.2.1.1 . The local hepatologist is the expert usually consulted by the treating physician for assessment and management of 
potential hepatic disease. This would usually be a hepatologist, but may be a gastroenterologist.  
d Unless an alternative monitoring schedule is agreed by the Investigator and UCB responsible physician. Determination of stabi lization is at the discretion of the 
Investigator in consultation wit h the hepatologist (as applicable) and UCB responsible physician, as needed.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 84 of 209 12.2.1.1  Consultation with Medical Monitor and local hepatologist  
Potential drug -induced liver injury events require n otification of the Medical Monitor within 
24 hours (eg, by laboratory alert), and the subject must be discussed with the Medical Monitor as 
soon as possible. If required, the subject must also be discussed with the local hepatologist. The 
local hepatologis t is the expert usually consulted by the treating physician for assessment and 
management of potential hepatic disease. This would usually be a hepatologist, but may be a 
gastroenterologist. If determined necessary, this discussion should be followed by a full 
hepatology assessment (see Section  12.2.1.3 ) and SAE report (if applicable).  
12.2.1.2  Immediate action: determination of IMP discontinuation  
All PDILI e vents require immediate action, testing, and monitoring.  
The immediate action is dependent on the laboratory values and symptoms of hepatitis or 
hypersensitivity and ranges from continuation of IMP (followed by immediate investigation) to 
immediate and per manent discontinuation (see Section  6.3.1  and Table  12‒3 for details).  
When IMP is discontinued, all concomitant medications and herbal supplements that are not 
medically necessary should also be discontinued. The Investigator should also consider dose 
reduction for medically necessary concomitant m edication and consider changing any medically 
required concomitant medication known to be hepatotoxic to a suitable alternative.  
12.2.1.2.1  IMP restart/rechallenge  
Rechallenge with IMP can occur only if ALL of the following requirements are met:  
 The results of addit ional testing and monitoring described in Section  12.2.1.3   and 
Section  12.2.1.4   confirm a nondrug -related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie, a subsequent alternative diagnosis fully 
explains the hepatic findings).  
 The subject has shown clear therapeutic benefit from the IMP.  
 Subject’s ALT or AST elevations do not exceed ≥5xULN.  
 Subject’s total bilirubin is <2xULN.  
 Subject has no signs or symptoms of hypersensitivity or hepatitis.  
 The rechallenge is approved by the UCB responsible physician, DMC, and a hepatologist. 
The hepatologist must be external to UCB but may be a member of the DMC. It is 
recommended that the hepatologist be a local hepatology expert or the hepatologist treating 
the subject.  
 Subject agrees to the Investigator -recommended monitoring plan.  
12.2.1.3  Testing: identification/exclusion of alternative etiology  
The measurements and additional information required for the assessment of PDILI events when 
there is a reasonable possibility  that they may have been caused by the IMP are detailed  in 
Table  12‒4 (laboratory measurements) and Table  12‒5 (additional information). Results of the 
laboratory measurements and information collected are to be submitted to the Sponsor on the 
corresponding eCRF. If the medical history of the subject indicates a requirement for other 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 85 of 209 assessments not includ ed below, these additional assessments should be completed and 
submitted, as applicable.  
All blood samples should be stored, if possible. If tests are done locally for more rapid results, a 
concurrent sample must also be sent to the central laboratory.  
The following measurements are to be assessed:  
Table  12‒4: PDILI laboratory measurements  
Virology -related  Hepatitis A IgM antibody  
HBsAg  
Hepatitis E IgM antibody  
HBcAb -IgM 
Hepatitis C RNA  
Cytomegalovirus IgM antibody  
Epstein -Barr viral capsid antigen IgM antibody (if unavailable, obtain 
heterophile antibody or monospot testing)  
Immunology  Anti-nuclear antibody (qualitative and quantitative)  
Anti-smooth muscle antibody (qualitative and quantitative)  
Type 1 anti -liver kidney microsomal antibodies (qualitative and quantitative)  
Hematology  Eosinophil count  
Urinalysis  Urine drug screena 
Chemistry  Amylase  
Sodium, potassium, chloride, glucose, BUN, creatinine  
Total bilirubin, ALP, AST, ALT, GGT, total cholesterol, albumin  
If total bilirubin ≥1.5xULN, obtain fractionated bilirubin to obtain % direct 
bilirubin  
Serum CPK and LDH  to evaluate possible muscle injury causing transaminase 
elevation  
Additional  Prothrombin time/INRb 
Serum pregnancy testc 
PK 
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; CPK=creatine phosphokinase; GGT=gamma glutamyltransferase; HBcAb -IgM=hepatitis B core 
antibody -IgM; HBsAg=hepatitis B surface antigen; IgM=immunoglobulin M; INR=international normalized ratio; 
LDH=lactate dehydrogenase; PDILI=potential drug -induced liver injury; PK=pharmacokinetic; RNA=ribonucleic 
acid; ULN=upper limit of normal  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 86 of 209 Table  12‒4: PDILI laboratory measurements  
a Tests in addition to the specified analytes may be performed based on the Investigator’s medical judgment and 
subject history.  
b Measured only for subjects with ALT >8xULN, elevations in total bilirubin, and symptoms of hepatitis or 
hypersensitivity. Hepatiti s symptoms include fatigue, nausea, vomiting, and right upper quadrant pain or 
tenderness; hypersensitivity symptoms include eosinophilia (>5%), rash, and fever (without clear alternative 
cause).  
c For women of childbearing potential.  
The following additional information is to be collected:  
Table  12‒5: PDILI information to be collected  
New or updated information  
Concomitant prescription and over -the-counter medications (eg, acetaminophen, herbal remedies, 
vitamins); dosages and dates should be included.  
Pertinent medical history, including the following:  
 History of liver disease (eg, autoimmune hepatitis, nonalcoholic steatohepatitis or other “fatty 
liver di sease”)  
 Adverse reactions to drugs  
 Allergies  
 Relevant family history or inheritable disorders (eg, Gilbert’s syndrome, alpha -1 antitrypsin 
deficiency)  
 Recent travel  
Progression of malignancy involving the liver (Note: Metastatic disease to the liver, by it self, should not 
be used as an explanation for significant AST and/or ALT elevations.)  
The appearance or worsening of clinical symptoms of hepatitis or hypersensitivity (eg, fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, decreased appetite, abdominal pain, jaundice, fever, or 
rash)  
Recent clinically significant hypotension or hypoxemia with compromised cardiopulmonary function  
Alcohol and illicit drug use  
Results of liver imaging or liver biopsy, if done  
Results of any specialis t or hepatology consult, if done  
Any postmortem/pathology reports  
ALT=alanine aminotransferase; AST=aspartate aminotransferase; PDILI=potential drug -induced liver injury  
12.2.1.4  Follow -up evaluation  
Potential drug -induced liver injury events require follow -up monitoring as described in 
Table  12‒3. Monitoring should continue until liver chemistry val ues normalize, stabilize, or 
return to baseline. Determination of stabilization is at the discretion of the Investigator in 
consultation with the hepatologist (as applicable) and UCB responsible physician, as needed.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 87 of 209 12.3 Other safety measurements  
12.3.1  Assessment an d management of TB and TB risk factors  
All subjects will be assessed for tuberculosis (TB) at Screening and at the timepoints specified in 
the Schedule of Assessments ( Table  5‒1 and Table  5‒2) through physical examination for signs 
and symptoms of TB, chest x -ray (Section  12.3.1.2 ), laboratory testing ( Section  12.3.1.1 ), and 
subject questionnaire ( Section  12.3.1.3 ). 
For the purposes of this study, TB definitions are as follows:  
a. Known TB infection:  
 Active TB infection or clinical signs and symptoms suspicious for TB (pulmonary or 
extra -pulmonary).  
 History of active TB infection involving any organ system or findings in other organ 
systems consistent wit h TB infection, unless adequately treated and proven to be fully 
recovered upon consult with a TB specialist.  
 Any evidence by radiography or other imaging modalities consistent with previously 
active TB infection that is not reported in the subject’s medic al history.  
b. High risk of acquiring TB infection:  
 Known close exposure to another person with active TB infection within the 3 months 
prior to Screening  
 Time spent in a healthcare delivery setting or institution where individuals infected with 
TB are hou sed and where the risk of transmission of infection is high.  
c. Latent TB infection (unless appropriate prophylaxis is initiated at least 8 weeks prior to IMP 
dosing and continued to completion of prophylaxis):  
 The absence of signs, symptoms, or physical findings suggestive of TB infection with a 
positive IGRA test (or 2 indeterminate IGRA test results) and a chest x -ray (or other 
imaging) without evidence of TB infection. If the result of the IGRA test is 
indeterminate, the particular IGRA test previously  performed may be repeated once; if 
positive or indeterminate on retest, the subject may not be randomized to IMP without 
further evaluation by a TB specialist and discussion with the Study Physician, if LTB 
infection is identified. The retest must be done  during the protocol -defined Screening 
window.  
Note: If available, respiratory or other specimens must also be smear and culture negative 
for TB (CDC diagnosis of LTB infection) http://www.cdc.gov/TB/topic 
/testing/default.htm).  
d. NTMB infection is defined a s a clinical infection caused by mycobacterial species other than 
those belonging to the Mycobacterium tuberculosis complex.  
e. Tuberculosis test conversion:  
 A positive IGRA result for the current test when previous IGRA test results were 
negative. All subjec ts with TB test conversion must immediately stop IMP administration 
and be referred to a TB specialist for further evaluation. Confirmed TB  test conversions 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 88 of 209 should be classified as due to LTBI, active  TB infection, or NTMB, and reported to the 
UCB PS funct ion. 
Subject eligibility, retesting requirements, and treatment requirements are depicted in 
Figure  12-1. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 89 of 209 Figure  12-1: Schematic diagram of TB test results and study eligibility  
IGRA TB test
IGRA TB test 
negativeIGRA TB test 
indeterminate IGRA TB test 
positive
Repeat IGRA TB 
testa
IGRA TB test 
negativeIGRA TB test 
indeterminate IGRA TB test 
positiveSubject eligible for 
study
Subject eligible for 
studyEvaluation by TB 
specialist
Latent or active 
TB negativeLatent TB 
positiveActive TB 
positive
Subject eligible for 
study
TB treatment 
initiatedNo TB treatment 
initiated
Subject eligible for 
studybSubject NOT 
eligible for studySubject NOT 
eligible for study
IGRA=interferon-gamma release assay; TB=tuberculosis
a IGRA retest must be done during the protocol-defined Screening window
b Subjects with LTBI may enter the study only after they have completed at least 8 weeks of appropriate 
prophylactic therapy and thereafter, will continue and complete the entire regimen.
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 90 of 209 12.3.1.1  Tuberculosis assessment by IGRA  
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB test is 
recommended) will be performed as described Table  5‒1 and Table  5‒2 for all subjects. The test 
results will be reported as positive, negative, or indeterminate. Positive and indeterminate TB test 
results must be reported as a n AE and appropriately updated once the final diagnosis is known 
(eg, active TB, latent TB, or false positive TB test). UCB also recommends that a TB specialist 
be consulted where TB (latent or active) is suspected or if there are doubts regarding test res ults. 
If latent or active TB is identified, subject must undergo appropriate study -specified withdrawal 
procedures. The retest during Screening must be done during the protocol -defined Screening 
window.  
12.3.1.2  Chest x -ray for tuberculosis  
A plain posteroanterior chest x -ray must be performed in the Screening Period unless one has 
been performed within 3 months prior to the Screening Visit. The chest x -ray (or, if done, 
Computed Axial Tomography of the Chest) must be clear of signs of TB infection (previous or 
current) before first IMP administration. All chest imaging (particularly x -rays) should be 
available for review by the Investigator before randomization of the subject. The chest x -ray 
reading should be repeated if the TB test was confirmed positive. If the s econd read of the 
pretreatment chest x -ray is confirmed to be clear, the subject may be included in the study 8 
weeks after the start of the TB prophylactic treatment. If the pretreatment chest x -ray is not 
available for a re -read, it should be repeated af ter notification to the radiologist that this subject 
is IGRA positive, and confirmed to be clear for signs of TB.  
The chest imaging must be negative for any old or recent TB infection as determined by a 
qualified radiologist and/or pulmonary physician. An y new clinically significant findings post 
Baseline on chest x -ray must be documented in the source documents and the eCRF as an AE.  
12.3.1.3  Tuberculosis questionnaire  
The questionnaire “Evaluation of signs and symptoms of tuberculosis” should be used as a 
source document. The questionnaire will be completed as described in specified in Table  5‒1 and 
Table  5‒2. The questionnaire will assist with the identification of subjects who may require 
therapy for TB. A subject who answers “Yes” to the question  
 
 at Screening is excluded. A “Yes” response to any of the other questions within the 
questionnaire at Screening should trigger further careful assessment to determine if subject has 
LTB or active TB (see Exclusion Criterion # 12, Section  6.2). A “Yes” response to any of the 
questions during the study should trigger further assessments to  determine if the subject has 
either LTB or active TB infection.  
12.3.1.4  Tuberculosis management  
LTB infection and active TB identified during study  
During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further adminis tration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. Evidence of 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed in determinate on repeat), or the subject’s questionnaire or history and physical 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 91 of 209 indicates that TB infection or exposure may have occurred. Evidence of active TB includes, in 
addition to the aforementioned tests, signs and symptoms of organ involvement. In e ither 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB should be withdrawn from the study and receive appropriate TB or 
prophylaxis therapy.  
If a TB specialist excludes an active TB inf ection the subject can proceed with the IMP no earlier 
than 4 weeks after the start of an appropriate prophylactic therapy.  
Any presumptive diagnosis or diagnosis of a TB infection is a reportable event. Confirmed active 
TB must be reported as an SAE. The Investigator is to complete and submit the TB Follow -Up 
Form provided.  
The subject should be transferred to the care of his/her physician and managed according to the 
best available standard of care. Subjects identified as having converted to active TB dur ing the 
study must be withdrawn and scheduled to return for the PEOT Visit as soon as possible but no 
later than the next scheduled study visit and complete all PEOT Visit assessments.  
The subject should be encouraged to complete a SFU Visit (20 weeks afte r the final dose of 
IMP).  
If infection with NTMB is identified during the study, the same procedure as for active TB 
acquired during the study must be followed.  
12.3.2  Pregnancy testing  
Pregnancy testing will consist of serum testing at the Screening Visit. The p regnancy test will be 
urine at all other visits.  
The Screening Visit serum pregnancy testing results must be negative and received and reviewed 
prior to randomization. A negative urine pregnancy test result should be obtained immediately 
prior to each admi nistration of IMP at the visits specified in Table  5‒1. Pregnancy tests should 
be administered to all female subjects of childbearing potential, regardl ess of their use of birth 
control.  
12.3.3  Vital signs  
Vital signs will be collected at every visit and will include systolic and diastolic BP, pulse rate, 
and body temperature (oral, axillary, or otic). Subjects should be sitting for 5 minutes before and 
during vital signs assessments.  
Vital signs are to be measured prior to blood sampling, and prior to dosing, where applicable.  
12.3.4  12-lead electrocardiograms  
Twelve -lead standard ECGs will be recorded at the visits specified in the Schedule of Study 
Assessments ( Table  5‒1 and Table  5‒2) and read by a central ECG reader.  
Full details of ECG recording will be provided in the ECG Manual.  
12.3.5  Physical examination  
A physical examination will be performed at the visits specified Table  5‒1 and Table  5‒2. The 
physical examination will include general appearance; ear, nose, and  throat; eyes, hair, and skin; 
respiratory; CV; GI; musculoskeletal; hepatic; neurological (including limb reflexes); and mental 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 92 of 209 status. All physical examinations will also include evaluation of signs and symptoms of active 
TB and risk for exposure to TB. Findings considered clinically significant changes since the 
physical examination at the Screening Visit will be recorded as AEs.  
For subjects on Escape treatment a physical examination will be performed at Escape 
Week  12/PEOT and the SFU Visit.  
12.3.6  Height and  body weight  
Height will be measured at Baseline, only.  
Body weight will be measured at the visits specified in the Schedule of Study Assessments 
(Table  5‒1 and Table  5‒2). 
12.3.7  Assessment of suicidal ideation and behavior  
Suicidal ideation and behavior will be assessed by using the eC -SSRS; the questionnair e will be 
self-administered by the subject and assessed by trained study personnel. This scale will be used 
to assess suicidal ideation and behavior that may occur during the study. The visits at which the 
eC-SSRS assessments will be performed are specifie d in the Schedule of Study Assessments 
(Table  5‒1 and Table  5‒2). 
The eC -SSRS is a standardized and validated instrument developed for the assessment of the 
severity and frequency of suicidal ideation and behavior (Mundt et al, 2010; Posner et al, 2011). 
Subjects respond to standardized clinical questions that are presented in a uniform fashion. The 
eC-SSRS defines 5 subtypes of suicidal ideation and behavior in addition to self -injurious 
behavior with no suicidal intent. The eC -SSRS takes approximately 3 to 10 minutes to complete.  
Refer to Sectio n 6.3 for eC -SSRS -related withdrawal criteria.  
12.4 Other study measurements  
12.4.1  Demographic information  
Demographic information will be collected in all subj ects and include age, gender, race and 
ethnicity. Information on demographics will be collected according to local rules and regulations. 
Demographic information will be recorded in the eCRF.  
12.4.2  Medical history  
A complete medical history will be collected as part of the Screening assessment and include all 
clinically relevant past or coexisting medical conditions and surgeries. Findings will be recorded 
in the eCRF.  
12.4.3  Psoriasis history  
A detailed history of each subject’s PSO history will be collected and includ e the date of onset 
and past treatments for PSO.  
12.4.4  Data Monitoring and Adjudication Committees  
The DMC membership includes experienced clinicians and a statistician, all of whom have 
expertise in clinical trials. Cardiovascular and Neuropsychiatric Adjudicat ion Committees will 
also periodically review data from this trial. Both Data Monitoring and Adjudication Committee 
members may not participate in the study as principal or co -Investigators, or as study subject 
care physicians. The duration of membership fo r the committees will be inclusive of planned 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 93 of 209 analyses for PS0013.  Detailed role, scope, responsibilities, and complete procedures, as well as 
the identity of members, are described in the separate committee charters.  
13 STUDY MANAGEMENT AND  ADMINISTRATION  
13.1 Adherence to protocol  
The Investigator should not deviate from the protocol. However, the Investigator should take any 
measure necessary in deviation from or not defined by the protocol in order to protect clinical 
study subjects from any immediate hazard to  their health and safety. In this case, this action 
should be taken immediately, without prior notification of the regulatory authority,  IRB/IEC, or 
Sponsor.  
After implementation of such measure, the Investigator must notify the CPM of the Sponsor 
within 24 hours and follow any local regulatory requirements.  
13.2 Monitoring  
UCB (or designee) will monitor the study to meet the Sponsor’s monitoring SOPs, ICH -GCP 
guideline, and applicable regulatory requirements, and to ensure that study initiation, conduct, 
and c losure are adequate. Monitoring of the study may be delegated by UCB to a CRO or a 
contract monitor.  
The Investigator and his/her staff are expected to cooperate with UCB (or designee) and to be 
available during the monitoring visits to answer questions su fficiently and to provide any 
missing information. The Investigator(s)/institution(s) will permit direct access to source 
data/documents for study -related monitoring, audits, IRB/IEC review, and regulatory 
inspection(s).  
The Investigator will allow UCB (or  designee) to periodically review all eCRFs and 
corresponding source documents (eg,  hospital and laboratory records for each subject). 
Monitoring visits will provide UCB (or designee) with the opportunity to evaluate the progress 
of the study, verify the a ccuracy and completeness of eCRFs, ensure that all protocol 
requirements, applicable authorities’ regulations, and Investigator’s obligations are being 
fulfilled, and resolve any inconsistencies in the study records.  
13.2.1  Definition of source data  
All source do cuments must be accurate, clear, unambiguous, permanent, and capable of being 
audited. They should be made using some permanent form of recording (ink, typing, printing, 
optical disc). They should not be obscured by correction fluid or have temporary attac hments 
(such as removable self -stick notes). Photocopies and/or printouts of eCRFs are not considered 
acceptable source documents.  
Source documents are original records in which raw data are first recorded. These may include 
hospital/clinic/general practit ioner records, charts, diaries, x -rays, laboratory results, printouts, 
pharmacy records, care records, ECG or other printouts, completed scales, or QOL 
questionnaires, for example. Source documents should be kept in a secure, limited access area.  
Source do cuments that are computer generated and stored electronically must be printed for 
review by the monitor (eg,  ECG reports). Once printed, these copies should be signed and dated 
by the Investigator and become a permanent part of the subject’s source documen ts. The 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 94 of 209 Investigator will facilitate the process for enabling the monitor to compare the content of the 
printout and the data stored in the computer to ensure all data are consistent.  
Electronic data records, such as Holter monitor records or electroenceph alogram records, must 
be saved and stored as instructed by UCB (or designee).  
Patient -reported outcome measures (eg, DLQI, EQ -5D-3L, SF -36, Patient Global Assessment of 
PSO, and PGADA) and ePRO diary data will be entered electronically by the subject.  
The ePRO diary data will be entered into an electronic diary by the subject. The data collection 
and database management system will be supplied by a vendor and will be compliant with the 
US Food and Drug Administration Part 11. The data collected on the ePRO diary will be 
uploaded to a central server database and will be sent electronically to UCB (or a designated 
CRO).  
13.2.2  Source data verification  
Source data verification ensures accuracy and credibility of the data obtained. During monitoring 
visits, reported da ta are reviewed with regard to being accurate, complete, and verifiable from 
source documents (eg,  subject files, recordings from automated instruments, tracings [ECG], 
x-ray films, laboratory notes). All data reported on the eCRF should be supported by so urce 
documents, unless otherwise specified in Section  13.2.1 . 
13.3 Data handling  
13.3.1  Case Report Form completion  
The Investigator is responsible for prompt r eporting of accurate, complete, and legible data in the 
eCRFs and in all required reports.  
Any change or correction to the eCRF after saving must be accompanied by a reason for the 
change.  
Corrections made after the Investigator’s review and approval (by m eans of a 
password/electronic signature) will be reapproved by the Investigator.  
The Investigator should maintain a list of personnel authorized to enter data into the electronic 
eCRF.  
Detailed instructions will be provided in the eCRF Completion Guideline s. 
13.3.2  Database entry and reconciliation  
Case Report Forms/external electronic data will be entered/loaded into a validated electronic 
database using a clinical data management system (CDMS). Computerized data cleaning checks 
will be used in addition to manual  review to check for discrepancies and to ensure consistency of 
the data. This study is performed using Electronic Data Capture: the data are entered into the 
eCRFs once and are subsequently verified.  
An electronic audit trail system will be maintained wit hin the CDMS to track all data changes in 
the database once the data have been saved initially into the system or electronically loaded. 
Regular backups of the electronic data will be performed.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 95 of 209 13.3.3  Subject Screening and Enrollment log/Subject Identification C ode list  
The subject’s screening and enrollment will be recorded in the Subject Screening and Enrollment 
Log. 
The Investigator will keep a Subject Identification Code list. This list remains with the 
Investigator and is used for unambiguous identification of each subject.  
The subject’s consent and enrollment in the study must be recorded in the subject’s medical 
record. These data should identify the study and document the dates of the subject’s 
participation.  
13.4 Termination of the study  
UCB reserves the right  to temporarily suspend or prematurely discontinue this study either at a 
single site, multiple sites, or at all sites at any time for reasons including, but not limited to, 
safety or ethical issues, inaccurate or incomplete data recording, noncompliance, or 
unsatisfactory enrollment with respect to quality or quantity.  
If the study is prematurely terminated or suspended, UCB (or its representative) will inform the 
Investigators/institutions and the regulatory authority(ies) of the termination or suspension  and 
the reason(s) for the termination or suspension, in accordance with applicable regulatory 
requirement(s). The IRB/IEC should also be informed and provided with reason(s) for the 
termination or suspension by the Sponsor or by the Investigator/instituti on, as specified by the 
applicable regulatory requirement(s). In addition, arrangements will be made for the return of all 
unused IMP and other material in accordance with UCB procedures for the study.  
13.5 Archiving and data retention  
The Investigator will mai ntain adequate records for the study, including eCRFs, medical records, 
laboratory results, Informed Consent documents, drug dispensing and disposition records, safety 
reports, information regarding participants who discontinued, and other pertinent data.  
All essential documents are to be retained by the Investigator until at least 2 years after the last 
approval of a marketing application in an ICH region and until there are no pending or 
contemplated marketing applications in an ICH region, or at least 2 years have elapsed since the 
formal discontinuation of clinical development of the IMP. These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirement(s) or by an 
agreement with UCB (Committee for Prop rietary Medicinal Products [CPMP]/ICH/135/95, 2002 
[Section  4.9.5]). The Investigator will contact UCB for authorization prior to the destruction of 
any study records or in the event of accidental loss or destruction of any study records. The 
Investigator will also notify UCB should he/she relocate or move the study -related files to a 
location other than that specified in the Sponsor’s trial master file.  
13.6 Audit and inspection  
The Investigator will permit study -related audits mandated by UCB, after reasonable  notice, and 
inspections by domestic or foreign regulatory authorities.  
The main purposes of an audit or inspection are to confirm that the rights and well -being of the 
subjects enrolled have been protected, that enrolled subjects (ie,  signing consent and undergoing 
study procedures) are appropriate for the study, and that all data relevant for the evaluation of the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 96 of 209 IMP have been processed and reported in compliance with the planned arrangements, the 
protocol, investigational site, and IRB/IEC SOPs, ICH GCP , and applicable regulatory 
requirements.  
The Investigator will provide direct access to all study documents, source records, and source 
data. If an inspection by a regulatory authority is announced, the Investigator will immediately 
inform UCB (or designe e). 
13.7 Good Clinical Practice  
Noncompliance with the protocol, ICH -GCP, or local regulatory requirements by the 
Investigator, institution, institution staff, or designees of the Sponsor will lead to prompt action 
by UCB to secure compliance. Continued noncomp liance may result in the termination of the 
site’s involvement in the study.  
14 STATISTICS  
A description of statistical methods follows and will be described in more detail in the SAP.  
14.1 Definition of analysis sets  
The Enrolled Set will consist of all subjects who have given informed consent.  
The Randomized Set (RS) will consist of all randomized subjects.  
The Safety Set (SS) will consist of all subjects that received at least 1 dose of the IMP.  
The Full Analysis Set (FAS) will consist of all randomized subjects  that received at least 1 dose 
of the IMP and have a valid measurement for each of the co -primary efficacy variables at 
Baseline.  
The Escape Subject Set (ESS) will consist of all subjects who receive at least 1 dose of escape 
bimekizumab 320mg treatment ei ther due to not achieving a PASI90 response at Week  16 or 
experiencing a relapse after entering the Randomized -Withdrawal Period. Summaries based on 
the ESS will be split between subjects who enter the escape arm: 1) due to PASI90 non -response 
at Week 16 o r 2) due to relapse during the Randomized -Withdrawal Period (after achieving 
PASI90 response at Week 16).  
The Week  16 Responder Set (WK16ResS) will consist of all subjects who achieve a PASI90 
response at Week  16and receive at least 1 dose of the IMP durin g the Randomized -Withdrawal 
Period at Week  16 or later.  
The Active Medication Set (AMS) will consist of all subjects who have received at least 1 dose 
of active IMP (bimekizumab). The AMS will be used for summaries of safety that include all 
data from the Initial Treatment Period and/or Randomized -Withdrawal Period .  
The Per -Protocol Set (PPS) will consist of all subjects in the RS who had no important protocol 
deviations affecting the co -primary efficacy variables. Important protocol deviations will be 
pre-defined and subjects with important protocol deviations will be evaluated during ongoing 
data cleaning meetings prior to unblinding of the data.  
The Pharmacokinetics Per -Protocol Set (PK -PPS) consists of all randomized subjects who 
received at least 1 dos e of the IMP and provided at least 1 quantifiable plasma concentration 
post-dose without important protocol deviations that would affect the concentration.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 97 of 209 14.2 General statistical considerations  
Summary statistics will consist of frequency tables for categoric al variables. For continuous 
variables, summary statistics will consist of the number of available observations, arithmetic 
mean, SD, median, minimum, and maximum unless stated otherwise.  
All statistical tests will be performed based on a 2 -sided significa nce level of 5% unless stated 
otherwise.  
The statistical analysis of the co -primary efficacy variables and selected secondary efficacy 
variables will account for multiplicity and control the familywise Type I error rate at a 2 -sided 
alpha level of 0.05 by using a fixed sequence testing procedure.  
The first 2 hypotheses (H 1 and H 2) test whether bimekizumab is superior to placebo for PASI90 
response and IGA response at Week  16. These are the hypothesis tests corresponding to the co -
primary endpoints. If both are rejected at a 2 -sided alpha level of 0.05, that alpha will be passed 
to the next test in the sequence, allowing the testing procedure to proceed.  
The hypotheses associated with the subsequent tests are for secondary efficacy endpoints and are 
based on testing for superiority relative to placebo. See Figure  14-1 for details on this procedure.  
Figure  14-1: Sequence of testing  
 
IGA=Investigator’s Global Assessment; PASI=Psoriasis Area Severity Index, PSD=patient symptom diary; 
PSO=psoriasis; Q4W=every 4 weeks; Q8W=every 8 weeks.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 98 of 209 14.3 Planned efficacy analyses  
14.3.1  Analysis o f the primary efficacy variable  
The co -primary efficacy variables for this study will be PASI90 response and IGA response at 
Week  16, and the corresponding analyses will be based on the RS. A subject will be classified as 
a PASI90 responder if the PASI sco re at Week  16 has improved at least 90% from Baseline, and 
an IGA responder will be any subject with a score of 0  or 1 (Clear or Almost Clear) with at least 
a 2-category improvement from Baseline in the IGA score. The primary analyses will be based 
on the stratified Cochran -Mantel -Haenszel (CMH) test where region and prior biologic exposure 
(yes/no) will be used as stratification variables. Region and prior biologic exposure have been 
selected as stratification variables in the analysis because they are str atification variables in the 
randomization and because they may have an impact on efficacy. Pairwise treatment 
comparisons will be made based on the CMH test using the p -value for the general association.  
Nonresponder imputation (NRI) will be used to accou nt for missing data in the primary analysis. 
Specifically, any subject who withdraws from IMP prior to Week  16 or who has missing data for 
the co -primary efficacy variables at the Week  16 time point will be considered a nonresponder. 
Based on previous stud ies of biologics in subjects with moderate to severe chronic plaque PSO, 
it is expected that the number of subjects who discontinue prior to Week  16 will be low. For the 
small percentage of subjects for whom primary endpoint data are unavailable at Week  16, this 
lack of data is suggestive of an ineffective IMP, thereby supporting the imputation of 
nonresponse. Therefore, NRI is considered an appropriate method for handling missing data 
since achieving the clinical response and making it through 16 weeks of IMP treatment are both 
critical components of the primary outcome.  
14.3.1.1  Sensitivity analyses  
The primary efficacy analysis described in Section  14.3.1 will be repeated based on the FAS and 
the PPS.  
As a sensitivity analysis to the primary analysis method, logistic regression based on the RS will 
be used. The odds ratio of the responder rates at Week  16 will be estimated and tested between 
treatment groups using a logistic regression model with factors of treatment group, region, and 
prior biologic exposure (yes/no). The odds ratio, associated CI, and p -value based on the Wald 
test will be presented. If the logistic regression model is unable to converge, then prior biologic 
exposure may be dropped from the model to facilitate convergence. If the model is sti ll unable to 
converge, then region may be removed from the model as well. As with the primary analysis, 
missing data will be handled using NRI.  
The center -by-treatment interaction will be tested by replacing region with center in the logistic 
regression mo del described above and adding a center center -by-treatment interaction term. In 
the model, center will be based on the original centers prior to pooling. However, if the model is 
unable to converge due to a low number of subjects at a given center, a pool ing algorithm (to be 
described in the SAP) will be applied in order to allow the model to converge.  
In order to obtain reasonable estimates of variability for a treatment arm at a given center, a 
minimum of 15 subjects will be considered acceptable for a c enter to be included in the model 
without pooling. Given the 4:1 randomization allocation scheme, this should provide a minimum 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 99 of 209 of about 12 subjects in the bimekizumab arm and 3 subjects in the placebo arm. Centers with 
fewer than 15 subjects will be eligi ble for pooling.  
The following center pooling algorithm will be used for each geographic region:  
 If a center has 15 or more subjects, then no pooling will be done for that center.  
 Centers with fewer than 15 subjects will be ordered from largest to smallest  with pooling 
proceeding in the following manner:  
 Two or more centers will be combined until the cumulative subject total is at least 15.  
 Once a pooled center has at least 15 subjects, the process will continue in an iterative 
fashion for the subsequent ce nters in the ordered list, where a new pooled center begins 
each time at least 15 subjects has been reached in the previous pool.  
 If this iterative process reaches the end of the ordered list of centers where the final 
pooled center has fewer than 15 subje cts, then the subjects from the centers in that pool 
will be combined with the pooled center formed in the previous iteration.  
This procedure is only to be performed within a geographic region – there will be no pooling of 
centers across regions.  
If the ce nter-by-treatment interaction is not found to be significant (α=0.10), then no further 
analyses will be performed. On the other hand, if the interaction is significant, further analyses 
will be conducted to determine which center or centers may be the sour ce of the interaction. This 
will be done by running the logistic regression model (including the interaction term) where each 
center will be systematically removed from the model. The impact of a given center will be 
based on the change in the interaction p-value when that center is removed. The center or centers 
that appear to be driving the significant interaction effect will then be removed from the model to 
verify that conclusions remain the same with or without the influential center(s).  
Additional sen sitivity analyses to evaluate varying assumptions related to the handling of 
missing data will also be performed and are described in greater detail in Section  14.7. 
14.3.2  Other efficacy analyses  
14.3.2.1  Analysis of the secondary efficacy variables  
14.3.2.1.1  Initial Treatment Period  
The secondary efficacy variables for the Initial Treatment Period will be analyzed for all subjects 
in the RS.  
For the binary secondary efficacy  variables assessing the superiority of bimekizumab versus 
placebo, the stratified CMH test as specified for the primary analysis will be implemented. As in 
the primary analysis, NRI will be used to account for missing data  
For continuous change from Baseline efficacy variables (Patient Symptom Diary item scores for 
pain, itch, and scaling), an analysis of covariance (ANCOVA) model will be used with fixed 
effects of treatment, region, and prior biologic exposure and Baseline value as covariates. 
Missing data for these variables will be imputed using multiple imputation (MI) and is further 
described in Section  14.7. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 100 of 209 Sensit ivity analyses for the handling of missing data will be performed for the secondary 
variables during the Initial Treatment Period that are part of the fixed sequence testing 
procedures. These analyses will be described in Section  14.7. 
14.3.2.1.2  Randomized -Withdrawal Period  
PASI90 response at Week 56 for subjects in the WK16ResS will be evaluated using a stratified 
CMH test where region and prior biologic exposure will be used as stratification variables, 
similar to the approach specified for the primary analysis. In this analysis, both dose regimens 
(Q4W and Q8W) within a given bimekizumab dose will be pooled such that each bimekizumab 
dose (regardless of regimen) will be compared to placebo. Missing data will be handled via NRI. 
Specifically, if a subject has missing data at Week 56, has discontinued from study treatment, or 
has met the criterion for relapse during the Randomized -Withdrawal Period, they wi ll be treated 
as a non -responder at Week 56 for this analysis.  
While not part of the fixed sequence testing procedure, it is a secondary objective to assess the 
maintenance of efficacy of bimekizumab dosing Q4W versus Q8W at Week 56. While multiple 
variabl es and analyses will be used to assess this objective, the secondary efficacy variable that 
will be used for this assessment is also PASI90 response at Week 56 for subjects in the 
Wk16ResS. This analysis will be based on simple percentages of PASI90 respon ders at Week 56 
for each dosing regimen (Q4W and Q8W). Subjects with missing data at Week 56 or who meet 
the criterion for relapse will be counted as non -responders.  
14.3.2.1.3  Testing Procedure  
The testing of secondary efficacy variables as outlined in the fixed seq uence testing procedure 
(see Section  14.3.2 ) will account for missing data based on the approaches described above (NRI 
for binary variables, and MI for continuous variables). In addition to this, sensitivity analyses for 
the handling of missing data will be performed for the binary and continuous secondary efficacy 
variables that are part of the fixed sequence testing procedures. These analyses are de scribed in 
Section  14.7. 
14.3.2.2  Analysis of the other efficacy variables  
The other efficacy variables in the Initial Treatment Period will be analyzed for a ll subjects in the 
RS. For the Randomized -Withdrawal Period, summaries will be based on the WK16ResS and 
the ESS, as appropriate.  
Binary (responder) variables will be summarized using frequency tables by treatment group for 
each visit.  
Continuous variables  will be summarized using descriptive statistics by treatment group for each 
visit.  
Time to PASI50/75/90/100 response during the Initial Treatment Period will be estimated and 
presented using the Kaplan -Meier product -limit method for each treatment. Time t o a given 
response will be defined as the length in days from the first dose of IMP treatment until the first 
date when the response is achieved. Subjects who discontinue IMP prior to achieving a response 
will be censored at the date of IMP discontinuation . Subjects who reach the Week  16 Visit 
without achieving the given response (and should, therefore, be allocated to escape treatment) 
will be censored at the date of the Week  16 Visit. The median time to response, including the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 101 of 209 2-sided 95% CI, will be calc ulated for each treatment. Between -group differences will be 
analyzed with the log -rank statistic.  
Time to relapse (defined as not achieving a PASI75 response) for subjects in the WK16ResS will 
be estimated and presented using the Kaplan -Meier product -limit method for each treatment. 
Time to relapse will be defined as the length in days from date of first re -randomized IMP 
treatment in the Randomized -Withdrawal Period until the date when relapse is confirmed via the 
PASI assessment. Subjects who discontinue  IMP prior to a recorded relapse will be considered 
as having relapsed on the date of early discontinuation. This is considered reasonable as early 
discontinuation is indicative of ineffective IMP treatment. Subjects who reach the Week 56 Visit 
without rel apsing will be censored at the date of the Week 56 Visit. The median time to 
response, including the 2 -sided 95% CI, will be calculated for each treatment. Between -group 
differences will be analyzed with the log -rank statistic. These between -group differen ces will 
compare each bimekizumab dose (separately for each regimen as well as pooled regimen) to 
placebo based on the re -randomized treatment groups (ie, independent of the initial 
randomization).  
All other efficacy variables will be summarized based on i mputed data (NRI and multiple 
imputation for binary and continuous variables, respectively), unless otherwise specified in the 
SAP. In some cases, variables may also be summarized based on observed case data (ie, subjects 
with missing data or who have prem aturely discontinued IMP are treated as missing). There may 
be cases where the multiple imputation model fails to converge. In such situations, the last 
observation carried forward (LOCF) approach will instead be used to impute the missing data. If 
LOCF is  used instead of multiple imputation for this reason, this will be clearly specified in the 
corresponding table summary. Should there be no missing data for a study variable, then only 
observed case data will be produced. Note that for LOCF imputation, any  missing data or data 
collected following discontinuation of IMP will be imputed with the most recent previous value. 
See Section  14.7 for further d etails.  
14.4 Subgroup analyses  
Subgroup analyses will be performed on the co -primary and secondary efficacy variables for the 
Initial Treatment Period that are part of the fixed sequence testing procedure described in 
Section  14.3.1 . The following variables for subgroup analyses will be defined: age, gender, 
disease duration, region, weight, body mass index, prior systemic chemotherapy or phototherapy, 
prior biologic exposure, prior systemic therapy of any kind, Baseline disease severity, and 
antibody positivity . These summaries will be based on imputed data (NRI or MI) and will 
include descriptive statistics only. Note that the approach for deriving des criptive statistics using 
MI is outlined in Section  14.7. 
14.5 Planned safety and other analyses  
14.5.1  Safety analyses  
Safety variables will be analyzed for al l subjects in the SS. The AMS will be used for summaries 
of safety that include data from the Initial Treatment Period and/or Randomized -Withdrawal 
Period. Additional summaries focusing on safety during the Randomized -Withdrawal Period will 
also be prepare d and will be based on the WK16ResS.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 102 of 209 Adverse events will be coded according to the Medical Dictionary for Regulatory Activities 
(MedDRA). Adverse events will be summarized descriptively by treatment group, primary 
system organ class, High Level Term (HLT),  and preferred term. Additional tables will 
summarize adverse events by intensity and relationship to study drug, adverse events leading to 
withdrawal from the study, SAEs, and deaths.  
For subjects who switch treatment, AEs will be allocated to the treatme nt the subject was on the 
day the event occurred. If the event occurs on the day of the switch, it will be attributed to the 
initial treatment, unless the event has a HLT of “Injection Site Reactions”, in which case it will 
be attributed to the new treatme nt. 
Laboratory values (including markedly abnormal labs), urinary values, vital signs and extent of 
exposure will be presented descriptively by treatment group. Definitions for markedly abnormal 
laboratory values will be provided in the SAP.  
14.5.2  Pharmacokineti c analyses  
Pharmacokinetic variables will be analyzed for all subjects in the PK -PPS. Bimekizumab plasma 
concentrations will be summarized for each treatment at each scheduled visit.  
14.5.3  Immunogenicity analyses  
Anti-bimekizumab antibody detection (including po sitivity) will be summarized by treatment at 
each scheduled visit.  
14.6 Handling of protocol deviations  
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful impact on study conduct, or on the primary efficacy,  key safety, or PK outcomes for 
an individual subject. The criteria for identifying important protocol deviations will be defined 
within the appropriate protocol -specific document at study start. Important protocol deviations 
will be reviewed as part of th e ongoing data cleaning process and all important deviations will be 
identified and documented prior to unblinding to confirm exclusion from analysis sets.  
14.7 Handling of dropouts or missing data  
Study variables with multiple components may have rules to account for partial missing data of 1 
or more components. Such rules will be defined in the SAP. The following rules are outlined for 
cases where variables are completely missing, including partial missing data where the data 
handling rules conclude that t he variable should be treated as completely missing.  
The analysis of the co -primary efficacy variables will use NRI for handling of missing data. That 
is, subjects with missing data or who have discontinued IMP prior to Week  16 will be considered 
as nonres ponders for the primary analysis. The following sensitivity analyses for the co -primary 
efficacy variables will be performed:  
1. Missing data will be addressed by using MI (Markov -Chain Monte Carlo [MCMC] method 
for intermittent missing data, followed by mono tone regression for monotone missing data) 
to evaluate the effect of the method for handling missing data on the analysis. The actual 
PASI/IGA scores will be imputed and then dichotomized to obtain the response status. The 
treatment differences for each im puted data set will subsequently be evaluated using the 
stratified CMH test with region and prior biologic exposure as stratification variables as used 
in the primary analysis . The results from each of the imputed data sets will be combined for 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 103 of 209 overall inf erence using Rubin’s rules, which account for the uncertainty associated with the 
imputed values (Rubin, 1987). This will be done using SAS PROC MIANALYZE. This 
procedure assumes a missing at random (MAR) pattern of missingness and corresponds to an 
estiman d of what has been called the difference in outcome improvement if all subjects 
tolerated or adhered to treatment (Mallinckrodt et al, 2012). This is an estimand of efficacy to 
evaluate the de jure hypothesis.  
1. Deviations from the MAR pattern assumed above will be evaluated. A sensitivity analysis 
will be performed in which, as with the above analysis, intermittent missing data will be 
imputed using MI based on the MCMC method. However, the remaining monotone missing 
data will be assumed to follow a missing not at random pattern. These data will be imputed 
using reference -based imputation in which the imputation model is based on data from the 
placebo group, thereby assuming that monotone missing data follow a trajectory similar to 
the placebo group (Mallinck rodt et al, 2012). As specified in the previous procedure, actual 
PASI/IGA scores will be imputed and then dichotomized to get the response status. The 
treatment differences for each imputed data set will subsequently be evaluated using the 
stratified CMH test as used in the primary analysis. The estimand in this procedure is the 
difference in outcome improvement in all randomized subjects at the planned endpoint of the 
study attributable to the initially randomized medication (Mallinckrodt et al, 2012). Th is is an 
estimand of effectiveness to evaluate the de facto hypothesis.  
2. A final sensitivity analysis will be based on observed data at Week  16. Subjects with missing 
data or who have prematurely discontinued IMP will be treated as missing. The same 
stratif ied CMH test as in the primary efficacy analysis will be used.  
Further details on the MI procedures will be provided in the SAP.  
Missing data for binary secondary efficacy variables during the Initial Period will be imputed 
using NRI.  
Missing data for the binary secondary efficacy variable during the Randomized -Withdrawal 
Period (PASI90 at Week 56 among Week 16 PASI90 responders) will be handled via NRI. 
Specifically, if a subject has missing data at Week 56, has discontinued from study treatment, or 
has me t the criterion for relapse during the Randomized -Withdrawal Period, they will be treated 
as a non -responder at Week 56 for this analysis.  
Missing data for continuous secondary efficacy variables will be imputed using MI. The MI 
procedure for continuous va riables will be similar to sensitivity analysis #1 described above for 
the co -primary efficacy endpoints with the following differences: 1) the imputation model will 
use the change from Baseline (instead of actual) values by visit and no dichotomization wi ll be 
necessary; and 2) the analysis model will be based on ANCOVA as opposed to the stratified 
CMH test.  
For other continuous efficacy variables, MI will be used to impute missing data when possible. If 
the imputation model cannot converge, LOCF will be used. The MI procedure will be similar to 
sensitivity analysis #1 described above with the following differences: 1) the imputation model 
will use the change from Baseline (instead of actual) values by visit and no dichotomization will 
be necessary; 2) ins tead of using the stratified CMH test, the imputed data sets will be combined 
and simple means and standard errors will be calculated using Rubin’s rules (via SAS PROC 
MIANALYZE). For calculation of other descriptive statistics such as the median, min and max, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 104 of 209 Rubin's rules do not apply. Multiple imputation estimates will be computed by simply averaging 
the estimates from the multiple repetitions of the imputation algorithm. This is the same 
approach that will be used when summarizing continuous secondary e fficacy variables by 
subgroup.  
14.8 Planned interim analysis and data monitoring  
After the final Week 56 visit, an interim analysis will be performed and a corresponding interim 
CSR may be written. A final analysis and updated final CSR will be prepared once al l data 
(through the SFU visit) have been collected.  
14.9 Determination of sample size  
A total of 400 subjects will be randomly assigned in a 4:1 ratio to the following treatment 
groups:  
 Bimekizumab 320mg (320 subjects)  
 Placebo (80 subjects)  
The primary efficacy  analysis is based on the comparison of bimekizumab to placebo for the co -
primary efficacy variables of PASI90 response and IGA response at Week  16. The assumed 
responder rates for PASI90 at Week  16 are 75% and 2% for bimekizumab and placebo, 
respectively.  Additionally, the assumed responder rates for IGA are 85% and 5% for 
bimekizumab and placebo, respectively. The assumed responder rates for bimekizumab are 
based on the Phase 2b PS0010 data. The power to show statistical superiority of bimekizumab 
relativ e to placebo under these assumptions is >99% for the co -primary endpoints.  
15 ETHICS AND REGULATOR Y REQUIREMENTS  
15.1 Informed consent  
Subject’s informed consent must be obtained and documented in accordance with local 
regulations, ICH -GCP requirements, and the et hical principles that have their origin in the 
principles of the Declaration of Helsinki.  
Prior to obtaining informed consent, information should be given in a language and at a level of 
complexity understandable to the subject in both oral and written for m by the Investigator (or 
designee). Each subject will have the opportunity to discuss the study and its alternatives with 
the Investigator.  
Prior to participation in the study, the ICF should be signed and personally dated by the subject 
and by the person  who conducted the informed consent discussion (Investigator or designee). 
The subject must receive a copy of the signed and dated ICF. As part of the consent process, 
each subject must consent to direct access to his/her medical records for study -related 
monitoring, auditing, IRB/IEC review, and regulatory inspection.  
If the ICF is amended during the study, the Investigator (or the sponsor, if applicable) must 
follow all applicable regulatory requirements pertaining to the approval of the amended ICF by 
the IRB/IEC and use of the amended form.  
All studies conducted at centers in the United States must include the use of a Health Insurance 
Portability and Accountability Act Authorization form.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 105 of 209 The subject may withdraw his/her consent to participate in the st udy at any time. A subject is 
considered as enrolled in the study when he/she has signed the ICF. A eCRF must not be started, 
nor may any study specific procedure be performed for a given subject, without having obtained 
his/her written consent to particip ate in the study.  
15.2 Subject identification cards  
Upon signing the Informed Consent and Assent Form (as applicable), the subject will be 
provided with a subject identification card in the language of the subject. The Investigator will 
fill in the subject identifying information and medical emergency contact information. The 
Investigator will instruct the subject to keep the card with him/her at all times.  
15.3 Institutional Review Boards and Independent Ethics 
Committees  
The study will be conducted under the au spices of an IRB/IEC, as defined in local regulations, 
ICH-GCP, and in accordance with the ethical principles that have their origin in the Declaration 
of Helsinki.  
The Investigator/UCB will ensure that an appropriately constituted IRB/IEC that complies wi th 
the requirements of the current ICH -GCP version or applicable country -specific regulations will 
be responsible for the initial and continuing review and approval of the clinical study. Prior to 
initiation of the study, the Investigator/UCB will forward copies of the protocol, ICF, IB, 
Investigator’s curriculum vitae (if applicable), advertisement (if applicable), and all other 
subject -related documents to be used for the study to the IRB/IEC for its review and approval.  
Before initiating a study, the Inv estigator will have written and dated full approval from the 
responsible IRB/IEC for the protocol.  
The Investigator will also promptly report to the IRB/IEC all changes in the study, all 
unanticipated problems involving risks to human subjects or others, a nd any protocol deviations, 
to eliminate immediate hazards to subjects.  
The Investigator will not make any changes in the study or study conduct without IRB/IEC 
approval, except where necessary to eliminate apparent immediate hazards to the subjects. For 
minor changes to a previously approved protocol during the period covered by the original 
approval, it may be possible for the Investigator to obtain an expedited review by the IRB/IEC as 
allowed.  
As part of the IRB/IEC requirements for continuing review of  approved studies, the Investigator 
will be responsible for submitting periodic progress reports to the IRB/IEC (based on IRB/IEC 
requirements), at intervals appropriate to the degree of subject risk involved, but no less than 
once per year. The Investigat or should provide a final report to the IRB/IEC following study 
completion.  
UCB (or its representative) will communicate safety information to the appropriate regulatory 
authorities and all active Investigators in accordance with applicable regulatory requ irements. 
The appropriate IRB/IEC will also be informed by the Investigator or the Sponsor, as specified 
by the applicable regulatory requirements in each concerned country. Where applicable, 
Investigators are to provide the Sponsor (or its representative)  with evidence of such IRB/IEC 
notification.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 106 of 209 15.4 Subject privacy  
UCB staff (or designee) will affirm and uphold the subject’s confidentiality. Throughout this 
study, all data forwarded to UCB (or designee) will be identified only by the subject number 
assigned  at Screening.  
The Investigator agrees that representatives of UCB, its designee, representatives of the relevant 
IRB/IEC, or representatives of regulatory authorities will be allowed to review that portion of the 
subject’s primary medical records that dir ectly concerns this study (including, but not limited to, 
laboratory test result reports, ECG reports, admission/discharge summaries for hospital 
admissions occurring during a subject’s study participation, and autopsy reports for deaths 
occurring during t he study).  
15.5 Protocol amendments  
Protocol changes may affect the legal and ethical status of the study and may also affect the 
statistical evaluations of sample size and the likelihood of the study fulfilling its primary 
objective.  
Significant changes to the  protocol will only be made as an amendment to the protocol and must 
be approved by UCB, the IRB/IEC, and the regulatory authorities (if required), prior to being 
implemented.  
16 FINANCE, INSURANCE, AND PUBLICATION  
Insurance coverage will be handled according  to local requirements.  
Finance, insurance, and publication rights are addressed in the Investigator and/or CRO 
agreements, as applicable.  
17 REFERENCES  
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schäfer I. Epidemiology and 
comorbidity of psor iasis in children. Br J Dermatol. 2010;162:633 -6. 
Christophers E, Barker JN, Griffiths CE, Daudén E, Milligan G, Molta C, et al. The risk of 
psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in 
European derma tology clinics. J Eur Acad Dermatol Venereol. 2010;24:548 -54. 
Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. National Institutes of 
Health, National Cancer Institute, Division of Cancer Treatment and Diagnosis. 
http://ctep.cancer.gov/ protocolDevelopment/electronic_applications/ctc.htm. Updated 03 Mar 
2016.  
CPMP/ICH/135/95 Note for guidance on Good Clinical Practice (EMEA) Jul 2002.  
Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive 
symptoms and clinic al depression in psoriasis patients: a systematic review and meta -analysis. 
J Invest Dermatol. 2014;134:1542 -51. 
Feldman SR. A quantitative definition of severe psoriasis for use in clinical trials. J Dermatolog 
Treat. 2004;15(1):27 -9. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 107 of 209 Food and Drug Admini stration. Guidance for Industry. Drug -induced liver injury: premarketing 
clinical evaluation. US Dept of Health and Human Services, Center for Drug Evaluation and 
Research, Center for Biologics Evaluation and Research, 07/2009.  
Gelfand JM, Neimann AL, Shin  DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial 
infarction in patients with psoriasis. JAMA. 2006;296:1735 -41. 
Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A, et al. Prevalence of 
metabolic syndrome in patients with psoriasis: a hospital -based case -control study. 
Br J Dermatol. 2007;157:68 -73. 
Gottlieb AB. Psoriasis: Emerging therapeutic strategies. Nat Rev Drug Discov. 2005;4:19 -34. 
Husni ME, Qureshi AA, Keonig AS, Pedersen R, Robertson D. Utility of the PASE 
questionnaire, psoriatic arthritis (PsA) prevalenece and PsA improvement with anti -TNF 
therapy: results from the PRISTINE trial. J Dermatolog Treat. 2014;25(1):90 -5. 
Icen M, Crowson CS, McEvoy MT, Dann FJ, Gabriel SE, Maradit Kremers H. Trends in 
incidence of adult -onset  psoriasis over three decades: a population -based study. J Am Acad 
Dermatol. 2009;60:394 -401. 
Kroenke K, Spitzer RL, Williams JB. The PHQ -9: validity of a brief depression severity 
measure. J Gen Intern Med. 2001;16:606 –13. 
Krueger G, Ellis CN. Psoriasis –recent advances in understanding its pathogenesis and treatment. 
J Am Acad Dermatol. 2005;53(1 Suppl 1):S94 -100. 
Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on 
quality of Life. Results of a 1998 National Psoriasis Fou ndation patient -membership survey. 
Arch Dermatol. 2001;137:280 -4. 
Kurd SK, Smith N, VanVoorhees A, Troxel AB, Badmaev V, Seykora JT, et al. Oral curcumin 
in the treatment of moderate to severe psoriasis vulgaris: a prospective clinical trial. J Am Acad 
Dermatol. 2008;58:625 -31. 
Kurd SK, Gelfand JM. The prevalence of previously diagnosed and undiagnosed psoriasis in US 
adults: results from NHANES 2003 -2004. J Am Acad Dermatol. 2009;60:218 -24. 
Langley RG, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, cl inical features, and quality 
of life. Ann Rheum Dis. 2005;64(Suppl II):ii18 –ii23. 
Mallinckrodt CH, Lin Q, Lipkovich I, Molenberghs G. A structured approach to choosing 
estimands and estimators in longitudinal clinical trials. Pharm Stat. 2012;11:456 -61. 
Maruish, ME (Ed.). User’s manual for the SF -36v2 Health Survey (3rd ed.). Lincoln, RI: 
QualityMetric Incorporated. 2011.  
Mukhtar R, Choi J, Koo JY. Quality of life issues in psoriasis. Dermatol Clin. 2004;22:389 -95. 
Mundt JC, Greist JH, Gelenberg AJ, Katzeln ick DJ, Jefferson JW, Modell JG. Feasibility and 
Validation of a Computer -Automated Columbia -Suicide severity Rating Scale Using Interactive 
Voice Response Technology. J Psychiatr Res. 2010;44(16):1224 -8. 
Ortonne JP. Redefining clinical response in psorias is: targeting the pathological basis of disease. 
J Drugs Dermatol. 2004;3:13 -20. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 108 of 209 Parisi R, Symmons DP, Griffiths CE, Ashcroft DM, Identification and Management of Psoriasis 
and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis:  A 
systematic review of incidence and prevalence. J Invest Dermatol. 2013;133:377 –385. 
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The 
Columbia -Suicide Severity Rating Scale: Initial Validity and Internal Consistency Findings F rom 
Three Multisite Studies With Adolescents and Adults. Am J Psychiatry. 2011;168(12):1266 -77. 
Puig L, Thom H, Mollon P, Tian H, Ramakrishna GS. Clear or almost clear skin improves the 
quality of life in patients with moderate -to-severe psoriasis: a syste matic review and meta -
analysis. J Eur Acad Dermatol Venereol. 2017;31(2):213 -220. 
Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United 
States. J Am Acad Dermatol. 2014;70:512 -6. 
Raychaudhuri SP, Gross J. A comparative stu dy of pediatric onset psoriasis with adult onset 
psoriasis. Pediatric Dermatology. 2000; 17(3):174 –178. 
Rubin DB. 1987. Multiple Imputation for Nonresponse in Surveys. New York: John Wiley and 
Sons.  
Valizadeh A, Khosravi A, Zadeh LJ, Parizad EG. Role of IL -25 in Immunity. J Clin Diagn Res. 
2015;9(4):OE01 –OE04.  
Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, et al. Psoriasis severity 
and the prevalence of major medical comorbidity: a population -based study. JAMA Dermatol. 
2013;149:1173 -9. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 109 of 209 18 APPENDICES  
18.1 Protocol Amendment 1  
Rationale for the amendment  
The purpose of this amendment was the following:   
 Update the study design to remove the ustekinumab arm  
 Remove the mandatory withdrawal at Week 28 or later  
 Clarify the number of subjects to be screened  
 Add assessment of the Patient Symptom Diary (daily) to the Screening and Week 16 Visits  
 Clarify the dosing window  
 Add percentage of BSA as an assessment at all visits  
 Clarify the PGADA will be performed on all subjects at Baseline  
 Remove the WPAI -SHP V2.0  
 Remove the criterion that excluded subjects exposed to more than 3 biologic response 
modifiers (including no more than 1 IL -17) 
 Clarify that subjects who experienced primary failure (no response within 12 weeks) to 1 or 
more IL -17 biologic re sponse modifiers or more than 1 biologic response modifiers other 
than an IL -17 should be excluded from the study  
 Remove the withdrawal criterion that subjects who do not achieve a PASI50 response by 
Week 28 or later be withdrawn from the study  
 Correct dis crepancies between Section 8 Study procedures by visit and Table 5 -1 Schedule of 
study assessments  
 Clarify that the same assessor should evaluate the subject at each efficacy assessment  
 Clarify in footnote c of Table 12 -2 Laboratory measurements the visits  in which the urine 
drug screen will be performed  
 Update the assessment and management of TB and TB risk factors  
 Update the sequence testing and definition of the Escape Subject Set (ESS) and Active 
Medication Set (AMS)  
In addition, minor spelling, editori al, and formatting changes were made, and the List of 
Abbreviations was updated . 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 110 of 209 Modifications and changes  
Specific changes  
Change #1  
A PHASE 3, MULTICENT ER, DOUBLE -BLIND, AC TIVE COMPARATOR -  AND 
PLACEBO -CONTROLLED S TUDY WITH A 16 -WEEK INITIAL TREATMENT PERIOD 
FOLLOWED BY A 40 -WEE K RANDOMIZED -WITHDRA WAL PERIOD TO EVALUA TE 
THE EFFICACY AND SAF ETY OF BIMEKIZUMAB I N ADULT SUBJECTS WIT H 
MODERATE TO SEVERE C HRONIC PLAQUE PSORIA SIS 
Has been changed to:  
A PHASE 3, MULTICENT ER, DOUBLE -BLIND , ACTIVE COMPARATOR -  AND 
PLACEBO -CONTROLLED S TUDY WITH A N 16-WEEK  INITIAL TREATMENT P ERIOD 
FOLLOWED BY A 40-WEEK  RANDOMIZED -WITHDRAW AL PERIOD TO EVALUAT E 
THE EFFICACY AND SAF ETY OF BIMEKIZUMAB I N ADULT SUBJECTS WIT H 
MODERATE TO SEVERE C HRONIC PLAQUE PSORIA SIS 
 
Change #2  
Section  1 Summary  
This is a Phase 3, multicenter, randomized, double -blind, active comparator - and placebo -
controlled study consisting of a 16 -week Initial Treatment Period followed by a 40 -week 
Randomized -Withdrawal Period to evaluate the efficacy and safety, ph armacokinetics (PK) of 
bimekizumab compared with ustekinumab and placebo in adult subjects with moderate to severe 
chronic plaque psoriasis (PSO).  
The study population consists of adult subjects (≥18 years of age) with a diagnosis of moderate 
to severe chr onic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score  ≥3 
[on a 5 -point scale]) who are a candidate for ustekinumab, or for systemic PSO thera py and/or 
phototherapy and/or photochemotherapy.  
Approximately 750 subjects will be screened in order to have 560 subjects randomized in the 
study. There will be approximately 240 subjects in the bimekizumab treatment arm, 240 subjects 
in the ustekinumab treatment arm, and 80 subjects in the placebo treatment arm. For each 
subject, the study will last a maximum of 76  weeks and will consist of 4 periods, a Screening 
Period (2 to 4 weeks), a double -blind, active comparator - and placebo -controlled Initial 
Treatment Period (16 weeks), a double -blind, active comparator - and placebo -controlled 
Randomized -Withdrawal Period (40 weeks) Period, and a Safety Follow -Up (SFU) Period (20 
weeks after the last dose of investigational medicinal product [IMP]). After complet ing the 
study, eligible subjects will be allowed to enroll in an open -label study.  
During the Initial Treatment Period eligible subjects will be randomized 3:3:1 to receive the 
following blinded IMP regimens:  
 Bimekizumab 320mg administered sc Q4W  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 111 of 209  Ustekinum ab (45mg or 90mg, depending on subject weight) administered sc at Baseline and 
4 weeks later, followed by ustekinumab sc every 12 weeks  
 Placebo administered sc Q4W  
Investigational medicinal product will be administered in the clinic at Baseline, Week  4, We ek 8, 
and Week 12. At the Week  16 study visit, bimekizumab subjects who have achieved a PASI90 
response will enter the 40 -week Randomized -Withdrawal Period. Dosing will be based on 
treatment group assignment at initial randomization as follows:  
 Subjects initially randomized to bimekizumab 320mg Q4W will be re -randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg Q8W or placebo (ie, treatment 
withdrawal)  
 Subjects in the ustekinumab treatment arm will be re -randomized 1:1 to either bimekizum ab 
320mg Q4W or bimekizumab 320mg Q8W  
 Subjects initially randomized to placebo will continue to receive placebo (Q4W)  
Subjects who do not achieve a PASI90 response at Week  16 of the Initial Treatment Period will 
be allocated to an escape arm and receive op en-label bimekizumab 320mg Q4W for 12  weeks. 
Subjects who achieve a PASI50 response at Week  12 of the open -label escape arm will be 
allowed to enroll in the open -label study.  
Subjects who were in the bimekizumab 320mg Q4W treatment arm in the Initial Treat ment 
Period and who relapse at Week  20 or later during the Randomized -Withdrawal Period (up to 
Week  56) will be allocated to an escape arm and receive open -label bimekizumab 320mg Q4W 
for 12  weeks. Relapse is defined as not achieving a PASI75 response. Sub jects who achieve a 
PASI50 response at Week  12 of the open -label escape arm will be allowed to enroll in the open -
label study.  
Subjects who were in the ustekinumab or placebo treatment arms in the Initial Treatment Period 
and do not achieve a PASI50 respon se at Week  28 or later will be withdrawn from the study.  
Has been changed to:  
This is a Phase 3, multicenter, randomized, double -blind, active comparator - and placebo -
controlled study consisting of a 16 -week Initial Treatment Period followed by a 40 -week 
Randomized -Withdrawal Period to evaluate the efficacy,  and safety, and pharmacokinetics (PK) 
of bimekizumab compared with ustekinumab and  placebo in adult subjects with moderate to 
severe chronic plaque psoriasis (PSO).  
The study population consists of adul t subjects (≥18 years of age) with a diagnosis of moderate 
to severe chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score  ≥3 
[on a 5 -point scale]) who are a candidate for ustekinumab, or for systemic PSO therapy and/or 
phototherapy and/or photochemotherapy.  
Approximately 535750 subjects will be screened in order to have 400560 subjects randomized in 
the study. There will be approximately  320240 subjects in the bimekizumab treatment arm , 240 
subjects in the ustekinumab treatment arm,  and 80 subjects in the placebo treatment arm. For 
each subject, the study will last a maximum of 76  weeks and will consist of 4 periods, a 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 112 of 209 Screening Period (2 to  4 weeks), a double -blind, active comparator - and placebo -controlled 
Initial Treatment Period (16 weeks), a double -blind, active comparator - and placebo -controlled 
Randomized -Withdrawal Period (40 weeks) Period, and a Safety Follow -Up (SFU) Period (20 
week s after the last dose of investigational medicinal product [IMP]). After completing the 
study, eligible subjects will be allowed to enroll in an open -label study.  
During the Initial Treatment Period,e Eligible subjects will be randomized 43:3:1 to receive 
the following blinded IMP regimens:  
 Bimekizumab 320mg administered sc Q4W  
 Ustekinumab (45mg or 90mg, depending on subject weight) administered sc at Baseline 
and 4  weeks later, followed by ustekinumab sc every 12 weeks  
 Placebo administered sc Q4W  
Investigational medicinal product will be administered in the clinic at Baseline, Week  4, Week  8, 
and Week 12. At the Week  16 study visit, bimekizumab and placebo  subjects who have 
achieved a PASI90 response will enter the 40 -week Randomized -Withdrawal Per iod. Dosing 
will be based on treatment group assignment at initial randomization as follows:  
 Subjects initially randomized to bimekizumab 320mg Q4W will be re -randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg Q8W or placebo (ie, treatme nt 
withdrawal)  
 Subjects in the ustekinumab treatment arm will be re -randomized 1:1 to either 
bimekizumab 320mg Q4W or bimekizumab 320mg Q8W  
 Subjects initially randomized to placebo will continue to receive placebo (Q4W) provided 
the subject is a PASI90 res ponder  
Subjects who do not achieve a PASI90 response at Week  16 of the Initial Treatment Period will 
be allocated to an escape arm and receive open -label bimekizumab 320mg Q4W for 12  weeks. 
Subjects who achieve a PASI50 response at Week  12 of the open -label escape arm will be 
allowed to enroll in the open -label study.  
All s Subjects who were in the bimekizumab 320mg Q4W treatment arm in the Initial 
Treatment Period and who relapse at Week  20 or later during the Randomized -Withdrawal 
Period (up to Week  56) wi ll be allocated to an escape arm and receive open -label bimekizumab 
320mg Q4W for 12  weeks. Relapse is defined as not achieving a PASI75 response. Subjects who 
achieve a PASI50 response at Week  12 of the open -label escape arm will be allowed to enroll in 
the open -label study.  
Subjects who were in the ustekinumab or placebo treatment arms in the Initial Treatment 
Period and do not achieve a PASI50 response at Week  28 or later will be withdrawn from 
the study.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 113 of 209 Change #3  
Section 2.1.2  Current treatments for psoriasis  
 Brodalumab has been approved in the US for the treatment of moderate to severe plaque 
psoriasis in adult patients who are candidates for systemic therapy or phototherapy and 
have failed to respond or have lost response to other systemic therapies . Brodalumab is a 
human monoclonal IgG2 antibody that selectively binds to human IL -17RA and inhibits 
its interactions with cytokines IL -17A, IL -17F, IL -17C, IL -17A/F heterodimer and IL -25. 
Blocking IL  17RA inhibits IL -17 cytokine -induced responses includ ing the release of 
pro-inflammatory cytokines and chemokines. Brodalumab has a black box warning 
regarding suicidal ideation and behavior.  
Has been changed to:  
 Brodalumab has been approved in the US for the treatment of moderate to severe plaque 
psoriasis in adult patients who are candidates for systemic therapy or phototherapy and 
have failed to respond or have lost response to other systemic therapies. In the EU, 
brodalumab is indicated for the treatment of moderate to severe plaque PSO in 
adult patients who are candidates for systemic therapy. Brodalumab is a human 
monoclonal IgG2 antibody that selectively binds to human IL -17RA and inhibits its 
interactions with cytokines IL -17A, IL -17F, IL -17C, IL -17A/F heterodimer and IL -25. 
Blocking IL  17RA inhibits IL-17 cytokine -induced responses including the release of 
pro-inflammatory cytokines and chemokines. Brodalumab has a black box warning 
regarding suicidal ideation and behavior.  
 
Change #4  
Section 2.2.1.1  Completed studies  
Four clinical studies of bimekiz umab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, and 
UP0031 in 12 healthy volunteers. Three studies (RA0123, PS0010, and PS0016) are ongoing in 
subjects with moderate to severe rheumatoid arthritis (RA0123) and in subjects with moderate to 
severe PSO (PS0010 and PS0016).  
Has been changed to:  
Four clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, and 
UP0031 in 12 healthy volunteers. Three studies (RA0123, PS0010, and PS0016) are ongoing 
in subjects with moderate to severe rheumatoid arthritis (RA0123) and in subjects with 
moderate to severe PSO (PS0010 and PS0016).  
 
Change #5  
Section 2.2.1.2 Ongoing studies  
Five additional studies of bimekizumab in the treatment of PSO are ongoing.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 114 of 209 Has been changed to:  
Four additional studies of bimekizumab in the treatment of PSO and 1 study in healthy 
volunteers are ongoing. Five additional studies of bimekizumab in the treatment of PSO 
are ongoing.  
 
Change #6  
Section 3.2 Secondary objectives  
The following bullet has been deleted:  
 Evaluate the efficacy of bimekizumab compared to ustekinumab after 12, and 16 weeks of 
treatment  
 
Change #7  
Section 3.3 Other objectives  
The following bullet has been deleted:  
 Assess work productivity  
 
Change #8  
Section 4.2.1  Secondary efficacy variables  
The following bullets have been deleted:  
 PASI90 response at Week 12  
 IGA response at Week 12  
 
Change #9  
Section 4.3.1 Other efficacy variable(s)  
The following bullet has been added:  
 Absolute and percent change from Baseline in the produc t of IGA and BSA (IGAxBSA)  
 
Change #10  
Section 4.3.1 Other efficacy variable(s)  
The following bullet has been deleted:  
 Change from Baseline in Work Productivity and Activity Impairment Questionnaire -specific 
health problem (WPAI -SHP) V2.0 adapted to PSO s cores  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 115 of 209 Change #11  
Section 5.1 Study description  
PS0013 is a Phase 3, multicenter, randomized, double -blind, active comparator - and placebo -
controlled study consisting of a 16 -week Initial Treatment Period followed by a 40 -week 
Randomized -Withdrawal Period  to evaluate the efficacy and safety of bimekizumab in adult 
subjects with moderate to severe chronic plaque PSO. To be eligible to participate in this study, 
subjects must be adults with a diagnosis of moderate to severe PSO (Baseline PASI ≥12 and 
BSA aff ected by PSO ≥10% and IGA score ≥3 [on a 5 -point scale]) who are a candidate for 
ustekinumab, or for systemic PSO therapy and/or phototherapy and/or photochemotherapy. 
Subjects may have been previously exposed to a biologic therapy (see Exclusion Criterion  #21 
and #22, Section  6.2). 
Has been changed to:  
PS0013 is a Phase 3, multicenter, randomized, double -blind, active comparator - and placebo -
controlled study consisting of a 16 -week Initial Treatment Period followed by a 40 -week 
Randomized -Withdrawal Period  to evaluate the efficacy and safety of bimekizumab in adult 
subjects with moderate to severe chronic plaque PSO. To be eligible to participate in this study, 
subjects must be adults with a diagnosis of moderate to severe PSO (Baseline PASI ≥12 and 
BSA aff ected by PSO ≥10% and IGA score ≥3 [on a 5 -point scale]) who are a candidate for 
ustekinumab, or  for systemic PSO therapy and/or phototherapy and/or photochemotherapy. 
Subjects may have been previously exposed to a biologic therapy (see Exclusion Criterion  #21 
and #23, Section  6.2). 
 
Change #12  
Section 5.2 Study periods  
This study will include 4 periods, a Screening Period (2 to 4 weeks), an active comparator - and 
placebo -controlled, Initial Treatment Period (16  weeks), an active comparator - and placebo -
controlled Randomized -Withdrawal Period (40  weeks), and a SFU Period (20 weeks after the 
last dose of IMP). After completing the study, eligible subjects will be allowed to enroll in an 
open -label study. Subjects enrolling into the open -label study  will not have the PS0013 SFU 
Visit.  
Subjects who do not achieve a PASI90 response at Week  16 of the Initial Treatment Period will 
be allocated to escape treatment (see Section  5.2.5 ). Subjects who were in the biekizumab 320mg 
Q4W treatment arm in the Initial Treatment Period and who relapse at Week  20 or later during 
the Randomized -Withdrawal Period (up to Week  56) will be allocated to escape treatme nt (see 
Section  5.2.5 ). Relapse is defined as not achieving a PASI75 response . Subjects who achieve a 
PASI50 response at Week  12 of the open -label es cape arm will be allowed to enroll in the open -
label study.  
Has been changed to:  
This study will include 4 periods: a Screening Period (2 to 4 weeks), a n active comparator - and 
placebo -controlled Initial Treatment Period (16  weeks), a n active comparator - and placebo -
controlled Randomized -Withdrawal Period (40  weeks), and a SFU Period (20 weeks after the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 116 of 209 last dose of IMP). After completing the study, eligible subjects will be allowed to enroll in an 
open -label study. Subjects enrolling into the open -label s tudy will not have the PS0013 SFU 
Visit.  
Subjects who do not achieve a PASI90 response at Week  16 of the Initial Treatment Period will 
be allocated to escape treatment (see Section  5.2.5 ). All sSubjects who were in the 
bimekizumab 320mg Q4W treatment arm in the Initial Treatment Period and who relapse 
at Week  20 or later during the Randomized -Withdrawal Period (up to Week  56) will be allocated 
to escape treatment (see Section  5.2.5 ). Relapse is defined as not achieving a PASI75 response . 
Subjects who achieve a PASI50 response at Week  12 of the open -label escape arm will be 
allowed to enroll in the open -label study.  
 
Change #13  
Section 5.2.2 Initial Treatment Period  
During the active com parator - and placebo -controlled Initial Treatment Period, approximately 
560 subjects will be randomized 3:3:1 to receive the following blinded IMP regimens:  
 Bimekizumab 320mg administered Q4W (240 subjects)  
 Ustekinumab (240 subjects):  
 For subjects weighing  ≤100kg (220lbs), 45mg sc initially and 4 weeks later  
 For subjects weighing >100kg (220lbs), 90mg sc initially and 4 weeks later  
 Placebo administered Q4W (80 subjects)  
Has been changed to:  
During the active comparator - and placebo -controlled Initial Treatm ent Period, approximately 
400560 subjects will be randomized 3:34:1 to receive the following blinded IMP regimens:  
 Bimekizumab 320mg administered Q4W ( 320240 subjects)  
 Ustekinumab (240 subjects):  
 For subjects weighing ≤100kg (220lbs), 45mg sc initially and  4 weeks later  
 For subjects weighing >100kg (220lbs), 90mg sc initially and 4 weeks later  
 Placebo administered Q4W (80 subjects)  
 
Change #14  
Section 5.2.3  Randomized -Withdrawal Period  
At the Week  16 study visit, bimekizumab subjects who have achieved a PAS I90 response will 
enter into a double -blind, active comparator - and placebo -controlled, Randomized -Withdrawal 
Period lasting 40  weeks. Subjects who do not achieve a PASI90 response at the Week  16 study 
visit will be allocated to the escape arm (see Section  5.2.5 ). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 117 of 209 During the Randomized -Withdrawal Period, dosing will be based on treatment group assignment 
at initial randomization as follows:  
 Subjects i nitially randomized to bimekizumab 320mg Q4W will be re -randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg Q8W or placebo (ie, treatment 
withdrawal)  
 Subjects in the ustekinumab treatment arm who achieve a PASI90 response at Week  16 will 
be re -randomized 1:1 to either bimekizumab 320mg Q4W or bimekizumab 320mg Q8W  
 Subjects initially randomized to placebo who achieve a PASI90 response at Week 16 will 
continue to receive placebo (Q4W)  
Investigational medicinal product will be administered in  the clinic at Week  16 and Q4W 
thereafter through Week  52. The assessments to be performed at each visit of the Randomized -
Withdrawal Period are presented in  Table 5 -1. 
Subjects who were in the bimekizumab 320mg Q4W treatment arm in the Initial Treatment 
Period and who relapse at Week  20 or later during the Randomized -Withdrawal Period (up to 
Week  56) will be allocated to the escape arm (see Section 5.2.5). Relapse is def ined as not 
achieving a PASI75 response.  
Subjects who were in the ustekinumab or placebo treatment arms in the Initial Treatment Period 
and do not achieve a PASI50 response at Week  28 or later will be withdrawn from the study  at 
the time point when the PAS I50 response is not achieved.  
Has been changed to:  
At the Week  16 study visit, bimekizumab subjects who have achieved a PASI90 response will 
enter into a double -blind, active comparator - and placebo -controlled , Randomized -Withdrawal 
Period lasting 40  weeks . Subjects who do not achieve a PASI90 response at the Week  16 study 
visit will be allocated to the escape arm (see Section  5.2.5). 
During the Randomized -Withdrawal Period, dosing will be based on treatment group assignment 
at initial randomization as follows:  
 Subjects initially randomized to bimekizumab 320mg Q4W will be re -randomized 1:1:1 to 
either bimekizumab 320mg Q4W or bimekizumab 320mg Q8 W or placebo (ie, treatment 
withdrawal)  
 Subjects in the ustekinumab treatment arm who achieve a PASI90 response at Week  16 
will be re -randomized 1:1 to either bimekizumab 320mg Q4W or bimekizumab 320mg 
Q8W  
 All Ssubjects  initially randomized to placebo who achieve a PASI90 response at Week 16  
will continue to receive placebo (Q4W)  
Investigational medicinal product will be administered in the clinic at Week  16 and Q4W 
thereafter through Week  52. The assessments to be performed at each visit of the Randomized -
Withdrawal Period are presented in Table 5 -1. 
All s ubjects who were in the bimekizumab 320mg Q4W or ustekinumab treatment arms in 
the Initial Treatment Period and  who relapse at Week  20 or later during the Randomized -
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 118 of 209 Withdrawal Period (up to Week  56) will be allocated to the escape arm (see Section  5.2.5 ). 
Relapse is defined as not achieving a PASI75 response.  
Subjects who were in the placebo treatment arm in the Initial Treatment Period and do not 
achieve a PASI50 response at Week  28 or later will be withd rawn from the study  at the 
time point when the PASI50 response is not achieved.  
 
Change #15  
Section 5.2.5 Escape Treatment  
As described above, subjects who do not achieve a PASI90 response at Week  16 of the Initial 
Treatment Period and subjects who were in  the bimekizumab 320mg Q4W treatment arm in the 
Initial Treatment Period and who relapse at Week  20 or later during the Randomized -Withdrawal 
Period (up to Week  56) will receive open -label bimekizumab 320mg Q4W for 12  weeks (ie, 
escape treatment).  
For subj ects who relapse during the Randomized -Withdrawal Period, the subject should 
complete the 12 -week escape treatment period even if this extends to a time point beyond what 
would have been the Week 56 visit (if the subject had not escaped).  
Subjects who achi eve a PASI50 response by the end of the 12 weeks of escape treatment are 
eligible to enroll in the open -label study. The Schedule of Study Assessments for subjects 
receiving escape treatment is provided in Table  5‒2. 
Subjects who do not achieve a PASI50 response after 12 weeks of escape treatment should be 
withdrawn (see Section 6.3), and will have a SFU Visit 20 weeks after their last dose of IMP.  
Has b een changed to:  
As described above, subjects who do not achieve a PASI90 response at Week  16 of the Initial 
Treatment Period and all subjects who were in the bimekizumab 320mg Q4W treatment arm 
in the Initial Treatment Period and who relapse at Week  20 or later during the Randomized -
Withdrawal Period (up to Week  56) will receive open -label bimekizumab 320mg Q4W for 
12 weeks (ie, escape treatment).  
For subjects who relapse during the Randomized -Withdrawal Period, the subject should 
complete the 12 -week escap e treatment period even if this extends to a time point beyond what 
would have been the Week 56 visit (if the subject had not escaped).  
Subjects who achieve a PASI50 response by the end of the 12 weeks of escape treatment are 
eligible to enroll in the open -label study. The Schedule of Study Assessments for subjects 
receiving escape treatment is provided in Table  5‒2. 
Subjects who do not achieve a PASI50 r esponse after 12 weeks of escape treatment should 
be withdrawn (see Section 6.3), and will have a SFU Visit 20 weeks after their last dose of 
IMP.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 119 of 209 Change #16  
Section 5.3  Study duration per subject  
For each subject, the study will last a maximum of up to 7 6 weeks, as follows:  
 Screening Period: 2 to 4 weeks  
 Double -blind, active comparator - and placebo -controlled Initial Treatment Period: 16 weeks  
 Double -blind, active comparator - and placebo -controlled Randomized -Withdrawal Period: 
40 weeks  
 Escape treatment (if required): 12 weeks  
 Safety Follow -Up Period: a SFU Visit is planned 20 weeks after the last dose of IMP (for 
subjects not enrolling in the open -label study)  
Has been changed to:  
For each subject, the study will last a maximum of up to 76 weeks, as foll ows:  
 Screening Period: 2 to 4 weeks  
 Double -blind, active comparator - and placebo -controlled Initial Treatment Period: 16 
weeks  
 Double -blind, active comparator - and placebo -controlled Randomized -Withdrawal Period: 
40 weeks  
 Escape treatment (if required): 12  weeks  
 Safety Follow -Up Period: a SFU Visit is planned 20 weeks after the last dose of IMP (for 
subjects not enrolling in the open -label study)  
 
Change #17  
Section 5.4  Planned number of subjects and site(s)  
Approximately 750 subjects will be screened in or der to have 560 subjects randomized in the 
study. There will be approximately 240 subjects in the bimekizumab treatment arm, 240 subjects 
in the ustekinumab treatment arm, and 80 subjects in the placebo treatment arm. The planned 
number of study sites is a pproximately 100. Every eligible subject who signs an ICF will be 
randomized.  
Has been changed to:  
Approximately 535750 subjects will be screened in order to have 400560 subjects randomized in 
the study. There will be approximately 320240 subjects in the bimekizumab treatment arm , 240 
subjects in the ustekinumab treatment arm,  and 80 subjects in the placebo treatment arm. The 
planned number of study sites is approximately 100. Every eligible subject who signs an ICF will 
be randomized.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 120 of 209 Change #18  
Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Informed consentc X                Xd   
Inclusion/exclusion  X X                  
Urine drug screen  X                 X  
Demographic data  X                   
Psoriasis history  X                   
Significant past medical 
history and concomitant 
diseases  X Xe                  
Physical examf,g X       X  X   X   X  X X 
Height   X                  
Body weight   X      X  X   X   X  X  
Vital signsh X X X X X X X X X X X X X X X X X X X 
Hematology and 
biochemistry  X X X X X X X X X X  X  X  X  X X 
Urinalysis  X X      X  X  X  X  X  X X 
ECG  X       X    X    X  X  
Pregnancy testingi X X   X X X X X X X X X X X X X X X 
Hepatitis B and C testingj X                   
HIV testingk X                   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 121 of 209 Change #18  
Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Chest x -rayl X                   
IGRA Tuberculosis test  X                X   
Tuberculosis 
questionnaire  X X      X  X   X    X X X 
Blood sample for 
bimekizumab plasma 
concentrationsm  X X X X X X X X X   X   X  X X 
Blood sample for 
anti-bimekizumab 
antibodiesm  X   X X X X X X   X   X  X X 
Blood sample for 
genomic, proteomic, 
metabolomics, and 
candidate biomarker 
analysesc,m  X X   X X X          X  
Blood sample for 
genetic/ epigenetic 
analysesc,m  X                X  
PASI  X X X X X X X X X X X X X X X X X X X 
IGA  X X X X X X X X X X X X X X X X X X X 
DLQI   X  X X  X X X X X  X   X  X  X  
PHQ -9 X X   X X X X X X X X X  X X X X X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 122 of 209 Change #18  
Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
eC-SSRS  X X X X X X X X X X X X X X X X X X X 
Patient Symptom Diary 
(daily)  X X X X X X X             
Scalp IGA   X Xn Xn Xn Xn Xn Xn Xn Xn  Xn  Xn  Xn  Xn  
mNAPSI   X   Xo Xo Xo Xo Xo Xo  Xo  Xo  Xo  Xo  
pp-IGA  X Xp Xp Xp Xp Xp Xp Xp Xp  Xp  Xp  Xp  Xp  
EQ-5D-3L  X   X X X X  X  X  X  X  X  
SF-36  X   X X X X  X  X  X  X  X  
Patient Global 
Assessment of PSOq          X  X  X  X  X  
PASE   X                X  
PGADAr  X      X  X  X  X  X  X  
WPAI -SHP V2.0   X      X  X    X    X  
Concomitant medication  X X X X X X X X X X X X X X X X X X X 
Adverse  events  X X X X X X X X X X X X X X X X X X X 
IRTs,t X X X X X X X X X X X X X X X X X X X 
Bimekiz umab, 
ustekinumab, or placebo 
administrations,t  X   X X X Xu X X X X X X X X X   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 123 of 209 Change #18  
Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
CRF=Case R eport Form; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC -SSRS=electronic Columbia -Suicide Severity 
Rating Scale; EQ -5D-3L= Euro -Quality of Life 5 -Dimensions, 3 levels; GI=gastrointestinal; HCV=hepatitis C virus; HIV=hum an immunodeficiency virus; 
IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal product; IRT=interactive response 
technologyPASE=Psoriatic Arthritis Screening and Evaluation; PASI=Psoriasis Area and Sever ity Index; PEOT=Premature End of Treatment Visit;  
PGADA=Patient’s Global Assessment of Disease Activity; PHQ -9=Patient Health Questionnaire 9; PsA=psoriatic arthritis; PSO=psoriasis; SF -36=Short Form 36 
item Health Survey; SFU=Safety Follow -Up; scalp IGA=s calp-specific Investigator’s Global Assessment; TB=tuberculosis; WPAI -SHP=Work Productivity and 
Activity Impairment Questionnaire -specific health problem  
a Visit windows of ± 3 days from the first dose at all visits except SFU. The SFU Visit window is -3 and +7 days from last dose.  
b The SFU Visit will occur 20 weeks after the last dose.  
c A separate Informed Consent Form will be required for subjects who decide to participate in the genomics, genetics, and prote omics substudy. The Informed 
Consent Form mu st be signed prior to collecting any samples for the substudy. The samples will be stored at -80°C at the central biorepository for up to 20 
years.  
e Ensure no significant changes in medical history.  
f Includes evaluation of signs and symptoms of active TB  and risk for exposure to TB.  
g The physical examination will include examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI.  
h Vital signs (blood pressure, pulse rate, and temperature) are to be measured prior to blood samplin g, and prior to dosing, where applicable.  
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits  
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2)  positive 
for anti -hepatitis B core antibody (HBcAb+) and negative for anti -hepatitis B surface antibody (HBsAb−) are excluded. A positive test for HCV is defined as: 1) 
positive for hepatit is C antibody (anti -HCV Ab), and 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also 
excluded. Subjects will also be tested for anti -hepatitis  B surface antibody.  
k The HIV test results will not be recorded in the eCRF.  
l Screening chest x -ray must occur within 3 months prior to the Screening Visit.  
m All blood samples taken prior to dosing.  
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline.  
o The mN APSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 124 of 209 Change #18  
Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
p The pp -IGA will only be assessed in subjects with palmoplantar involvement (pp -IGA score >0) at Baseline.  
q The Patient Global Assessment of psoriasis will be per formed as part of the patient symptoms diary on a weekly basis from baseline through the initial treatment 
period with a +3 day completion window. During the maintenance period this assessment will be completed at each clinic visit specified with a ±3 day 
completion window.  
r The PGADA is assessed only for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47).  
s IMP administration is based on randomization.  
t For bimekizumab, the minimum time between doses should be no less than 24 days and no more than 32 days.  
u At Week 16 subjects will be re -allocated based on original treatment and response to treatment and will receive their first Maintenance Treatment Period dos e. 
 
Has been changed to:  
Table  5-1: Schedule of study asse ssments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Informed consentc X                Xd   
Inclusion/exclusion  X X                  
Urine drug screen  X                 X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 125 of 209 Table  5-1: Schedule of study asse ssments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Demographic data  X                   
Psoriasis history  X                   
Significant past medical 
history and concomitant 
diseases  X Xe                  
Physical examf,g X       X  X   X   X  X X 
Height   X                  
Body weight   X      X  X   X   X  X  
Vital signsh X X X X X X X X X X X X X X X X X X X 
Hematology and 
biochemistry  X X X X X X X X X X  X  X  X  X X 
Urinalysis  X X      X  X  X  X  X  X X 
ECG  X       X    X    X  X  
Pregnancy testingi X X   X X X X X X X X X X X X X X X 
Hepatitis B and C testingj X                   
HIV testingk X                   
Chest x -rayl X                   
IGRA Tuberculosis test  X                X   
Tuberculosis 
questionnaire  X X      X  X   X    X X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 126 of 209 Table  5-1: Schedule of study asse ssments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Blood sample for 
bimekizumab plasma 
concentrationsm  X X X X X X X X X   X   X  X X 
Blood sample for 
anti-bimekizumab 
antibodiesm  X   X X X X X X   X   X  X X 
Blood sample for 
genomic, proteomic, 
metabolomics, and 
candidate biomarker 
analysesc,m  X X   X X X          X  
Blood sample for 
genetic/ epigenetic 
analysesc,m  X                X  
PASI  X X X X X X X X X X X X X X X X X X X 
IGA  X X X X X X X X X X X X X X X X X X X 
Percentage of BSA  X X X X X X X X X X X X X X X X X X X 
DLQI   X  X X  X X X X X X X X  X  X  X  
PHQ -9 X X   X X X X X X X X X  X X X X X  
eC-SSRS  X X X X X X X X X X X X X X X X X X X 
Patient Symptom Diary 
(daily)  X X X X X X X X  X          
Scalp IGA   X Xn Xn Xn Xn Xn Xn Xn Xn  Xn  Xn  Xn  Xn  
mNAPSI   X   Xo Xo Xo Xo Xo Xo  Xo  Xo  Xo  Xo  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 127 of 209 Table  5-1: Schedule of study asse ssments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
pp-IGA  X   Xp Xp Xp Xp Xp Xp  Xp  Xp  Xp  Xp  
EQ-5D-3L  X   X X X X  X  X  X  X  X  
SF-36  X   X X X X  X  X  X  X  X  
Patient Global 
Assessment of PSOq          X  X  X  X  X  
PASE   X                X  
PGADAr  X   X X  X  X  X  X  X  X  
WPAI -SHP V2.0   X      X  X    X    X  
Concomitant medication  X X X X X X X X X X X X X X X X X X X 
Adverse  events  X X X X X X X X X X X X X X X X X X X 
IRTs,t X X X X X X X X X X X X X X X X X X X 
Bimekiz umab, 
ustekinumab, or placebo 
administrations,t  X   X X X Xu X X X X X X X X X   
CRF=Case R eport Form; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC -SSRS=electronic Columbia -Suicide Severity 
Rating Scale; EQ -5D-3L= Euro -Quality of Life 5 -Dimensions, 3 levels; GI=gastrointestinal; HCV=hepatitis C virus; HIV=hum an immunodeficiency virus; 
IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal product; IRT=interactive response 
technologyPASE=Psoriatic Arthritis Screening and Evaluation; PASI=Psoriasis Area and Sever ity Index; PEOT=Premature End of Treatment Visit;  
PGADA=Patient’s Global Assessment of Disease Activity; PHQ -9=Patient Health Questionnaire 9; PsA=psoriatic arthritis; PSO=psoriasis; SF -36=Short Form 36 
item Health Survey; SFU=Safety Follow -Up; scalp IGA=s calp-specific Investigator’s Global Assessment; TB=tuberculosis ; WPAI -SHP=Work Productivity 
and Activity Impairment Questionnaire -specific health problem  
a Visit windows of ± 3 days from the first dose at all visits except SFU. The SFU Visit window is -3 and +7 days from last dose.  
b The SFU Visit will occur 20 weeks after the last dose for subjects who do not enroll in the open -label study . 
c A separate Informed Consent Form will be required for subjects who decide to participate in the genomics, genetics, and proteomics substudy. The Informed 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 128 of 209 Table  5-1: Schedule of study asse ssments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Consent Form must be signed prior to collecting any samples for the substudy. The samples will be stored at -80°C at the central biorepository for up to 20 
years.  
e Ensure no significant changes in medical hi story.  
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB.  
g The physical examination will include examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI.  
h Vital signs ( sitting systolic and di astolic  blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable.  
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits  
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2)  positive 
for anti -hepatitis B core antibody (HBcAb+) and negative for anti -hepatitis B surfac e antibody (HBsAb−) are excluded. A positive test for HCV is defined as: 1) 
positive for hepatitis C antibody (anti -HCV Ab), and 2) positive via a confirmatory test for HCV (for example, HCV polymerase chain reaction) are also 
excluded. Subjects will also be tested for anti -hepatitis  B surface antibody.  
k The HIV test results will not be recorded in the eCRF.  
l Screening chest x -ray must occur within 3 months prior to the Screening Visit.  
m All blood samples taken prior to dosing.  
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline.  
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.  
p The pp -IGA will only be assessed in subjects with palmoplantar inv olvement (pp -IGA score >0) at Baseline.  
q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from baseline Screening  through the 
Initial Treatment Period with a +3 day completion window. Duri ng the Randomized -Withdrawal P eriod this assessment will be completed at each clinic visit 
specified with a ±3 day completion window.  
r The PGADA is assessed only for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47).  
s IMP administration is based on randomization.  
t The dosing window is ±7 days relative to the scheduled dosing visit. For bimekizumab, the minimum time between doses should be no less than 24 days 
and no more than 32 days.  
u At Week 16 subjects will be re -allocated based on original treatment and response to treatment and will receive their first Randomized -Withdrawal  Period 
dose.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 129 of 209  
Change #19  
Table  5-2: Schedule of study assessments for subjects allocated to escape treatment  
                 Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
eC-SSRS  X X X X X 
Urine drug screen     X  
Physical exam     X X 
Body Weight  X   X  
Vital signsc X X X X X 
Hematology and biochemistry  X X X X X 
Urinalysis  X   X X 
ECG     X  
Pregnancy testingd X X X X X 
IGRA Tuberculosis test     X  
Tuberculosis questionnaire     X X 
Blood sample for bimekizumab plasma concentrationse X X X X X 
Blood sample for anti -bimekizumab antibodiese X X X X X 
Blood sample for genomic, proteomic, metabolomics, and , candidate 
biomarker  analysese X   X  
Blood sample for genetic/epigenetic analysese    X  
PASI  X X X X X 
IGA X X X X X 
DLQI  X X  X  
PHQ -9 X X X X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 130 of 209 Table  5-2: Schedule of study assessments for subjects allocated to escape treatment  
                 Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
scalp IGAf X X  X  
mNAPSIg X   X  
pp-IGAh X X  X  
EQ-5D-3L X   X  
SF-36 X   X  
Patient Global Assessment of PSOi X   X  
PASE  X   X  
PGADAj X   X  
WPAI -SHP V2.0  X   X  
Concomitant medication  X X X X X 
Adverse events  X X X X X 
IRT X X X X X 
Bimekizumab administrationk X X X   
BL=baseline; BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; EQ -5D-3L=Euro -Quality of Life 5 -Dimensions, 
3 levels; ET=Early Termination; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IRT=interactive response technology ; 
mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area and Severity Index; PEOT=Premature End of Treatment Visit;  PGADA=Patient’s G lobal 
Assessment of Disease Activity; PHQ -9=Patient Health Questionnaire 9; SF -36=Short Form 36 -item Health Survey; SFU=Safety Follow -Up; TB=tuberculosis; 
WPAI -SHP=Work Productivity and Activity Impairment Questionnaire -specific health problem  
a Visit windows of +/ - 3 days from the first dose at all visits except SFU. SFU Visit window is -3 and +7 days from last dose.  
b The SFU Visit will occur 20 weeks after the last dose.  
c Vital signs (blood pressure, pulse rate, and temperature) are to be measured p rior to blood sampling, and prior to dosing, where applicable.  
d A urine pregnancy test will be performed at every study dosing visit. Pregnancy test results must be negative prior to admini stering study drug.  
e All blood samples taken prior to dosing.  
i During escape treatment, this assessment will be completed at each clinic visit specified with a ±3 day completion window.  
f The scalp IGA will only be assessed for those subjects with scalp involvement at Baseline.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 131 of 209 Table  5-2: Schedule of study assessments for subjects allocated to escape treatment  
                 Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
g The mNAPSI will be assessed only in sub jects with nail involvement at Baseline.  
h The pp -IGA will only be assessed in subjects with palmoplantar involvement at Baseline.  
i The PGADA is assessed only for subjects with PsA at Baseline.  
k The minimum time between doses should be no less than 24 days and no more than 32 days.  
Has been changed to:  
Table  5-2: Schedule of study assessments for subjects allocated to escape treatment  
                 Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
eC-SSRS  X X X X X 
Urine drug screen     X  
Physical exam     X X 
Body Weight  X   X  
Vital signsc X X X X X 
Hematology and biochemistry  X X X X X 
Urinalysis  X   X X 
ECG     X  
Pregnancy testingd X X X X X 
IGRA Tuberculosis test     X  
Tuberculosis questionnaire     X X 
Blood sample for bimekizumab plasma concentrationse X X X X X 
Blood sample for anti -bimekizumab antibodiese X X X X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 132 of 209 Table  5-2: Schedule of study assessments for subjects allocated to escape treatment  
                 Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
Blood sample for genomic, proteomic, metabolomics, and , candidate 
biomarker  analysese X   X  
Blood sample for genetic/epigenetic analysese    X  
PASI  X X X X X 
IGA X X X X X 
Percentage of BSA  X X X X X 
DLQI  X X X X  
PHQ -9 X X X X  
scalp IGAf X X X X  
mNAPSIg X X X X  
pp-IGAh X X X X  
EQ-5D-3L X   X  
SF-36 X   X  
Patient Global Assessment of PSOi X   X  
PASE  X   X  
PGADAj X X X X  
WPAI -SHP V2.0  X   X  
Concomitant medication  X X X X X 
Adverse events  X X X X X 
IRT X X X X X 
Bimekizumab administrationk X X X   
BL=baseline; BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; EQ -5D-3L=Euro -Quality of Life 5 -Dimensions, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 133 of 209 Table  5-2: Schedule of study assessments for subjects allocated to escape treatment  
                 Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
3 levels; ET=Early Termination; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IRT=interactive response technology ; 
mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area and Severity Index; PEOT=Premature End of Treatment Visit;  PGADA=Patient’s Global 
Assessment of Disease Activity; PHQ -9=Patient Health Questionnaire 9; SF -36=Short Form 36 -item Health Survey; SFU=Safety Follow -Up; TB=tuberculosis; 
WPAI -SHP=Work Productivity and Activity Impairment Questionnaire -specific health problem  
a Visit windows of +/ - 3 days from the first dose at all visits except SFU. SFU Visit window is -3 and +7 days from last dose.  
b The SFU Visit will occur 20 weeks after the last dose for subjects who do not enrolled in the open -label study . 
c Vital signs ( sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable.  
d A urine pregnancy test will be performed at every study dosing visit. Pregnancy test results must be negative prior to ad ministering study drug.  
e All blood samples taken prior to dosing.  
f During escape treatment, this assessment will be completed at each clinic visit specified with a ±3 day completion  
f  The scalp IGA will only be assessed for those subjects with scalp in volvement at Baseline.  
g The mNAPSI will be assessed only in subjects with nail involvement at Baseline.  
h The pp -IGA will only be assessed in subjects with palmoplantar involvement at Baseline.  
i The PGADA is assessed only for subjects with PsA at Baselin e. 
k   The dosing window is ±7 days relative to the scheduled dosing visit.  The minimum time between doses should be no less than 24 days and no more 
than 32 days.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 134 of 209 Change #20  
Figure 5 -1 Schematic diagram  
 
IGA=Investigator’s Global Assessment; PASI=Psoriasis Area and Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeks; SFU=Safety Follow -Up 
Note: Subjects who do not achieve a PASI90 response at Week  16 of the Initial Treatment Period will be allocated to an escape arm and receive open -label 
bime kizumab 320mg Q4Wfor 12 weeks  
          Bimekizumab 320mg Q8WBimekizumab 
320mg Q4WScreening
N=240
N=80Initial Treatment Period
Bimekizumab extension 
study
to evaluate response to 
treatment and long -term 
safety
SFU Visit
20 Weeks after last dose for 
subjects not enrolling in 
extension study
12-week, open-label escape 
arm: Bimekizumab 
320mg Q4WBimekizumab 320mg Q4WRandomized - Withdrawal Period
<PASI90
<PASI90          Placebo Q4W  PASI90
Randomize 
1:1:1
relapse
Week 16
Co-Primary 
Endpoint: PASI90 
Response
IGA responseRandomization56 BaselineN=560Relapse: <PASI75 at 
Week 20 or later
Ustekinumab  PASI90N=24012-week, open-label escape arm: 
Bimekizumab 320mg Q4W
20          Bimekizumab 320mg Q8W          Bimekizumab 320mg Q4W   PASI90
Randomize 
1:1
<PASI50: Mandatory study withdrawal at Week 28 
or later
28      Placebo          Placebo Q4W   PASI90<PASI90
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 135 of 209 Note: Subjects who do not achieve a PASI90 response at Week  16 will be allocated to an escape arm and receive open -label bimekizumab 320mg Q4W for 
12 weeks  
Note: Relapse is defined as not achieving a PASI75 response. Subjects in the bimekizumab 320 Q4W treatment arm in the Initial Treatment Period who get re -
randomized at Week 16 and who relapse at Week 20 or later will be allocated to an escape arm and receive open -label bimekizumab 320mg Q4Wfor 12 weeks.  
Note: Subjects in eit her the ustekinumab treatment arm or the placebo treatment arm in the Initial Treatment Period who get re -randomized at Week 16 and who 
do not achieve a PASI50 response at Week 28 or later will be withdrawn from the study at the time point when the PASI50 response is not achieved.  
Has been changed to:  
          Bimekizumab 320mg Q8WBimekizumab 
320mg Q4WScreening
N=320Initial Treatment Period
Bimekizumab extension 
study
to evaluate response to 
treatment and long-term 
safety
SFU Visit
20 Weeks after last dose for 
subjects not enrolling in 
extension study          Bimekizumab 320mg Q4WRandomized - Withdrawal Period
<PASI90          Placebo Q4W  PASI90
Randomize 
1:1:1
relapse
Week 16
Co-Primary 
Endpoint: PASI90 ResponseIGA responseRandomization56 BaselineN=400Relapse: <PASI75 at Week 20 or later
Placebo  PASI90N=80
12-week, open-label escape arm: 
Bimekizumab 320mg Q4W
20          Placebo
28<PASI90relapseRelapse: <PASI75 at 
Week 20 or later
IGA=Investigator’s Global Assessment; PASI=Psoriasis Area and Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeks; SFU=Safet y Follow -Up 
Note: Subjects who do not achieve a PASI90 r esponse at Week  16 of the Initial Treatment Period will be allocated to an escape arm and receive open -
label bimekizumab 320mg Q4Wfor 12 weeks  
Note: Subjects who do not achieve a PASI90 response at Week  16 will be allocated to an escape arm and receive ope n-label bimekizumab 320mg Q4Wfor 
12 weeks.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 136 of 209 Note: Relapse is defined as not achieving a PASI75 response. All s ubjects in the bimekizumab 320mg Q4W and ustekinumab treatment arms in the Initial 
Treatment Period who get re -randomized at Week 16 and who relaps e at Week 20 or later will be allocated to an escape arm and receive open -label 
bimekizumab 320mg Q4Wfor 12 weeks.  
Note: Subjects in either the ustekinumab treatment arm or  the placebo treatment arm in the Initial Treatment Period will continue to receive placebo Q4W 
at Week 16 and later visits provided a PASI90 response was achieved at Week 16 who get re -randomized at Week 16 and who do not achieve a PASI50 
response at Week 28 or later will be withdrawn from the study at the time point when the PASI50 respo nse is not achieved . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 137 of 209 Change #21  
Section 5.8.1  Study design  
A randomized, double -blind, placebo - and active -controlled study design has been selected in 
order to demonstrate efficacy and safety of bimkeizumab for  regulatory approval. The study 
population will include adults with moderate to severe chronic plaque PSO and allow subjects 
who have received previous biologic treatment as well as those who are biologic treatment naïve. 
The primary efficacy outcome measu res (based on PASI and IGA) and other efficacy 
assessments included in this study are consistent with those used for other PSO studies and are 
considered appropriate for establishing efficacy of bimekizumab. An initial treatment period of 
16 weeks will be used to demonstrate the efficacy of bimekizumab over PBO and ustekinumab. 
The study duration extends beyond the initial treatment period (to 56 weeks) to collect 
information on dosing beyond initial treatment, including the impact on efficacy and safety of  
withdrawing bimekizumab treatment from those who responded at Week 16.  
At Week 16, subjects on ustekinumab treatment are re -allocated to treatment with bimekizumab 
320mg Q4W or Q8W. This allows for a controlled evaluation of the safety and efficacy of 
switching from a product with one mechanism of action to another, which is known to occur in 
clinical practice due to either loss of response or access. In a recent PSO study in which subjects 
underwent a switch to a treatment with a different mechanism of ac tion there was no evidence of 
an increased safety risk following the switch (Reich 2017).  
The results of the Phase 2b study PS0010 indicate that approximately 80% of subjects in the 
bimekizumab 320mg Q4W treatment arm achieved a high level of response (PAS I90). Subjects 
who do not achieve a PASI90 response at Week 16 are allocated to a 12 -week escape treatment 
with bimekizumab 320mg Q4W. Allocating subjects who do not achieve a PASI90 on placebo or 
ustekinumab to the bimekizumab 320mg Q4W escape arm provide s them with the opportunity to 
potentially achieve a higher level of efficacy. Beyond just achieving a higher level of skin 
clearance, there is evidence that PASI90 is associated with higher levels of patient satisfaction 
(as measured by DLQI) compared wit h a lower PASI75 threshold (Puig et al, 2017). If Week 16 
PASI90 responders initially randomized to ustekinumab or placebo lose response over time, the 
mandatory withdrawal criterion for subjects who do not achieve a PASI50 response at Week 28 
or later wil l ensure that subjects do not continue to receive prolonged exposure to study 
treatment that is providing a sub -optimal response, regardless of their initial randomized 
treatment.  
Has been changed to:  
A randomized, double -blind, placebo - and active -control led study design has been selected in 
order to demonstrate efficacy and safety of bim ekizumab for regulatory approval. The study 
population will include adults with moderate to severe chronic plaque PSO and allow subjects 
who have received previous biologi c treatment as well as those who are biologic treatment naïve. 
The primary efficacy outcome measures (based on PASI and IGA) and other efficacy 
assessments included in this study are consistent with those used for other PSO studies and are 
considered appro priate for establishing efficacy of bimekizumab. An initial treatment period of 
16 weeks will be used to demonstrate the efficacy of bimekizumab over placebo PBO and 
ustekinumab . The study duration extends beyond the initial treatment period (to 56 weeks) t o 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 138 of 209 collect information on dosing beyond initial treatment, including the impact on efficacy and 
safety of withdrawing bimekizumab treatment from those who responded at Week 16.  
At Week 16, subjects on ustekinumab treatment are re -allocated to treatment with  
bimekizumab 320mg Q4W or Q8W. This allows for a controlled evaluation of the safety 
and efficacy of switching from a product with one mechanism of action to another, which is 
known to occur in clinical practice due to either loss of response or access. In  a recent PSO 
study in which subjects underwent a switch to a treatment with a different mechanism of 
action there was no evidence of an increased safety risk following the switch (Reich 2017).  
The results of the Phase 2b study PS0010 indicate that approxi mately 80% of subjects in the 
bimekizumab 320mg Q4W treatment arm achieved a high level of response (PASI90). Subjects 
who do not achieve a PASI90 response at Week 16 in PS0013  are allocated to a 12 -week escape 
treatment with bimekizumab 320mg Q4W. Allocat ing subjects who do not achieve a PASI90 on 
placebo or ustekinumab  to the bimekizumab 320mg Q4W escape arm provides them with the 
opportunity to potentially achieve a higher level of efficacy. Beyond just achieving a higher level 
of skin clearance, there i s evidence that PASI90 is associated with higher levels of patient 
satisfaction (as measured by DLQI) compared with a lower PASI75 threshold (Puig et al, 2017). 
If Week 16 PASI90 responders initially randomized to ustekinumab or placebo lose 
response over time, the mandatory withdrawal criterion for subjects who do not achieve a 
PASI50 response at Week 28 or later will ensure that subjects do not continue to receive 
prolonged exposure to study treatment that is providing a sub -optimal response, regardless 
of their initial randomized treatment. All subjects who relapse at Week 20 or later will be 
allocated to an escape arm and receive open -label bimekizumab 320mg Q4Wfor 12 weeks. 
Subjects in the placebo treatment arm in the Initial Treatment Period who are >PA SI90 at 
Week 16 and >PASI75 at Week 20 or later will continue to receive placebo at Week 16 and 
later visits.  
  
Change #22  
Section 6.1 Inclusion criterion #6  
6. Subject has a known hypersensitivity to any excipients of bimekizumab or ustekinumab.  
Has been  changed to:  
6. Subject has a known hypersensitivity to any excipients of bimekizumab  or ustekinumab . 
 
Change #23  
Section 6.1 Inclusion criterion #7  
The following criterion has been deleted:  
7. Subject must be considered, in the opinion of the Investigator , to be a suitable candidate for 
treatment with ustekinumab per regional labeling and has no contraindications to receive 
ustekinumab as per the local label.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 139 of 209 Change #24  
Section 6.2  Exclusion criterion #21  
The following criteria have been deleted:  
21. Subject has had previous exposure to ustekinumab.  
22. Subject has been exposed to more than 3 biological response modifiers (including no more 
than 1 IL -17). 
 
Change #25  
Section 6.2 Exclusion criterion #23  
23. Subject has experienced one primary failure to an IL -17 biolog ical response modifier (no 
response within 12 weeks).  
Has been changed to:  
23. Subject has experienced one primary failure to an IL -17 biological response modifier  (no 
response within 12 weeks) to 1 or more  IL -17 biologic response modifier (eg, 
brodalumab , ixekizumab, secukinumab) OR more than 1 biologic response modifier 
other than an IL -17. 
 
Change #26  
Section 6.2 Exclusion criterion #27  
27. Subject has presence of severe depression, indicated by a score ≥15 using the screening 
PHQ -9. Medication used to treat depression should be stable for 4 weeks prior to baseline.  
Has been changed to:  
27. Subject has presence of severe depression, indicated by a score ≥of 15 to 19  using the 
screening Patient Health Questionnaire 9  (PHQ -9). Medication used to treat depr ession 
should be stable for 4 weeks prior to Baseline.  
 
Change #27  
Section 6.3 Withdrawal criterion #3  
The following criterion has been deleted:  
3. Subject who was in the ustekinumab or placebo arm in the Initial Treatment Period does not 
achieve a PASI50 re sponse at Week 28 or later.  
 
Change #28  
Section 6.3 Withdrawal criterion #8  
The following criterion has been deleted:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 140 of 209 8. Subjects who do not achieve at least a PASI50 response after 12 weeks of escape treatment 
should be withdrawn (see Section  5.2.5 ), and  will have a SFU Visit 20 weeks after their last 
dose of IMP.  
 
Change #29  
Section 6.3 Withdrawal Criteria, Mental Health Criterion #2  
2. Moderately severe depression as indicated by a PHQ -9 score ≥ 15 if this represents an 
increase of 3 points compared to last visit.  
Has been changed to:  
2. Moderately severe depression as indicated by a PHQ -9 score ≥of 15 to 19 if this represents 
an increase of 3 points compared to last visit.  
 
Change #30  
Section 7.1 Treatment(s) to be administered  
The IMPs used in this study are bimekizumab, ustekinumab, and placebo.  
 Bimekizumab will be supplied in a  
 for sc 
injection.  
 Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 1mL PFS for sc injection.  
 Ustekinumab is commercially available and will be supplied in a 0.5mL PFS at a 
concentration of 45mg/0.5ml.  
Has been changed to:  
The IMPs used in this study are bimekizumab , ustekinumab,  and placebo.  
 Bimekizumab will be supplied in a  
 for sc  
injection.  
 Placebo will be supplied as 0.9% sodium chloride aqueous solution (physiological saline, 
preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 1mL PFS for sc injection.  
 Ustekinumab is commercially available and will be supplied in a 0.5 mL PFS at a 
concentration of 45mg/0.5ml.  
 
Change #31  
Section 7.2 Treatment(s) to be administered  
Double -blind Initial Treatment Period dosing  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 141 of 209 Because of differences in the dosing schedule between bimekizumab and ustekinumab, all 
subjects will receive 2 inj ections sc Q4W based on the following dosing scheme:  
 Subjects randomized to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 
160mg injections sc Q4W.  
 Subjects randomized to receive ustekinumab will receive ustekinumab sc at Baseline and 
Week  4, followed by placebo (2 placebo injections sc) at Week  8 and Week  12. Because 
ustekinumab dosing is based on weight, on ustekinumab treatment weeks subjects ≤100kg 
(220lbs) will receive 1 ustekinumab 45mg sc injection and 1 placebo injection and subjects 
>100kg (220lbs) will receive 2 ustekinumab 45mg sc injections.  
 Subjects randomized to receive placebo will receive 2 placebo injections sc Q4W.  
Randomized -Withdrawal Period dosing  
Investigational medicinal product treatment during the Randomized -Withdrawal P eriod will be 
based on treatment group assignment at randomization (see Section  5.2.3).  
 Subjects who are to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 160mg 
injections sc Q4W.  
 Subjects reallocated to receive bimekizumab 320mg Q8W will alterna te between receiving 
bimekizumab (2 bimekizumab 160mg injections sc) followed 4 weeks later by placebo (2 
placebo injections sc).  
 Subject who are to receive placebo will receive 2 placebo injections sc Q4W.  
Subjects who do not achieve a PASI90 response at Week  16 and subjects who were in the 
bimekizumab 320mg Q4W treatment arm in the Initial Treatment Period and who relapse at 
Week  20 or later during the Randomized -Withdrawal Period (up to Week  56) will receive open -
label bimekizumab 320mg Q4W for 12  weeks (escape treatment, see Section 5.2.5 ). 
The dosing scheme is depicted in Table 7 -1.  
Subjects who do not achieve a PASI90 response at Week  16 and all subjects who relapse at 
Week  20 or later during the Randomized -Withdrawal Period (up to Week  56) will receive open -
label bimekizumab 320mg Q4W for 12  weeks (escape treatment, see Section  5.2.5 ). 
The dosing scheme is depicted in Table  7‒1.  
Table  7-1: Dosing Scheme  
Week  
Dose Assignment  0 4 8 12 16 20 24 28 32 36 40 44 48 52 
Bimekizumab 320mg 
Q4W/Q4W  ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Bimekizumab 320mg 
Q4W/Q8W  ●● ●● ●● ●● ●● ○○ ●● ○○ ●● ○○ ●● ○○ ●● ○○ 
Ustekinumab 45mg 
(subjects  ≤100kg)  ▲○ ▲○ ○○ ○○ n/a 
Ustekinumab 90mg ▲▲  ▲▲  ○○ ○○ n/a 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 142 of 209 Table  7-1: Dosing Scheme  
Week  
Dose Assignment  0 4 8 12 16 20 24 28 32 36 40 44 48 52 
(subjects >100kg)  
Placebo  ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ 
n/a=not applicable; Q4W=every 4 weeks; Q8W=every 8 weeks  
Note: A bimekizumab 160mg injection is depicted by a black circle (●).  A placebo injection is depicted by an open 
circle (○).A  ustekinumab  45mg injection is depicted by a black triangle ( ▲). 
Note: Subjects who do not achieve a PASI90 response at Week  16 and and subjects who were in the bimekizumab 
320mg Q4W treatment arm in the Initial Treatment Period and who relapse (defined not achieving a PASI75 
response at Week  20 or later) during the Randomized -Withdrawal Period (up to Week 52) will receive open -label 
bimekizumab 320mg Q4W for 12 weeks (ie, escape treatment).  
Has been c hanged to:  
Double -blind Initial Treatment Period dosing  
Because of differences in the dosing schedule between bimekizumab and ustekinumab, all 
subjects will receive 2 injections sc Q4W based on the following dosing scheme : 
 Subjects randomized to receive bi mekizumab 320mg Q4W will receive 2 bimekizumab 
160mg injections sc Q4W.  
 Subjects randomized to receive ustekinumab will receive ustekinumab sc at Baseline 
and Week  4, followed by placebo (2 placebo injections sc) at Week  8 and Week  12. 
Because ustekinumab dosing is based on weight, on ustekinumab treatment weeks 
subjects ≤100kg (220lbs) will receive 1 ustekinumab 45mg sc injection and 1 placebo 
injection and subjects >100kg (220lbs) will receive 2 ustekinumab 45mg sc injections.  
 Subjects randomized to recei ve placebo will receive 2 placebo injections sc Q4W.  
Randomized -Withdrawal Period dosing  
Investigational medicinal product treatment during the Randomized -Withdrawal Period will be 
based on treatment group assignment at randomization (see Section  5.2.3).  
 Subjects who are to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 160mg 
injections sc Q4W.  
 Subjects reallocated to receive bimekizumab 320mg Q8W will alternate between receiving 
bimekizumab (2 bimekizumab 160mg injections sc) followed 4 weeks lat er by placebo (2 
placebo injections sc).  
 Subjects  in the placebo treatment arm in the Initial Treatment Period who are ≥PASI90 
at Week 16 and ≥PASI75 at Week 20 or later will continue to receive placebo Q4W at 
Week 16 and later visits who are to receive pla cebo will receive 2 placebo injections sc 
Q4W . 
Subjects who do not achieve a PASI90 response at Week  16 and all subjects who were in the 
bimekizumab 320mg Q4W treatment arm in the Initial Treatment Period and who relapse 
at Week  20 or later during the Rand omized -Withdrawal Period (up to Week  56) will receive 
open -label bimekizumab 320mg Q4W for 12  weeks (escape treatment, see Section  5.2.5 ). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 143 of 209 The dosing scheme is depicted in Table 7 -1.  
Table  7-1: Dosing Scheme  
Week  
Dose Assignment  0 4 8 12 16 20 24 28 32 36 40 44 48 52 
Bimekizumab 320mg 
Q4W/Q4W  ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Bimekizumab 320mg 
Q4W/Q8W  ●● ●● ●● ●● ●● ○○ ●● ○○ ●● ○○ ●● ○○ ●● ○○ 
Placebo  ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ 
n/a=not applicable; Q4W=every 4 weeks; Q8W=every 8 weeks  
Note: A bimekizumab 160mg injection is depicted by a black circle (●). A placebo injection is depicted by an open 
circle (○). A ustekinumab  45mg injection is depicted by a black triangle ( ▲). 
Note: Subjects who do not achieve a ≥PASI90 response at Week  16 and andallsubjects who were in the 
bimekizumab 320mg Q4W treatment arm in the Initial Treatment Period and who  relapse (defined not 
achievi ng a ≥PASI75 response at Week  20 or later) during the Randomized -Withdrawal Period (up to Week 52) 
will receive open -label bimekizumab 320mg Q4W for 12 weeks (ie, escape treatment ). Subjects in the placebo 
treatment arm in the Initial Treatment Period that  are >PASI90 at Week 16 and >PASI 75 at Week 20 or 
later will continue to receive placebo Q4W at Week 16 and later visits.  
 
Change #32  
Section 7.3 Packaging  
Bimekizumab, ustekinumab, and placebo will be packaged and labeled according to Good 
Manufacturing Practice (GMP) guidelines and applicable laws or regulations. They will be 
suitably packaged in such a way as to protect the product from deterioration during transport and 
storage. Further information regarding storage and transport conditions are provide d in the IMP 
Handling Manual.  
Has been changed to:  
Bimekizumab , ustekinumab,  and placebo will be packaged and labeled according to Good 
Manufacturing Practice (GMP) guidelines and applicable laws or regulations. They will be 
suitably packaged in such a way as to protect the product from deterioration during transport and 
storage. Further information regarding storage and transport conditions are provided in the IMP 
Handling Manual.  
 
Change #33  
Section 7.4 Labeling  
Bimekizumab, ustekinumab, and placebo will be labeled in accordance with the current 
International Council for Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and 
GMP and will include any locally required statements. If necessary, labels will be translated into 
the local language.  
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 144 of 209 Bimekizumab , ustekinumab,  and placebo will be lab eled in accordance with the current 
International Council for Harmonisation (ICH) guidelines on Good Clinical Practice (GCP) and 
GMP and will include any locally required statements. If necessary, labels will be translated into 
the local language.  
 
Change #34 
Table 7 -2 Prohibited PSO medications  
Anti-TNFs:  
adalimumab (including biosimilar)  
etanercept (including biosimilar)  
infliximab (including biosimilar), golimumab, 
certolizumab pegol   
Any exposure to adalimumab  
1 month for etanercept  
3 months for everyth ing other than 
etanercept and adalimumab  
Other biologics and other systemic therapies:  
ustekinumab  
apremilast, tofacitinib  
alefacept, efalizumab, guselkimab  
 
briakinumab  
rituximab   
Any exposure for ustekinumab  
2 weeks for apremilast and tofacitinib  
3 months for alefacept, efalizumab, and 
guselkimab  
6 months for ustekinumab and briakinumab  
12 months for rituximab  
Anti-IL-17 therapy  
 3 months  
(bimekizumab is excluded per exclusion 
criteria)  
Has been changed to:  
Anti-TNFs:  
adalimumab (including biosimilar)  
etanercept (including biosimilar)  
infliximab (including biosimilar), golimumab, 
certolizumab pegol , adalimumab (including 
biosimilar)   
Any exposure to adalimumab  
1 month for etanercept  
3 months for everything other than 
etanercept and adalimumab  
Other biologics and other systemic therapies:  
ustekinumab  
apremilast, tofacitinib  
alefacept, efalizumab, guselk umab 
 
briakinumab  
rituximab   
6 months Any exposure  for ustekinumab  
2 weeks for apremilast and tofacitinib  
3 months for alefacept, efalizumab, and 
guselk umab 
6 months for ustekinumab and  
briakinumab  
12 months for rituximab  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 145 of 209 Anti-IL-17 therapy  
brodalumab  
ixekizumab  
secukinumab  3 months  
(bimekizumab is excluded per exclusion 
criteria)  
 
Change #35  
Section 7.8.1 Permitted concomitant treatments (medications and therapies)  
The following has been deleted:  
The following concomitant medications are permitted during the study.  
 
Change #36  
Section 7.9 Blinding  
The following paragraph has been deleted:  
Due to differences in presentation betwe en bimekizumab and ustekinumab, special precautions 
will be taken to ensure study blinding and study sites will have blinded and unblinded personnel.  
 
Change #37  
Section 7.9.1.1 Maintenance of the IMP blind  
All subject treatment details (bimekizumab, ustek inumab,  or placebo) will be allocated and 
maintained by the IRT system.  
Has been changed to:  
All subject treatment details (bimekizumab , ustekinumab,  or placebo) will be allocated and 
maintained by the IRT system.  
 
Change #38  
Section 7.10 Randomization and  numbering of subjects  
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region and prior biologic exposure 
(yes/no). The IRT will generate individ ual assignments for subject kits of IMP, as appropriate, 
according to the visit schedule. Efforts should be made to limit the enrollment of subjects with 
prior biologic exposure to approximately 30% of the total study population.  
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 146 of 209 An IR T will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region and prior biologic exposure 
(yes/no). The IRT will generate individual assignments for subject kits of IMP, as appropriate, 
according to the visit schedule.  Efforts should be made to limit the enrollment of subjects 
with prior biologic exposure to approximately 30% of the total study population . 
 
Change #39  
Section 7.10 Randomization and numbering o f subjects  
At Week 16, subjects may be reallocated to a new treatment group based on their PASI response.  
Has been changed to:  
At Week  16, subjects who received bimekizumab Q4W during the Initial Treatment Period  
may be reallocated to a new treatment group  based on their PASI response.  
 
Change #40  
Section 8 Study Procedures by Visit  
The minimum time between doses should be no less than 21 days and no more than 35 days.  
Has been changed to:  
The dosing window is ±7 days relative to the scheduled dosing visit. The minimum time 
between doses should be no less than 21 days and no more than 34 days.  
 
Change #41  
Section 8.1 Screening Visit (2 to 4 Weeks) and Section 8.2.5 Week 16 (±3 days relative to 
Baseline)  
The following bullets have been added:  
 Percentage of BSA  
 Patient Symptom Diary (daily)  
 
Change #42  
Section 8.2.1 Baseline Visit, Section 8.2.2 Weeks 1 and 2 (±3 days relative to Baseline), 
Section 8.2.3 Weeks 4 and 8 (±3 days relative to Base line), Section 8.2.4 Week 12 (±3 days 
relative to Baseline), Section 8.3.1 Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52 (±3 days 
relative to Baseline), Section 8.3.2 Week 56 (±3 days relative to Baseline), Section 8.4.1 
Escape Baseline Visit, Section 8.4.2  Escape Weeks 4 and 8 (±3 days), Section 8.4.3 Escape 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 147 of 209 Visit -Week 12/Premature End of Treatment (±3 days relative to Baseline), and Section 8.6 
Safety Follow -Up Visit (20 weeks after last dose, -3 days/+7 days)  
The following bullet has been added:  
 Percentag e of BSA  
 
Change #43  
Section 8.2.1 Baseline Visit  
After completion of the above -mentioned procedures, administration of bimekizumab, 
ustekinumab, or placebo will occur.  
Has been changed to:  
After completion of the above -mentioned procedures, administration  of bimekizumab , 
ustekinumab , or placebo will occur.  
 
Change #44  
Section 8.2.1  Baseline Visit  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Genomic, proteomic, metabolomics, and candid ate biomarker  analyses  
 Genetic/epigenetic analysis  
 PGADA (only for subjects with PsA)  
Has been changed to:  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (participating 
subjects only)  
 Genetic/epigenetic analysis (participating subjects only)  
 PGADA (only for subjects with PsA)  
 
Change #45  
Section 8.2.2 Weeks 1 and 2 (±3 days relative to Baseline)  
The following bullet has been deleted:  
 pp-IGA 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 148 of 209 Change #46  
Section 8.2.3 Weeks 4 and 8  (±3 days relative to Baseline)  
The following bullet has been added:  
 PGADA (Week 4 only)  
 
Change #47  
Section 8.2.3  Weeks 4 and 8 (±3 days relative to Baseline)  
After completion of the above -mentioned procedures, administration of bimekizumab, 
ustekinumab, or placebo will occur.  
Has been changed to:  
After completion of the above -mentioned procedures, administration of bimekizumab , 
ustekinumab , or placebo will occur . 
 
Change #48  
Section 8.2.2 Weeks 1 and 2 (±3 days relative to Baseline), Section 8.2.3 Weeks 4 and 8 (±3 
days relative to Baseline), Section 8.2.4 Week 12 (±3 days relative to Baseline), Section 8.2.5 
Week 16 (±3 days relative to Baseline), Section 8.3.2 Week 56 (±3 days relative to Baseline), 
Section 8.4.1 Escape Baseline Visit, and Section 8.4.3 Escape Visit -Week 12/Premature End 
of Treatment (±3 days relative to Baseline)  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (Week  1 only)  
Has been changed to:  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Genomic, proteomic, metabolomics, and candidate biomarker  analyses (Week  1 only) 
(participating subjects only)  
 
Change #49  
Section 8.2.5 Week 16 (±3 days relative to Baseline)  
After completion of the above -mentioned procedures, administration of bimekizum ab or placebo 
will occur.  
Has been changed to:  
After completion of the above -mentioned procedures, the Randomized -Withdrawal Period will 
begin  with administration of bimekizumab or placebo  will occur . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 149 of 209  
Change #50  
Section 8.2.5 Week 16 (±3 days relative to Baseline), Section 8.3.1 8.3.1  Weeks 20, 24, 28, 32, 
36, 40, 44, 48, and 52 (±3 days relative to Baseline), Section 8.3.2 Week 56 Visit (±3 days 
relative to Baseline), and Section 8.4.1 Escape Baseline Visit  
 PGADA (only for subjects with PsA)  
Has been cha nged to:  
 PGADA (only  for subjects with PsA at Baseline )  
 
Change #51  
Section 8.3.1 Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52 (±3 days relative to Baseline)  
 DLQI (Weeks 20, 28, 40, and 48 only)  
Has been changed to:  
 DLQI (Weeks 20, 2 48, 32, 40, and 48 onl y) 
 
Change #52  
Section 8.3.2 Week 56  (±3 days relative to Baseline) and Section 8.4.3 Escape Visit -Week 
12/Premature End of Treatment (±3 days relative to Baseline)  
 Collection of blood and urine samples for the following clinical laboratory tests should be  
obtained prior to dosing:  
 Genetic/epigenetic analysis  
Has been changed to:  
 Collection of blood and urine samples for the following clinical laboratory tests should be 
obtained prior to dosing:  
 Genetic/epigenetic analysis (participating subjects only)  
 
Change #53  
Section 8.4 Escape Treatment Period  
As described in Section 5.2.3, subjects who do not achieve a PASI90 response at Week 16 and 
subjects who were in the bimekizumab 320mg Q4W treatment arm in the Initial Treatment 
Period and who relapse (defined  as not achieving a PASI75 response) at Week 20 or later during 
the Randomized -Withdrawal Period (up to Week 56) will receive open -label bimekizumab 
320mg Q4W for 12 weeks (ie, escape treatment).  
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 150 of 209 As described in Section 5.2.3, subjects  who do not achieve a PASI90 response at Week 16 and 
all subjects who relapse at Week 20 or later will be allocated to an escape arm and receive 
open -label bimekizumab 320mg Q4W for 12 weeks  subjects who were in the bimekizumab 
320mg Q4W treatment arm in t he Initial Treatment Period and who relapse (defined as not 
achieving a PASI75 response) at Week 20 or later during the Randomized -Withdrawal 
Period (up to Week 56) will receive open -label bimekizumab 320mg Q4W for 12 weeks (ie, 
escape treatment). Subjects  should complete all visit procedures for their scheduled 
treatment visit and then only complete unique procedures for the escape baseline visit. No 
duplicate assessments should be performed when a subject enters the escape arm.  
 
Change #54  
Section 8.4.2  Escape Weeks 4 and 8 (±3 days)  
 Scalp IGA for subjects with scalp involvement at Baseline (Week 4 only)  
 pp-IGA for subjects with palmoplantar involvement at Baseline (Week 4 only)  
 Concomitant medication  
Has been changed to:  
 Scalp IGA for subjects with scalp involvement at Baseline (Week 4 only)  
 mNAPSI for subjects with nail involvement at Baseline  
 pp-IGA for subjects with palmoplantar involvement at Baseline (Week 4 only)  
 PGADA for subjects with PsA at Baseline  
 Concomitant me dication  
 
Change #55  
Section 9  Assessment of Efficacy  
The following text has been added:  
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp -IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professio nal 
(based on local requirements) who has had documented training on how to perform these 
assessments correctly. Preferably the same assessor should evaluate the subject at each 
assessment.  
 
Change #56  
Section 9.1 Psoriasis Area and Severity Index  
The percent area of involvement (BSA%) is estimated across 4 body areas; head, upper 
extremities, trunk, and lower extremities. Assessors will enter the degree of involvement for a 
given region as a percentage (0 -100%) which will then be mapped into a grad e on a scale of 0 -6 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 151 of 209 (0=none; 1=1% to <10% affected, 2=10% to <30% affected, 3=30% to <50% affected, 4=50% to 
<70% affected, 5=70% to <90% affected, 6=90% to 100% affected) (Table 9 -1). 
Has been changed to:  
The percent area of involvement (BSA%) is estimate d across 4 body areas; head, upper 
extremities, trunk, and lower extremities. Assessors will enter the degree of involvement for a 
given region as a percentage (0 -100%) which will then be mapped into a grade  on a scale of 
0 to 6 (0=none; 1=1% to <10% affec ted, 2=10% to <30% affected, 3=30% to <50% affected, 
4=50% to <70% affected, 5=70% to <90% affected, 6=90% to 100% affected) (Table 9 -1). 
 
Change #57  
Section 9.1 Psoriasis Area and Severity Index  
The total BSA affected by PSO will be derived based on the r egional BSA values provide d when 
assessing the PASI score.  
Has been changed to:  
The total BSA affected by PSO will be entered as a percentage from 0 to 100. derived  based 
on the regional BSA values provide d when assessing the PASI score . 
 
Change #58  
Section  9.4 Patient Health Questionnaire 9  
A of 15 to 19 is considered to indicate moderately severe major depression, and a score >20 is 
considered to be severe major depression.  
Has been changed to:  
A score of 15 to 19 is considered to indicate moderately sever e major depression, and a score 
≥20 is considered to be severe major depression.  
 
Change #59  
Section 9.11  Patient Symptom Diary responses  
UCB developed a new PRO measure that will be used to assess key symptoms relevant to 
patients with moderate to severe chronic plaque PSO. PS0010 used the draft PRO measure in 
selected countries to enable psychometric validation of the PRO. Site staff will train the 
participating subjects on the use of the electronic PRO (ePRO) diary at the BaselineVisit, 
following which t he device will be dispensed to the subject for home use until the Week 16 Visit. 
The ePRO diary will be administered on a daily basis from Baseline to the Week 16 Visit.  
Has been changed to:  
UCB developed a new PRO measure that will be used to assess key s ymptoms relevant to 
patients with moderate to severe chronic plaque PSO. PS0010 used the draft PRO measure in 
selected countries to enable psychometric validation of the PRO. Site staff will train the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 152 of 209 participating subjects on the use of the electronic PRO  (ePRO) diary at the Screening Baseline  
Visit, following which the device will be dispensed to the subject for home use until the Week 16 
Visit. The ePRO diary will be administered on a daily basis from Screening Baseline  to the 
Week 16 Visit.  
 
Change #60  
Section 9.14  WPAI -SHP V2.0  
The section has been deleted:  
The WPAI SHP V2.0 is a patient -reported questionnaire that assesses subject’s employment 
status, work absenteeism, work impairment while working (presenteeism), overall work, and 
daily activity impai rment attributable to a specific health problem (WPAI:SHP) (Reilly et al, 
1993). It has been used in several clinical studies of biologic therapy in subjects with plaque PSO 
(Kimball et al, 2012; Vender et al, 2012).  
Five out of 6 items of the WPAI -SHP are  regrouped into the 4 dimensions, with scores expressed 
as percentage, where higher numbers indicate greater impairment and less productivity, ie, worse 
outcomes, as described in the WPAI -SHP scoring rules.  
The WPAI -SHP V2.0 will be assessed at the visits specified in Table 5‒1 and Table 5‒2.  
 
Change #61  
Section 10.1 Pharmacokinetic variables  
The following text has been deleted:  
Pharmacokinetic samples from subjects receiving ustekinumab will not be analyzed, but stored 
for potential future PK analysis and anti-drug antibody determination.  
 
Change #62  
Section 12.1.1.4 Other safety topics of interest  
The following paragraph has been deleted:  
The following safety topics are prespecified as being of interest for this study, based on findings 
from the IMP clinic al program to date, potential risks generally associated with biologic 
immunomodulators, or findings from other medicines belonging to the same class of drugs. 
There are no specific AE reporting requirements for these topics, however special monitoring, 
additional data collection activities, and/or enhanced signal detection activities (within UCB), are 
in place.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 153 of 209 Change #63  
Section 12.2 Laboratory measurements  
Clinical laboratory assessments consist of serum chemistry, hematology, and urinalysis. A 
centrali zed laboratory will be used to supply all laboratory test supplies and analyze all blood 
and urine samples for hematology, biochemistry, and urinalysis measurements. Any unscheduled 
laboratory testing should also be collected using the central laboratory. Testing to rule out 
hepatitis B, hepatitis C, and HIV (see Exclusion Criterion # 9, Section  6.2) will be performed at 
Screening in addition to those measurements listed in Table 12 -2. 
Specific details regarding the handling and processing of serum chemistry, hematology, and  
urinalysis samples are provided in the study laboratory manuals.  
The following laboratory parameters will be measured:  
Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Basophils  Calcium  pH 
Eosinophils  Chloride  Albumin (protein)  
Lymphocytes  Magnesium  Glucose  
Atypical lymphocytes  Potassium  Blood  
Monocytes  Sodium  Leukocyte esterase  
Neutrophils  Glucose  Nitrite  
Hematocrit  BUN   
Hemoglobin  Creatinine  Urine dipstick for pregnancy testingb 
MCH  ALP   
MCHC  AST   
MCV  ALT   
Platelet count  GGT   
RBC count  Total bilirubin   
WBC count  LDH   
 Serum pregnancy testingb  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; ; GGT=gamma glutamyltransferase; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; 
MCHC=mean corpuscular hemoglobin concentration; MCV=mean corpuscular volume; RBC=red blood cell; 
WBC=white blood cell  
a A urine microscopic examination will be performed if the result for albumin (protein), leukocyte esterase, blood or 
nitrite is abnormal. A urine microscopic examination will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), h yaline casts, WBC casts, RBC casts, waxy casts, granular casts, calcium oxalate 
crystals, uric acid crystals, triphosphate crystals, yeast, bacteria, amorphous urates, and amorphous phosphates.  
b Pregnancy testing will consist of serum testing at the Scree ning. The pregnancy test will be urine at all other visits.  
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 154 of 209 Clinical laboratory assessments consist of serum chemistry, hematology, urinalysis, and urine 
drug screen . A centralized laboratory will be used to supply all laboratory test supplies and 
analyze all blood and urine samples for hematology, biochemistry, and urinalysis measurements. 
Any unscheduled laboratory testing should also be collected using the central laboratory. Testing 
to rule out hepatitis B, hepatitis C, and HIV (see  Exclusion Criterion # 9, Section  6.2) will be 
performed at Screening in addition to those measurements listed in Table 12 -2. 
Specific details regardi ng the handling and processing of serum chemistry, hematology, and 
urinalysis samples are provided in the study laboratory manuals.  
The following laboratory parameters will be measured:  
Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Basophils  Calcium  pH 
Eosinophils  Chloride  Albumin (protein)  
Lymphocytes  Magnesium  Glucose  
Atypical lymphocytes  Potassium  Blood  
Monocytes  Sodium  Leukocyte esterase  
Neutrophils  Glucose  Nitrite  
Hematocrit  BUN  Urine dipstick for pregnancy testingb 
Hemoglobin  Creatinine  Urine drug screenc 
MCH  ALP   
MCHC  AST   
MCV  ALT   
Platelet count  GGT   
RBC count  Total bilirubin   
WBC count  LDH   
 Serum pregnancy testingb  
ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; BUN=blood urea 
nitrogen; GGT=gamma glutamyltransferase; LDH=lactate dehydrogenase; MCH=mean corpuscular hemoglobin; 
MCHC=mean corpuscular hemoglobin concentration; MCV= mean corpuscular volume; PEOT=Premature End of 
Treatment;  RBC=red blood cell; WBC=white blood cell  
a A urine microscopic examination will be performed if the result for albumin (protein), leukocyte esterase, blood or 
nitrite is abnormal. A urine microscop ic examination will include: WBC, RBC, epithelial cells (squamous, 
transitional and renal tubular), hyaline casts, WBC casts, RBC casts, waxy casts, granular casts, calcium oxalate 
crystals, uric acid crystals, triphosphate crystals, yeast, bacteria, amorp hous urates, and amorphous phosphates.  
b Pregnancy testing will consist of serum testing at the Screening Visit . The pregnancy test will be urine at all other 
visits.  
c Urine drug screen will be performed at Screening Visit, and Week 56 or PEOT Visit.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 155 of 209 Change #64  
Section 12.3.1  Assessment and management of TB and TB risk factors, Item d  
d. Current or history of NTMB infection despite prior or current therapy.  
Has been changed to:  
d. NTMB infection is defined as a clinical infection caused by mycobacteria l species other 
than those belonging to the Mycobacterium tuberculosis complex Current or history of 
NTMB infection despite prior or current therapy . 
 
Change #65  
Section 12.3.1.1  Tuberculosis assessment by IGRA  
During conduct of the study, the TB assessment  by IGRA (QuantiFERON TB GOLD is 
recommended) will be performed as described in Table 5 -1  and Table 5 -2 for all subjects. The 
test results will be reported as positive, negative, or indeterminate. Positive TB test results must 
be reported as an adverse ev ent and appropriately updated once the final diagnosis is known (e.g. 
active TB, latent TB, or false positive TB test). UCB also recommends that a  TB specialist be 
consulted  where TB (latent or active) is suspected or if there are doubts regarding test res ults. If 
latent or active TB is identified, subject must undergo appropriate study -specified withdrawal 
procedures. The retest during Screening must be done during the protocol -defined Screening 
window.  
Has been changed to:  
During conduct of the study, the  TB assessment by IGRA (QuantiFERON TB GOLD is 
recommended) will be performed as described in Table 5 -1 and Table 5 -2 for all subjects. The 
test results will be reported as positive, negative, or indeterminate. Positive and indeterminate  
TB test results mu st be reported as an adverse event and appropriately updated once the final 
diagnosis is known (eg, active TB, latent TB, or false positive TB test). UCB also recommends 
that a  TB specialist be consulted  where TB (latent or active) is suspected or if there  are doubts 
regarding test results. If latent or active TB is identified, subject must undergo appropriate study -
specified withdrawal procedures. The retest during Screening must be done during the protocol -
defined Screening window.  
 
Change #66  
Section 14.1 Definition of analysis sets  
The Escape Subject Set (ESS) will consist of all subjects who receive at least 1 dose of escape 
bimekizumab 320mg treatment either due to not achieving a PASI90 response at Week  16 or 
experiencing a relapse after entering t he Randomized -Withdrawal Period.  
The Week  16 Responder Set (WK16ResS) will consist of all subjects who achieve a PASI90 
response at Week  16 and receive at least 1 dose of the IMP during the Randomized -Withdrawal 
Period at Week  16 or later.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 156 of 209 The Active Medic ation Set (AMS) will consist of all subjects who have received at least 1 dose 
of active IMP (bimekizumab or ustekinumab). The AMS will be used for summaries of safety 
that include all data from Baseline (Week 0) to Week 52.  
Has been changed to:  
The Escape  Subject Set (ESS) will consist of all subjects who receive at least 1 dose of escape 
bimekizumab 320mg treatment either due to not achieving a PASI90 response at Week  16 or 
experiencing a relapse after entering the Randomized -Withdrawal Period. Summaries based on 
the ESS will be split between subjects who enter the escape arm: 1) due to PASI90 non -
response at Week 16 or 2) due to relapse during the Maintenance Period (after achieving 
PASI90 response at Week 16).  
The Week  16 Responder Set (WK16ResS) will co nsist of all subjects who achieve a PASI90 
response at Week  16 and receive at least 1 dose of the IMP during the Randomized -Withdrawal 
Period at Week  16 or later.  
The Active Medication Set (AMS) will consist of all subjects who have received at least 1 dos e 
of active IMP (bimekizumab  or ustekinumab ). The AMS will be used for summaries of safety 
that include all data from the Initial Treatment Period and/or Randomized -Withdrawal 
Period Baseline (Week 0) to Week 52 . 
 
Change #67  
Section 14.2  General statistical  considerations  
The hypotheses associated with the subsequent tests are for secondary efficacy endpoints and are 
based on testing for superiority relative to placebo, or for non -inferiority or superiority relative to 
ustekinumab. Note that while subjects r andomized to ustekinumab may receive either the 45mg 
or 90mg dose (according to weight at Baseline), all subjects randomized to ustekinumab will be 
analyzed as a single group (and not broken out by dose) since the proposed strategy is consistent 
with the r ecommended weight -based dosing for ustekinumab. See Figure 14 -1 for details on this 
procedure.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 157 of 209  
Has been changed to:  
The hypotheses associated with the subsequent tests are for secondary efficacy endpoints and are 
based on testing for superiority relative to placebo, or for non -inferiority or superiority 
relative to ustekinumab. Note that while subjects randomized to ust ekinumab may receive 
either the 45mg or 90mg dose (according to weight at Baseline), all subjects randomized to 
ustekinumab will be analyzed as a single group (and not broken out by dose) since the 
proposed strategy is consistent with the recommended weigh t-based dosing for 
ustekinumab . See Figure 14 -1 for details on this procedure.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 158 of 209  
Change #68  
Section 14.3.1.1 Sensitivity analyses  
In order to obtain reasonable estimates of variability for a treatment arm at a given center, a 
minimum of 21 subjects will be  considered acceptable for a center to be included in the model 
without pooling. Given the 3:3:1 randomization allocation scheme, this should provide a 
minimum of about 9 subjects in each of the bimekizumab and ustekinumab arms and 3 subjects 
in the placeb o arm. Centers with fewer than 21 subjects will be eligible for pooling.  
The following center pooling algorithm will be used for each geographic region:  
 If a center has 21 or more subjects, then no pooling will be done for that center.  
 Centers with fewer t han 21 subjects will be ordered from largest to smallest with pooling 
proceeding in the following manner:  
 Two or more centers will be combined until the cumulative subject total is at least 21.  
 Once a pooled center has at least 21 subjects, the process wil l continue in an iterative 
fashion for the subsequent centers in the ordered list, where a new pooled center begins 
each time at least 21 subjects has been reached in the previous pool.  
 If this iterative process reaches the end of the ordered list of cente rs where the final 
pooled center has fewer than 21 subjects, then the subjects from the centers in that pool 
will be combined with the pooled center formed in the previous iteration.  
Has been changed to:  
In order to obtain reasonable estimates of variability for a treatment arm at a given center, a 
minimum of 1521 subjects will be considered acceptable for a center to be included in the model 
without pooling. Given the 4:3:3:1 randomization allocation sche me, this should provide a 
minimum of about 129 subjects in each of  the bimekizumab and ustekinumab  arms and 3 
subjects in the placebo arm. Centers with fewer than 1521 subjects will be eligible for pooling.  
The following center pooling algorithm will be used for each geographic region:  
 If a center has 1521 or more subjects, then no pooling will be done for that center.  
 Centers with fewer than 1521 subjects will be ordered from largest to smallest with pooling 
proceeding in the following manner:  
 Two or mor e centers will be combined until the cumulative subject total is at least 1521. 
 Once a pooled center has at least 1521 subjects, the process will continue in an iterative 
fashion for the subsequent centers in the ordered list, where a new pooled center beg ins 
each time at least 1521 subjects has been reached in the previous pool.  
 If this iterative process reaches the end of the ordered list of centers where the final 
pooled center has fewer than 1521 subjects, then the subjects from the centers in that pool  
will be combined with the pooled center formed in the previous iteration.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 159 of 209 Change #69  
Section 14.3.2.1.1  Initial Treatment Period  
For the binary secondary efficacy variables assessing the superiority of bimekizumab versus 
placebo or ustekinumab, the strat ified CMH test as specified for the primary analysis will be 
implemented. As in the primary analysis, NRI will be used to account for missing data. For the 
assessment of non -inferiority, a non -inferiority margin of 10% will be used and evaluated based 
on the confidence interval for the stratified Mantel -Haenszel risk difference between 
bimekizumab and ustekinumab. A non -inferiority margin of 10% has been selected as this is 
considered to be a clinically relevant difference that could influence the choice of  interventions 
used to treat chronic plaque PSO. Therefore, a difference within the 10% non -inferiority margin 
would suggest a similar impact on efficacy between the treatments.  
Has been changed to:  
For the binary secondary efficacy variables assessing the  superiority of bimekizumab versus 
placebo  or ustekinumab , the stratified CMH test as specified for the primary analysis will be 
implemented. As in the primary analysis, NRI will be used to account for missing data . For the 
assessment of non -inferiority, a  non-inferiority margin of 10% will be used and evaluated 
based on the confidence interval for the stratified Mantel -Haenszel risk difference between 
bimekizumab and ustekinumab. A non -inferiority margin of 10% has been selected as this 
is considered to be  a clinically relevant difference that could influence the choice of 
interventions used to treat chronic plaque PSO. Therefore, a difference within the 10% 
non-inferiority margin would suggest a similar impact on efficacy between the treatments.  
 
Change #7 0 
Section 14.3.2.2 Analysis of the other efficacy variables  
Time to PASI50/75/90/100 response during the Initial Treatment Period will be estimated and 
presented using the Kaplan -Meier product -limit method for each treatment. Time to a given 
response will be defined as the length in days from the first dose of IMP treatment until the first 
date when the response is achieved. Subjects who discontinue IMP prior to achieving a response 
will be censored at the date of IMP discontinuation. Subjects who reach the  Week  16 Visit 
without achieving the given response (and should, therefore, be allocated to escape treatment) 
will be censored at the date of the Week  16 Visit. The median time to response, including the 
2-sided 95% CI, will be calculated for each treatmen t. Between -group differences (bimekizumab 
vs placebo and bimekizumab vs ustekinumab)will be analyzed with the log -rank statistic.  
Has been changed to:  
Time to PASI50/75/90/100 response during the Initial Treatment Period will be estimated and 
presented usi ng the Kaplan -Meier product -limit method for each treatment. Time to a given 
response will be defined as the length in days from the first dose of IMP treatment until the first 
date when the response is achieved. Subjects who discontinue IMP prior to achie ving a response 
will be censored at the date of IMP discontinuation. Subjects who reach the Week  16 Visit 
without achieving the given response (and should, therefore, be allocated to escape treatment) 
will be censored at the date of the Week  16 Visit. The median time to response, including the 
2-sided 95% CI, will be calculated for each treatment. Between -group differences 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 160 of 209 (bimekizumab vs placebo and bimekizumab vs ustekinumab) will be analyzed with the log -
rank statistic.  
 
Change #71  
Section 14.5.1   Safety analyses  
Safety variables will be analyzed for all subjects in the SS. Additional summaries focusing on 
safety during the Randomized -Withdrawal Period will also be prepared and will be based on the 
WK16ResS.  
Has been changed to:  
Safety variables will be an alyzed for all subjects in the SS. The AMS will be used for 
summaries of safety that include data from the Initial Treatment Period and/or 
Randomized -Withdrawal Period. Additional summaries focusing on safety during the 
Randomized -Withdrawal Period will al so be prepared and will be based on the WK16ResS.  
 
Change #72  
Section 14.9 Determination of sample size  
A total of 560 subjects will be randomly assigned in a 3:3:1 ratio to the following treatment 
groups:  
 Bimekizumab 320mg (240 subjects)  
 Ustekinumab (240 subjects)  
 Placebo (80 subjects)  
The primary efficacy analysis is based on the comparison of bimekizumab to placebo for the co -
primary efficacy variables of PASI90 response and IGA response at Week  16. However, as 
described in Section  14.3.2.1.1  , Week  16 comparisons of bimekizumab against ustekinumab for 
PASI90 response and IGA response will also be part of a fixed sequence testing procedure to 
contro l for multiplicity. Therefore, this study has been powered to show statistical superiority to 
ustekinumab based on the co -primary endpoints.  
The assumed responder rates for PASI90 at Week  16 are 75%, 58%, and 2% for bimekizumab, 
ustekinumab, and placebo, r espectively. Additionally, the assumed responder rates for IGA are 
85%, 68%, and 5% for bimekizumab, ustekinumab, and placebo, respectively. The assumed 
responder rates for bimekizumab are based on the Phase 2b PS0010 data. The assumptions 
related to the r esponder rates for ustekinumab are based on those observed in the CLEAR study 
(Thaci et al, 2015). The power to show statistical superiority of bimekizumab relative to placebo 
under these assumptions is >99% for the co -primary endpoints.  
The power to detec t a statistically significant difference between bimekizumab and ustekinumab 
at a 2 -sided significance level of 0.05 is 97% for PASI90 response and >99% for IGA response. 
Because both co -primary endpoints are highly powered independently, and because PASI and 
IGA response tend to be highly correlated, the overall power for achieving superiority on both 
co-primary endpoints is not calculated here as it is similar to the lower of the individual tests. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 161 of 209 Note that the power for the non -inferiority testing betwee n bimekizumab and ustekimumab for 
both PASI90 and IGA responses is >99% based on a 1 -sided significance level of 0.025 and a 
non-inferiority margin of 10%.  
Has been changed to:  
A total of 400560 subjects will be randomly assigned in a 3:34:1 ratio to the following treatment 
groups:  
 Bimekizumab 320mg ( 320240 subjects)  
 Ustekinumab (240 subjects)  
 Placebo (80 subjects)  
The primary efficacy analysis is based on the comparison of bimekizumab to placebo for the co -
primary efficacy variables of PASI90 response and IGA response at Week  16. However, as 
described in Section  14.3.2.1.1  , Week  16 comparisons of bimekizumab against 
ustekinumab for PASI90 response and IGA response will also be part of a fixed sequence 
testing procedure to control for multiplicity. Therefore, t his study has been powered to 
show statistical superiority to ustekinumab based on the co -primary endpoints.  
The assumed responder rates for PASI90 at Week  16 are 75% , 58%,  and 2% for bimekizumab , 
ustekinumab,  and placebo, respectively. Additionally, the a ssumed responder rates for IGA are 
85%, 68%,  and 5% for bimekizumab , ustekinumab,  and placebo, respectively. The assumed 
responder rates for bimekizumab are based on the Phase 2b PS0010 data. The assumptions 
related to the responder rates for ustekinumab a re based on those observed in the CLEAR 
study (Thaci et al, 2015).  The power to show statistical superiority of bimekizumab relative to 
placebo under these assumptions is >99% for the co -primary endpoints.  
The power to detect a statistically significant di fference between bimekizumab and 
ustekinumab at a 2 -sided significance level of 0.05 is 97% for PASI90 response and >99% 
for IGA response. Because both co -primary endpoints are highly powered independently, 
and because PASI and IGA response tend to be high ly correlated, the overall power for 
achieving superiority on both co -primary endpoints is not calculated here as it is similar to 
the lower of the individual tests. Note that the power for the non -inferiority testing between 
bimekizumab and ustekimumab fo r both PASI90 and IGA responses is >99% based on a 1 -
sided significance level of 0.025 and a non -inferiority margin of 10%.  
 
Change #73  
The following references have been deleted:  
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially  rejective 
multiple test procedure. Statistics in Medicine. 2009;28:586 -604. 
Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements 
in patient -reported outcomes in moderate -to-severe psoriasis patients receiving continu ous or 
paused etanercept treatment over 54 weeks: the CRYSTEL study. J Eur Acad Dermatol 
Venereol. 2009;23(12):1374 -82. 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 162 of 209 International Menopause Society. Cornwall, UK: Menopause Terminology; c2015. 
http://www.imsociety.org/menopause_terminology.php. Accessed 25 Jan 2016.  
Kimball AB, Yu AP, Signorovitch J, Xie, J, Tsaneva M, Gupta SR, et al. The effects of 
adalimumab treatment and psoriasis severity on self -reported work productivity and activity 
impairment for patients with moderate to severe psoriasi s. J Am Acad Dermatol. 2012;66(2):e67 -
e75. 
Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti -interleukin -
23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate 
to severe psoriasis with r andomized withdrawal and retreatment: Results from the phase III, 
double -blind, placebo - and active comparator -controlled VOYAGE 2 trial. J Am Acad Dermatol 
2017; 76:418 -31. 
Thaçi D, Blauvelt A, Reich K, et al. Secukinumab is superior to ustekinumab in cle aring skin of 
subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. J Am 
Acad Dermatol 2015; 73:400 -09. 
Vender R, Lynde C, Ho V, Chau D, Poulin -Costello M. Work Productivity and Healthcare 
Resource Utilizatioin Outcomes f or Patients on Etanercept for Moderate -to-Severe Plaque 
Psoriasis: Results from a 1 -Year, Multicentre, Open -Lable, Single -Arm Study in a Clinical 
Setting. Appl Health Econ Health Policy. 2012:10(5):343 -53. 
18.2 Protocol Amendment 2  
Rationale for the amendment  
The purpose of this amendment was the following:   
 Update name and contact information for Clinical Project Manager  
 Extend the duration of the Screening Period, and therefore the overall study duration, by 
1 week  
 Update list of current treatment for PSO to reflect changes in labeling and approved countries  
 Update list of completed and ongoing bimekizumab studies to reflect completion of study 
UP0042  
 Clarify calculation of PASI responder rates  
 Remove references to PD assessments as they will not be conducted in this study  
 Update Schedule of study assessments to modify the visits at which the physical 
examination, TB questionnaire, body weight, ECG, and the Patient Symptom Diary (daily) 
are assessed  
 Clarify that all visits from first dose to Week 24 would have a ±3 day visit window, while all 
visits from Week 28 to end of study would have a ±7 day window  
 Clarify the dosing window  
 Modify exclusion criterion to clarify exclusion of subjects who have participated in other 
studies of bimekizumab, other medications ( systemic or topical), or devices  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 163 of 209  Modify exclusion criteria pertaining to history of malignancy, systemic disease, and major 
depression  
 Add new withdrawal criteria for subjects with newly diagnosed IBD  
 Clarify withdrawal criteria for subjects with depressio n or suicidal ideation or behavior  
 Update prohibited concomitant medications to include tildrakizumab and risankizumab  
 Corrected discrepancies between Section 8 Study procedures by visit and Table 5 -1 Schedule 
of study assessments  
 Revise PASE questionnaire  scoring  
 Clarify definition of abortion  
 Updated laboratory measurements to be performed  
 Provide additional details for requirements for IMP rechallenge in the event of PDILI  
 Update the definition of the FAS Set  
 Clarify regions for analyses  
In addition, mi nor spelling, editorial, and formatting changes were made, and the List of 
abbreviations was updated.  
 
Change #1  
Clinical Project Manager  
Name:   
Address:  UCB BioPharma SPRL, Allée de la Recherche, 60, Brussels,  
Belgium, B -1070  
Phone:   
Fax:  
Clinical Project Manager  
Name:    
Address:  UCB BioPharma SPRL, Allée de la Recherche, 60, Brussels,  
Belgium, B -1070 UCB Biosciences GmbH, Alfred Nobel 
Strasse, Monheim am Rhein, 40789, Germany  
Phone:   
Fax:  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 164 of 209 Change #2  
Section 1  Summary, second and third paragraphs  
The study population consists of adult subjects (≥18 years of age) with a diagnosis of moderate 
to severe chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score  ≥3 
[on a 5 -point scale]) who are candidates for adalimumab or for systemic PSO therapy and/or 
photo therapy and/or photochemotherapy.  
Approximately 535 subjects will be screened in order to have a total of 400 subjects randomized 
in the study. There will be approximately 320 subjects in the bimekizumab treatment arm and 80 
subjects in the placebo treatme nt arm. For each subject, the study will last a maximum of 76 
weeks and will consist of 4  periods, a Screening Period (2  to 4 weeks), a double -blind, active 
comparator -controlled Initial Treatment Period (16  weeks), a dose -blind Maintenance Treatment 
Perio d (40 weeks), and a Safety Follow -Up (SFU) Period (20 weeks after the last dose of the 
investigational medicinal product [IMP]).  
Has been changed to:  
The study population consists of adult subjects (≥18 years of age) with a diagnosis of moderate 
to sever e chronic plaque PSO (Baseline Psoriasis Area and Severity Index [PASI] ≥12 and body 
surface area [BSA] affected by PSO ≥10% and Investigator’s Global Assessment [IGA] score  ≥3 
[on a 5 -point scale]) who are candidates for adalimumab or for systemic PSO the rapy and/or 
phototherapy  and/or photochemotherapy . 
Approximately 535 subjects will be screened in order to have a total of 400 subjects randomized 
in the study. There will be approximately 320 subjects in the bimekizumab treatment arm and 80 
subjects in the placebo treatment arm. For each subject, the stud y will last a maximum of 76 77 
weeks and will consist of 4  periods, a Screening Period (2  to 4 5 weeks), a double -blind, active 
comparator -controlled Initial Treatment Period (16  weeks), a dose -blind Maintenance Treatment 
Period (40 weeks), and a Safety Fo llow-Up (SFU) Period (20 weeks after the last final  dose of 
the investigational medicinal product [IMP]).  
 
Change #3  
Section 1  Summary  
The following text has been added after the sixth paragraph:  
Subjects who complete the Randomized Withdrawal Period (af ter a Week  16 response 
[≥PASI90] on bimekizumab during the Initial Treatment Period ) will be allowed to enroll 
in an open -label study. Placebo -randomized subjects, who receive placebo during the entire 
Initial and Randomized -Withdrawal periods, that comple te Week 56 without relapse into 
the open -label escape arm will not be eligible for the open -label study.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 165 of 209 Change #4  
Section 2.1.2 Current treatments for psoriasis, first paragraph  
Therapy for patients with PSO varies according to the severity of disease. Limited or mild 
disease is often treated with topical therapies such as corticosteroids and vitamin D analogs. 
Patients with more severe disease are often treated with photochemotherapy, methotrexate, 
cyclosporine, the oral phosphodiesterase 4 (PDE4) inhib itor apremilast, or biologic agents, such 
as tumor necrosis factor (TNF) antagonists, interleukin (IL) -12/23 inhibitors, IL -23p19 inhibitors 
and IL -17A inhibitors. The effectiveness of TNF inhibitors in the treatment of PSO has been 
demonstrated in many Ph ase 3 clinical studies and has led to the approval of multiple TNF 
inhibitors for use in patients with moderate to severe PSO. Interleukin inhibitors approved for 
this indication include the IL -12/23 antagonist ustekinumab, the IL -23p19 antagonist 
guselkum ab (in the US only) the IL -17A inhibitors secukinumab and ixekizumab, and the 
IL-17 receptor antagonist brodalumab.  
Has been changed to:  
Therapy for patients with PSO varies according to the severity of disease. Limited or mild 
disease is often treated wi th topical therapies such as corticosteroids and vitamin D analogs. 
Patients with more severe disease are often treated with photochemotherapy  phototherapy , 
methotrexate, cyclosporine, the oral phosphodiesterase 4 (PDE4) inhibitor apremilast, or biologic 
agents, such as tumor necrosis factor (TNF) antagonists, interleukin (IL) -12/23 inhibitors, IL -
23p19 inhibitors and IL -17A inhibitors. The effectiveness of TNF inhibitors in the treatment of 
PSO has been demonstrated in many Phase 3 clinical studies and has  led to the approval of 
multiple TNF inhibitors for use in patients with moderate to severe PSO. Interleukin inhibitors 
approved for this indication include the IL -12/23 antagonist ustekinumab, the IL -23p19 
antagonist guselkumab (in the US only) , the IL -17A inhibitors secukinumab and ixekizumab, 
and the IL -17 receptor antagonist brodalumab.  
 
Change #5  
Section 2.1.2 Current treatments for psoriasis, third bullet  
 Chemophototherapy is a frequent option for moderate to severe patients, but the 
inconvenience of multiple treatment visits and varying efficacy limits its use in the market.  
Has been changed to:  
 Phototherapy Chemophototherapy is a frequent option for moderate to severe patients, but 
the inconvenience of multiple treatment visits and varying efficacy limits its use in the 
market.  
 
Change #6  
Section 2.1.2 Current treatments for psoriasis, final bullet, second and fourth sub -bullets  
 Ustekinumab has been approved in the US and the EU for the treatment of adult patients 
with moderate to severe plaque PSO w ho are candidates for phototherapy or systemic 
therapy. Ustekinumab is a human immunoglobulin (Ig) G1κ monoclonal antibody that 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 166 of 209 binds with specificity to the p40 protein subunit used by both the IL -12 and IL -23 
cytokines, naturally occurring cytokines that  are involved in inflammatory and immune 
responses, such as natural killer cell activation and CD4+ T -cell differentiation and 
activation.  
 Guselkumab has been approved in the US for the treatment of adult patients with 
moderate to severe plaque PSO who ar e candidates for systemic therapy or phototherapy. 
It is a human monoclonal IgG1λ antibody that selectively binds to the p19 subunit of 
interleukin 23 (IL -23) and inhibits its interaction with the IL -23 receptor. IL -23 is a 
naturally occurring cytokine tha t is involved in normal inflammatory and immune 
responses. Guselkumab inhibits the release of proinflammatory cytokines and 
chemokines.  
Has been changed to:  
 Ustekinumab has been approved in the US and the EU for the treatment of adult patients 
with moderate to severe plaque PSO who are candidates for phototherapy or systemic 
therapy. Ustekinumab is a human immunoglobulin (Ig) G1κ monoclonal antibody that 
binds with specificity to the p40 protein subunit used by both the IL -12 and IL -23 
cytokines, naturally occurring cytokines that are involved in inflammatory and immune 
responses, such as natural killer cell activation and CD4+ T -cell differentiation and 
activation.  
 Guselkumab has been approved in the US and the EU for the treatment of adult patients 
with moderate to severe plaque PSO who are candidates for systemic therapy or 
phototherapy. It is a human monoclonal IgG1λ antibody that selectively binds to the p19 
subunit of interleukin 23 (IL -23) and inhibits its interaction with the IL -23 receptor. 
IL-23 is a naturally occurring cytokine that is involved in normal inflammatory and 
immune responses. Guselkumab inhibits the release of proinflammatory pro-
inflammatory  cytokines and chemokines.  
 
Change #7  
Section  2.2.1.1 Completed studies  
Four clinical studies of bimekizumab have been completed: UP0008 in 39 subjects with mild to 
moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with PsA, and 
UP0031 in 12 healthy volunteers.  
Has been changed to:  
Four  Five clinical st udies of bimekizumab have been completed: UP0008 in 39 subjects with 
mild to moderate plaque PSO, RA0124 in 30 healthy volunteers, PA0007 in 53 subjects with 
PsA, and UP0031 in 12 healthy volunteers , and UP0042 in 48 healthy volunteers .  
And the following paragraph has been added:  
UP0042 was a randomized double -blind, placebo -controlled, single -dose, parallel -group 
study to evaluate the safety, tolerability, and pharmacokinetics of bimekizumab 
administered as subcutaneous injection to Japanese and Caucasian  healthy subjects. This 
study demonstrated that the PK profiles following single administration of 80mg, 160mg, 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 167 of 209 and 320mg with sc injection were dose proportional with a linear elimination in both 
Japanese and Caucasian subjects and that the PK profiles of  Japanese and Caucasian 
subjects were considered to be generally similar. A single dose of bimekizumab (80mg, 
160mg, or 320mg) administered as sc injection was generally safe and well tolerated in 
healthy Japanese and Caucasian subjects and no major differ ences in safety findings were 
observed between Japanese and Caucasian subjects.  
 
Change #8  
Section  2.2.1.2 Ongoing studies  
Four additional studies of bimekizumab in the treatment of PSO and 1 study in healthy 
volunteers are ongoing.  
 PS0010 is a Phase 2b, double -blind, placebo -controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and PD of bimekizumab in adult subjects with moderate to severe 
chronic plaque PSO.  
 PS0011 is a long -term extension study for subjects who completed PS0010 to assess  the 
long-term safety, tolerability, and efficacy of bimekizumab.  
 PS0016 is a Phase 2a, subject -blind, Investigator -blind study to evaluate the time course of 
PD response, safety, and PK of bimekizumab in adult subjects with moderate to severe 
chronic plaq ue PSO.  
 PS0018 is a long -term extension study for eligible subjects from PS0016 to assess the safety, 
tolerability, and efficacy of bimekizumab.  
 UP0042 is a Phase 1 study designed to evaluate the safety, tolerability, and PK of 
bimekizumab administered as an sc injection of 80mg, 160mg, or 320mg to Japanese and 
Caucasian healthy subjects.  
Has been changed to:  
Four additional studies of bimekizumab in the treatment of PSO and 1 study in healthy 
volunteers  are ongoing.  
 PS0010 is a Phase 2b, double -blind, pl acebo -controlled, dose ranging study to evaluate the 
safety, efficacy, PK, and pharmacodynamics (PD)  of bimekizumab in adult subjects with 
moderate to severe chronic plaque PSO.  
 PS0011 is a long -term extension study for subjects who completed PS0010 to ass ess the 
long-term safety, tolerability, and efficacy of bimekizumab.  
 PS0016 is a Phase 2a, subject -blind, Investigator -blind study to evaluate the time course of 
PD response, safety, and PK of bimekizumab in adult subjects with moderate to severe 
chronic p laque PSO.  
 PS0018 is a long -term extension study for eligible subjects from PS0016 to assess the safety, 
tolerability, and efficacy of bimekizumab.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 168 of 209  UP0042 is a Phase 1 study designed to evaluate the safety, tolerability, and PK of 
bimekizumab administered as an sc injection of 80mg, 160mg, or 320mg to Japanese 
and Caucasian healthy subjects.  
 
Change #9  
Section 4.3 Other variables  
The following text has been added:  
The other variables are listed below and will be evaluated according to the planned 
assessment s in Table 5 -1. 
 
Change #10  
Section 4.3.1 Other efficacy variables, last sentence in the last paragraph  
Note that PASI responder rates will always be calculated relative to the Baseline (first dose) 
Visit.  
Has been changed to:  
Note that  Unless otherwise s tated  PASI responder rates will  always  be calculated relative to 
the Baseline Visit (first dose).  
 
Change #11  
Section 4.4 Pharmacokinetic variable  
Section 4.5 Pharmacogenomic variables  
Section 4.6 Immunological variable  
Have been changed to:  
Section 4.3.3  Pharmacokinetic variable  
Section 4.3.4 Pharmacogenomic variables  
Section 4.3.5 Immunological variable  
 
Change #12  
Section 5.1 Study description  
PS0013 is a Phase 3, multicenter study consisting of a 16 -week, randomized, double -blind, 
parallel -group, activ e-comparator -controlled Initial Treatment Period followed by a 40 -week, 
Maintenance Treatment Period to evaluate the efficacy and safety of bimekizumab in adult 
subjects with moderate to severe chronic plaque PSO. To be eligible to participate in this stud y, 
subjects must be adults with a diagnosis of moderate to severe PSO (Baseline PASI ≥12 and 
BSA affected by PSO ≥10% and IGA score ≥3 [on a 5 -point scale]) who are candidates for 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 169 of 209 systemic PSO therapy and/or phototherapy and/or photochemotherapy. Adalimuma b will be 
administered per the local label. Up to 30% of subjects may have been previously exposed to a 
biologic therapy (see Exclusion Criterion  #23, Section  6.2). 
Has been changed to:  
PS0013 is a Phase 3, multicenter study consisting of a 16 -week, rando mized, double -blind, 
parallel -group, active -comparator -controlled Initial Treatment Period followed by a 40 -week, 
Maintenance Treatment Period to evaluate the efficacy and safety of bimekizumab in adult 
subjects with moderate to severe chronic plaque PSO. To be eligible to participate in this study, 
subjects must be adults with a diagnosis of moderate to severe PSO (Baseline PASI ≥12 and 
BSA affected by PSO ≥10% and IGA score ≥3 [on a 5 -point scale]) who are candidates for 
systemic PSO therapy and/or photot herapy  and/or photochemotherapy . Adalimumab will be 
administered per the local label. Up to 30% of subjects may have been previously exposed to a 
biologic therapy (see Exclusion Criterion  #23, Section  6.2). 
 
Change #13  
Section 5.2  Study periods  
This study will include 4 periods, a Screening Period (2 to 4 weeks), an Initial Treatment Period 
(16 weeks), a Maintenance Treatment Period (40 weeks), and a SFU Period (20  weeks after the 
last dose of IMP).  After completing the study, eligible subjects will be allo wed to enroll in an 
open -label study. Subjects enrolling into the open -label study will not have the PS0013 SFU 
Visit.  
Subjects who do not achieve a PASI90 response at Week  16 of the Initial Treatment Period will 
be allocated to escape treatment (see Secti on 5.2.5 ). All subjects who relapse at Week  20 or later 
during the Randomized -Withdrawal Period (up to Week  56) will be allocated to escape treatment 
(see Section  5.2.5 ). Relapse is defined as not achieving a PASI75 response . Subjects who 
achieve a PASI50 response at Week  12 of the open -label escape arm will be allowed to enroll in 
the open -label study.  
Has been changed to:  
This study will include 4 periods, a Screening Period (2 to 4 5 weeks), an Initial Treatment 
Period (16 weeks), a Maintenance Treatme nt Period (40 weeks), and a SFU Period (20  weeks 
after the last final  dose of IMP).  After completing the study, eligible subjects will be allowed to 
enroll in an open -label study. Subjects enrolling into the open -label study will not have the 
PS0013 SFU Vi sit. 
Subjects who do not achieve a PASI90 response at Week  16 of the Initial Treatment Period will 
be allocated to escape treatment (see Section  5.2.5 ). All subjects who relapse at Week  20 or later 
during the Randomized -Withdrawal Period (up to Week  56) wi ll be allocated to escape treatment 
(see Section  5.2.5 ). Relapse is defined as not achieving a PASI75 response . Subjects who 
achieve a PASI50 response at Week  12 of the open -label escape arm will be allowed to enroll in 
the open -label study.  
Subjects who c omplete the Randomized Withdrawal Period (after a Week 16 response 
[≥PASI90] on bimekizumab during the Initial Treatment Period) will be allowed to enroll 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 170 of 209 in an open -label study. Placebo -randomized subjects, who receive placebo during the entire 
Initial an d Randomized -Withdrawal periods, that complete Week 56 without relapse into 
the open -label escape arm will not be eligible for the open -label study.  
 
Change #14  
Section 5.2.1 Screening Period  
The Screening Period will last 2 weeks, but can be extended up to a total of 4 weeks.  
Has been changed to:  
The Screening Period will last 2 weeks, but can be extended up to a total of 4 5 weeks  in cases 
where a laboratory assessment needs to be repeated or to allow washout of prohibited 
medications . 
 
Change #15  
Section 5.3 Study duration per subject  
For each subject, the study will last a maximum of up to 76 weeks, as follows:  
 Screening Period: 2 to 4 weeks  
Has been changed to:  
For each subject, the study will last a maximum of up to 76 77 weeks, as follows:  
 Screening Period: 2 to 4 5 weeks  
 
Change #16  
Section 5.3 Study duration per subject  
After the 40 -week Randomized -Withdrawal Period, subjects will be allowed to enroll in an open -
label study,  in which case subjects will undergo the Week  56 study assessments be fore receiving 
their first open -label IMP dose . Subjects who achieve a PASI50 response in the open -label 
escape arm will also be allowed to enroll in the open -label study.   
Has been changed to:  
After the 40 -week Randomized -Withdrawal Period, subjects will  be allowed to enroll in an open -
label study,  in which case subjects will undergo the Week  56 study assessments before receiving 
their first open -label IMP dose . Subjects who achieve a PASI50 response in the open -label 
escape arm will also be allowed to en roll in the open -label study. Subjects who complete the 
Randomized Withdrawal Period (after a Week  16 response [≥PASI90] on bimekizumab 
during the Initial Treatment Period ) will be allowed to enroll in an open -label study. 
Placebo -randomized subjects, who receive placebo during the entire Initial and 
Randomized -Withdrawal periods, that complete Week 56 without relapse into the open -
label escape arm will not be eligible for the open -label study.   
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical  Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 171 of 209 Change #17  
Section 5.5 Anticpated regions and countries  
The regions planned for study conduct are Europe, Canada, and the US, with possible extension 
to other regions and countries.   
Has been changed to:  
The regions planned for study conduct are North America, Western  Europe, Canada, and the 
US Central/Easter n Europe, and Asia/Australia , with possible extension to other regions and 
countries.  
 
Change #18  
Section  5.6 Schedule of study assessments  
The schedule of study assessments for all subjects enrolled in the study is presented in  Table 5 -1. 
The Schedule of  Study Assessments for subjects allocated to escape treatment is presented in 
Table  5-2. 
Has been changed to:  
The schedule of study assessments for all subjects enrolled in the study is presented in  Table 5 -1. 
The Schedule of Study Assessments for subjects  allocated to escape treatment is presented in 
Table  5-2. At each visit, all study assessments should be performed prior to administration 
of IMP.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 172 of 209 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Informed consentc X                Xd   
Inclusion/exclusion  X X                  
Urine drug screen  X                 X  
Demographic data  X                   
Psoriasis history  X                   
Significant past medical 
history and concomitant 
diseases  X Xe                  
Physical examf, g X       X  X   X   X  X X 
Height   X                  
Body weight   X      X  X   X   X  X  
Vital signsh X X X X X X X X X X X X X X X X X X X 
Hematology and 
biochemistry  X X X X X X X X X X  X  X  X  X X 
Urinalysis  X X      X  X  X  X  X  X X 
ECG  X       X    X    X  X  
Pregnancy testingi X X   X X X X X X X X X X X X X X X 
Hepatitis B and C testingj X                   
HIV testingk X                   
Chest x -rayl X                   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 173 of 209 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
IGRA Tuberculosis test  X                X   
Tuberculosis 
questionnaire  X X      X  X   X    X X X 
Blood sample for 
bimekizumab plasma 
concentrationsm  X X X X X X X X X   X   X  X X 
Blood sample for 
anti-bimekizumab 
antibodiesm  X   X X X X X X   X   X  X X 
Blood sample for 
genomic, proteomic, 
metabolomics, and 
candidate biomarker 
analysesc,m  X X   X X X          X  
Blood sample for 
genetic/ epigenetic 
analysesc,m  X                X  
PASI  X X X X X X X X X X X X X X X X X X X 
IGA  X X X X X X X X X X X X X X X X X X X 
Percentage of BSA  X X X X X X X X X X X X X X X X X X X 
DLQI   X  X X  X X X X X X  X  X  X  X  
PHQ -9 X X   X X X X X X X X X  X X X X X  
eC-SSRS  X X X X X X X X X X X X X X X X X X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 174 of 209 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Patient Symptom Diary 
(daily)  X X X X X X X X  X          
Scalp IGA   X Xn Xn Xn Xn Xn Xn Xn Xn  Xn  Xn  Xn  Xn  
mNAPSI   X   Xo Xo Xo Xo Xo Xo  Xo  Xo  Xo  Xo  
pp-IGA  X   Xp Xp Xp Xp Xp Xp  Xp  Xp  Xp  Xp  
EQ-5D-3L  X   X X X X  X  X  X  X  X  
SF-36  X   X X X X  X  X  X  X  X  
Patient Global 
Assessment of PSOq          X  X  X  X  X  
PASE   X                X  
PGADAr  X   X  X X  X  X  X  X  X  
Concomitant medication  X X X X X X X X X X X X X X X X X X X 
Adverse  events  X X X X X X X X X X X X X X X X X X X 
IRTs,t X X X X X X X X X X X X X X X X X X X 
Bimekiz umab or placebo 
administrations,t  X   X X X Xu X X X X X X X X X   
BSA=body s urface area; CRF=Case Report Form; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC -SSRS=electronic 
Columbia -Suicide Severity Rating Scale; EQ -5D-3L= Euro -Quality of Life 5 -Dimensions, 3 levels; GI=gastrointestinal; HCV=hep atitis C virus; HIV=human 
immunodeficiency virus; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal product; 
IRT=interactive response technology; mNAPSI=Modified Nail Psoriasis Severity Index Score; PA SE=Psoriatic Arthritis Screening and Evaluation; 
PASI=Psoriasis Area and Severity Index; PD=pharmacodynamics; PEOT=Premature End of Treatment Visit;  PGADA=Patient’s Global Assessment of Disease 
Activity; PHQ -9=Patient Health Questionnaire 9; pp -IGA=palmopl antar Investigator’s Global Assessment; PsA=psoriatic arthritis; PSO=psoriasis; SF -36=Short 
Form 36 item Health Survey; SFU=Safety Follow -Up; scalp IGA=scalp -specific Investigator’s Global Assessment; TB=tuberculosis;  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 175 of 209 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
a Visit windows of ± 3 days from the  first dose at all visits except SFU. The SFU Visit window is -3 and +7 days from last dose.  
b The SFU Visit will occur 20 weeks after the last dose for subjects who do not enroll in the open -label study.  
c A separate Informed Consent Form will be required  for subjects who decide to participate in the genomics, genetics, and proteomics substudy. The Informed 
Consent Form must be signed prior to collecting any samples for the substudy. The samples will be stored at -80°C at the central biorepository for up t o 20 
years.  
d  
e Ensure no significant changes in medical history.  
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB.  
g The physical examination will include examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI.  
h Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blo od sampling, and prior to dosing, 
where applicable.  
i Pregnancy testing will consist of serum testing at  the Screening. The pregnancy test will be urine at all other visits  
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2)  positive 
for anti -hepatitis B c ore antibody (HBcAb+) and negative for anti -hepatitis B surface antibody (HBsAb−) are excluded. A positive test for HCV is defined as: 1) 
positive for hepatitis C antibody (anti -HCV Ab), and 2) positive via a confirmatory test for HCV (for example, HCV pol ymerase chain reaction) are also 
excluded. Subjects will also be tested for anti -hepatitis  B surface antibody.  
k The HIV test results will not be recorded in the eCRF.  
l Screening chest x -ray must occur within 3 months prior to the Screening Visit.  
m All b lood samples taken prior to dosing.  
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline.  
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.  
p The pp-IGA will only be assessed in subjects with palmoplantar involvement (pp -IGA score >0) at Baseline.  
q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from Scr eening through the Initial 
Treatment Period with a +3 day completion window. During the Randomized -Withdrawal Period this assessment will be completed at each clinic visit specified 
with a ±3 day completion window.  
r The PGADA is assessed only for subjects with PsA at Baseline (defi ned as a past medical history of PsA or PASE ≥47).  
s IMP administration is based on randomization.  
t The dosing window is ±7 days relative to the scheduled dosing visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 176 of 209 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
u At Week 16, subjects will be re -allocated based on original treatment and response t o treatment and will receive their first Randomized -Withdrawal Period dose.  
 
Has been changed to:  
Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal  Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Informed consentc X                Xd   
Inclusion/exclusion  X X                  
Urine drug screen  X                 X  
Demographic data  X                   
Psoriasis history  X                   
Significant past medical 
history and concomitant 
diseases  X Xe                  
Physical examf, g X X     X X  X   X   X  X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 177 of 209 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal  Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Height   X                  
Body weight   X     X X  X   X   X  X  
Vital signsh X X X X X X X X X X X X X X X X X X X 
Hematology and 
biochemistry  X X X X X X X X X X  X  X  X  X X 
Urinalysis  X X      X  X  X  X  X  X X 
ECG  X      X X    X    X  X  
Pregnancy testingi X X   X X X X X X X X X X X X X X X 
Hepatitis B and C testingj X                   
HIV testingk X                   
Chest x -rayl X                   
IGRA Tuberculosis test  X                X   
Tuberculosis 
questionnaire  X X     X X  X   X   X X X X 
Blood sample for 
bimekizumab plasma 
concentrationsm  X X X X X X X X X   X   X  X X 
Blood sample for 
anti-bimekizumab 
antibodiesm  X   X X X X X X   X   X  X X 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 178 of 209 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal  Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
Blood sample for 
genomic, proteomic, 
metabolomics, and 
candidate biomarker 
analysesc,m  X X   X X X  X        X  
Blood sample for 
genetic/ epigenetic 
analysesc,m  X                X  
PASI  X X X X X X X X X X X X X X X X X X X 
IGA  X X X X X X X X X X X X X X X X X X X 
Percentage of BSA  X X X X X X X X X X X X X X X X X X X 
DLQI   X  X X  X X X X X X  X  X  X  X  
PHQ -9 X X   X X X X X X X X X  X X X X X  
eC-SSRS  X X X X X X X X X X X X X X X X X X X 
Patient Symptom Diary 
(daily)  X X X X X X X X  X          
Scalp IGA   X Xn Xn Xn Xn Xn Xn Xn Xn  Xn  Xn  Xn  Xn  
mNAPSI   X   Xo Xo Xo Xo Xo Xo  Xo  Xo  Xo  Xo  
pp-IGA  X   Xp Xp Xp Xp Xp Xp  Xp  Xp  Xp  Xp  
EQ-5D-3L  X   X X X X  X  X  X  X  X  
SF-36  X   X X X X  X  X  X  X  X  
Patient Global 
Assessment of PSOq          X  X  X  X  X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 179 of 209 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal  Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
PASE   X                X  
PGADAr  X   X  X X  X  X  X  X  X  
Concomitant medication  X X X X X X X X X X X X X X X X X X X 
Adverse  events  X X X X X X X X X X X X X X X X X X X 
IRTs,t X X X X X X X X X X X X X X X X X X X 
Bimekiz umab or placebo 
administrations,t  X   X X X Xu X X X X X X X X X   
BSA=body s urface area; CRF=Case Report Form; CV=cardiovascular; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; eC -SSRS=electronic 
Columbia -Suicide Severity Rating Scale; EQ -5D-3L= Euro -Quality of Life 5 -Dimensions, 3 levels; GI=gastrointestinal; HCV=hep atitis C virus; HIV=human 
immunodeficiency virus; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IMP=investigational medicinal product; 
IRT=interactive response technology; mNAPSI=Modified Nail Psoriasis Severity Index Score; PA SE=Psoriatic Arthritis Screening and Evaluation; 
PASI=Psoriasis Area and Severity Index; PD=pharmacodynamics;  PEOT=Premature End of Treatment Visit;  PGADA=Patient’s Global Assessment of Disease 
Activity; PHQ -9=Patient Health Questionnaire 9; pp -IGA=palmopl antar Investigator’s Global Assessment; PsA=psoriatic arthritis; PSO=psoriasis; SF -36=Short 
Form 36 item Health Survey; SFU=Safety Follow -Up; scalp IGA=scalp -specific Investigator’s Global Assessment; TB=tuberculosis;  
a Visit windows of ± 3 days from the  first dose at all visits except SFU  to the Week 24 visit. Visit windows of ±7 days from the Week 28 visit to the Week 52 
visit. The SFU Visit window is ±7 days -3 and +7 days  from last final  dose.  
b The SFU Visit will occur 20 weeks after the last final  dose for subjects who do not enroll in the open -label study.  
c A separate Informed Consent Form will be required for subjects who decide to participate in the genomics, genetics, and prote omics substudy. The 
Informed Consent Form must be signed prior to co llecting any samples for the substudy.  All genomic, proteomic, and metabolomics samples  will be 
stored at -80°C at the central biorepository for up to 20 years.  
d A separate ICF will be required to be completed for the open -label study.  
e Ensure no signifi cant changes in medical history.  
f Includes evaluation of signs and symptoms of active TB and risk for exposure to TB.  
g The physical examination will include examination of the following systems: eyes, hair, and skin; respiratory; CV; and GI  be performed as per 
Section  12.3.5 . 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 180 of 209 Table  5-1: Schedule of study assessments  
Visita/ 
Week  
 
Protocol activity  
Screening   
Initial Treatment Period  
(weeks after first dose)  Randomized -Withdrawal  Period  
(weeks after first dose)  W56/ 
PEOT  SFUb Baseline 
(first dose)  
1 2 4 8 12 16 20 24 28 32 36 40 44 48 52   
h Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blo od sampling, and prior to dosing, 
where applicable.  
i Pregnancy testing will consist of serum testing at the Screening. The pregnancy test will be urine at all other visits  
j Subjects who have evidence of or test positive for hepatitis B by any of the following criteria: 1) positive for hepatitis B surface antigen (HBsAg+); 2)  positive 
for anti -hepatitis B co re antibody (HBcAb+) and negative for anti -hepatitis B surface antibody (HBsAb−) are excluded. A positive test for HCV is defined as: 1) 
positive for hepatitis C antibody (anti -HCV Ab), and 2) positive via a confirmatory test for HCV (for example, HCV poly merase chain reaction) are also 
excluded. Subjects will also be tested for anti -hepatitis  B surface antibody.  
k The HIV test results will not be recorded in the eCRF.  
l Screening chest x -ray must occur within 3 months prior to the Screening Visit.  
m All bl ood samples taken prior to dosing.  
n The scalp IGA will only be assessed for those subjects with scalp involvement (scalp IGA score >0) at Baseline.  
o The mNAPSI will be assessed only in subjects with nail involvement (mNAPSI score >0) at Baseline.  
p The p p-IGA will only be assessed in subjects with palmoplantar involvement (pp -IGA score >0) at Baseline.  
q The Patient Global Assessment of psoriasis will be performed as part of the patient symptoms diary on a weekly basis from Scr eening through the Initial 
Treatment Period with a +3 day completion window . During the Randomized -Withdrawal Period this assessment will be completed at each clinic visit  the 
specified visits with a ±3 day completion window . 
r The PGADA is assessed only for subjects with PsA at Baseline (defined as a past medical history of PsA or PASE ≥47).  
s IMP administration is based on randomization.  
t The dosing window is ±3 ±7 days relative to the scheduled dosing visit through Week 24. The dosing window is ±7 days from Week 28 through the  end of 
the study . 
u At Week 16, subjects will initially randomized to BKZ 320mg Q4W who achieve PASI90 response  be re-allocated based on original treatment and  re-
randomized 1:1:1 to either BKZ 320mg Q4W, BKZ 320mg Q8W or placebo; subjects initially rando mized to placebo who achieve PASI90  response at 
Week 16 will continue  to treatment  receive placebo;  and subjects who do not achieve PASI90 response at Week 16  will receive their first Randomized -
Withdrawal Period dose  be allocated to the escape arm . 
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 181 of 209 Table 5-2: Schedule of study assessments for subjects allocated to escape treatment  
Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
eC-SSRS  X X X X X 
Urine drug screen     X  
Physical exam     X X 
Body Weight  X   X  
Vital signsc X X X X X 
Hematology and biochemistry  X X X X X 
Urinalysis  X   X X 
ECG     X  
Pregnancy testingd X X X X X 
IGRA Tuberculosis test     X  
Tuberculosis questionnaire     X X 
Blood sample for bimekizumab plasma concentrationse X X X X X 
Blood sample for anti -bimekizumab antibodiese X X X X X 
Blood sample for genomic, proteomic, metabolomics, and candidate 
biomarker  analysese X   X  
Blood sample for genetic/epigenetic analysese    X  
PASI  X X X X X 
IGA X X X X X 
Percentage of BSA  X X X X X 
DLQI  X X X X  
PHQ -9 X X X X  
scalp IGAf X X X X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 182 of 209 Table 5-2: Schedule of study assessments for subjects allocated to escape treatment  
Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
mNAPSIg X X X X  
pp-IGAh X X X X  
EQ-5D-3L X   X  
SF-36 X   X  
Patient Global Assessment of PSOi X   X  
PASE  X   X  
PGADAj X X X X  
Concomitant medication  X X X X X 
Adverse events  X X X X X 
IRT X X X X X 
Bimekizumab administrationk X X X   
BL=baseline; BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; EQ -5D-3L=Euro -Quality of Life 5 -Dimensions, 
3 levels; ET=Early Termination; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IRT=interactive response technology ; 
mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area and  Severity Index; PEOT=Premature End of Treatment Visit; PGADA=Patient’s Global 
Assessment of Disease Activity; PHQ -9=Patient Health Questionnaire 9; SF -36=Short Form 36 -item Health Survey; SFU=Safety Follow -Up; TB=tuberculosis  
a Visit windows of +/ - 3 days  from the first dose at all visits except SFU. SFU Visit window is -3 and +7 days from last dose.  
b The SFU Visit will occur 20 weeks after the last dose for subjects who do not enroll in the open -label study.  
c Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blood sampling, and prior to dosing, 
where applicable.  
d A urine pregnancy test will be performed at every study dosing visit. Pregnancy test results must be negative prior to ad ministering study drug.  
e All blood samples taken prior to dosing.  
f The scalp IGA will only be assessed for those subjects with scalp involvement at Baseline.  
g The mNAPSI will be assessed only in subjects with nail involvement at Baseline.  
h The pp -IGA w ill only be assessed in subjects with palmoplantar involvement at Baseline.  
i During escape treatment, this assessment will be completed at each clinic visit specified with a ±3 day completion window.  
j The PGADA is assessed only for subjects with PsA at B aseline.  
k The dosing window is ±7 days relative to the scheduled dosing visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 183 of 209  
Has been changed to:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 184 of 209 Table  5-2: Schedule of study assessments for subjects allocated to escape treatment  
Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
eC-SSRS  X X X X X 
Urine drug screen     X  
Physical exam     X X 
Body Weight  X   X  
Vital signsc X X X X X 
Hematology and biochemistry  X X X X X 
Urinalysis  X   X X 
ECG     X  
Pregnancy testingd X X X X X 
IGRA Tuberculosis test     X  
Tuberculosis questionnaire     X X 
Blood sample for bimekizumab plasma concentrationse X X X X X 
Blood sample for anti -bimekizumab antibodiese X X X X X 
Blood sample for genomic, proteomic, metabolomics, and candidate 
biomarker  analysese X   X  
Blood sample for genetic/epigenetic analysese    X  
PASI  X X X X X 
IGA X X X X X 
Percentage of BSA  X X X X X 
DLQI  X X X X  
PHQ -9 X X X X  
scalp IGAf X X X X  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 185 of 209 Table  5-2: Schedule of study assessments for subjects allocated to escape treatment  
Visita/ Week  
 
Protocol activity  Open -label Escape Treatment (weeks after first dose)  Escape  
Week  12/ 
PEOT    
Escape BL  
(first dose)  Escape  
Week  4 Escape  
Week  8 SFUb 
mNAPSIg X X X X  
pp-IGAh X X X X  
EQ-5D-3L X   X  
SF-36 X   X  
Patient Global Assessment of PSOi X   X  
PASE  X   X  
PGADAj X X X X  
Concomitant medication  X X X X X 
Adverse events  X X X X X 
IRT X X X X X 
Bimekizumab administrationk X X X   
BL=baseline; BSA=body surface area; DLQI=Dermatology Life Quality Index; ECG=electrocardiogram; EQ -5D-3L=Euro -Quality of Life 5 -Dimensions, 
3 levels; ET=Early Termination; IGA=Investigator’s Global Assessment; IGRA=interferon -gamma release assay; IRT=inter active response technology ; 
mNAPSI=modified Nail Psoriasis Severity Index; PASI=Psoriasis Area and Severity Index; PEOT=Premature End of Treatment Visit;  PGADA=Patient’s Global 
Assessment of Disease Activity; PHQ -9=Patient Health Questionnaire 9; SF -36=Sh ort Form 36 -item Health Survey; SFU=Safety Follow -Up; TB=tuberculosis  
a Visit windows of +/- 3 days  ±7 days from the first dose at all visits except SFU. SFU Visit window is -3 and +7 days  ±7 days from last final  dose.  
b The SFU Visit will occur 20 weeks after the last final  dose for subjects who do not enroll in the open -label study.  
c Vital signs (sitting systolic and diastolic blood pressure, pulse rate, and body temperature) are to be measured prior to blo od sampling, and prior to dosing, 
where applicable.  
d A urine pregnancy test will be performed at every study dosing visit. Pregnancy test results must be negative prior to admini stering study drug.  
e All blood samples taken prior to dosing.  
f The scalp IGA will only b e assessed for those subjects with scalp involvement at Baseline.  
g The mNAPSI will be assessed only in subjects with nail involvement at Baseline.  
h The pp -IGA will only be assessed in subjects with palmoplantar involvement at Baseline.  
i During escape tr eatment, this assessment will be completed at each clinic visit specified with a ±3 day completion window . 
j The PGADA is assessed only for subjects with PsA at Baseline.  
k The dosing window is ±7 days relative to the scheduled dosing visit.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 186 of 209 Change #19  
Section 5.7 Schematic diagram, Figure 5 -1, final note after the figure  
Note: Subjects in the placebo treatment arm in the Initial Treatment Period will continue to 
receive placebo Q4W at Week 16 and la ter visits provided a PASI90 response was achieved at 
Week 16. All subjects initially randomized to placebo who achieve a PASI90 response at Week 
16 will continue to receive placebo (Q4W).6. Subject is a candidate for systemic PSO therapy 
and/or photothera py and/or photochemotherapy.  
Has been changed to:  
Note: Subjects in the placebo treatment arm in the Initial Treatment Period will continue to 
receive placebo Q4W at Week 16 and later visits provided a PASI90 response was achieved at 
Week 16. All subjects initially randomized to placebo who achieve a PASI90 response at 
Week 16 will continue to receive placebo (Q4W).  
 
Change #20  
Section 6.1  Inclusion criteria  
To be eligible to participate in this study, all of the following criteria must be met at Screening 
and be reconfirmed at the Baseline Visit:  
6. Subject is a candidate for systemic PSO therapy and/or phototherapy and/or 
photochemotherapy.  
Have been changed to:  
To be eligible to participate in this study, all of the following criteria must be met at Scree ning 
and be reconfirmed  at the Baseline Visit:  
6a. Subject is a candidate for systemic PSO therapy and/or phototherapy  and/or 
photochemotherapy . 
 
Change #21  
Section 6.2  Exclusion criteria  
3. Subject previously participated in another study of a medication (systemic) under 
investigation within the 12 weeks or at least 5 half -lives prior to the Screening Visit, 
whichever is greater, or is currently participating in another study of a medication (systemic) 
under investigation.  
4. Subject previously participated i n another study of a topical medication under investigation 
within the 4 weeks prior to the Screening Visit, or is currently participating in another study 
of a topical medication under investigation.  
5. Subject previously participated in another study of a m edical device under investigation 
within the 4  weeks prior to the Screening Visit, or is currently participating in another study 
of a medical device under investigation.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 187 of 209 14. Subject has any active malignancy or history of malignancy within 5 years prior to t he 
Screening Visit EXCEPT treated and considered cured cutaneous squamous or basal cell 
carcinoma, or in situ cervical cancer, or ductal carcinoma in situ of the breast.  
17. Subject has any systemic disease (eg, renal failure, heart failure, hypertension, liver disease, 
diabetes) considered by the Investigator to be uncontrolled, unstable, or likely to progress to 
a clinically significant degree during the course of the study.  
27. Subject has presence of severe depression, indicated by a score of 15 to 19 using  the 
screening PHQ 9. Medication used to treat depression should be stable for 4 weeks prior to 
Baseline.  
Have been changed to:  
3a. Subject previously participated in another study of a medication (systemic) under 
investigation within the 12 weeks or at le ast 5 half -lives prior to the Screening Visit, 
whichever is greater, or  is currently participating in another study of a medication 
(systemic) under investigation. Subject must be washed out of the medication for 12 
weeks or at least 5 half -lives prior to the Baseline Visit, whichever is greater.  
4a. Subject previously participated in another study of a topical medication under 
investigation within the 4 weeks prior to the Screening Visit, or  is currently participating 
in another study of a topical medicati on under investigation. Subject must be washed out of 
the medication for 4 weeks prior to the Baseline Visit.  
5a. Subject previously participated in another study of a medical device under investigation 
within the 4  weeks prior to the Screening Visit, or  is currently , or was within the 4 weeks 
prior to the Baseline Visit,  participating in another study of a medical device under 
investigation.  
14a. Subject has any active malignancy or history of malignancy within 5 years prior to the 
Screening Visit EXCEPT t reated and considered cured cutaneous squamous or basal cell 
carcinoma, or in situ cervical cancer , or ductal carcinoma in situ of the breast . 
17a. Subject has any systemic disease ( eg, renal failure, heart failure, hypertension, liver 
disease, diabetes ie, cardiovascular, neurological, renal, liver, metabolic, 
gastrointestinal, hematological, immunological, etc. ) considered by the Investigator to be 
uncontrolled, unstable, or likely to progress to a clinically significant degree during the 
course of the st udy. 
27a. Subject has presence of moderately severe major depression or  severe major  
depression, indicated by a score of >/=15 using the screening PHQ -9. Medication used to 
treat depression should be stable for 4 8 weeks prior to Baseline.  
 
Change #22  
Section 6.2  Exclusion criteria  
The following text has been added:  
30. Subject is taking or has taken prohibited psoriasis medications without meeting the 
mandatory washout period relative to the Baseline Visit ( Table 7 -2). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 188 of 209  
Change #23  
Section 6.3 Withdrawal criteria  
The following withdrawal criteria have been added, modified, and/or renumbered:  
11. Subjects with newly diagnosed inflammatory bowel disease (IBD) or with IBD flares 
during the study must:  
 Be referred, as appropriate, to a health care professional treating IBD, such as a 
gastroenterologist  
 Discontinue IMP and be followed -up until resolution of active IBD symptoms  
If IBD flares increase in severity or frequency during the study, the Investigator should use 
clinical judgement in deciding whether the subject should continue in the study and contact 
the Medical Monitor and UCB study physician to confirm the subject’s suitability for 
continued participation in the study.  
12. Subjects must be referred  immediately to a mental health  care professional and may be 
withdrawn from the study based upon the Investigator’s judgment of benefit/risk  for either 
of the following:  
 Active suicidal ideation as indicated by a positive response (“Yes”) to Question s 4 or 5 or to 
the suicidal behavior questions of the “Since Last Visit” version of the eC -SSRS.  
 Moderately severe major  depression as indicated by a PHQ -9 score of 15 to 19 if this 
represents an increase of 3 points compared to last visit.  
13. Subjects must be referred immediately to a menta l healthcare professional and  must be 
withdrawn in case of:  
 Any suicidal behavior since last visit.  
 Severe  major  depression as indicated by a PHQ -9 score ≥20.  
The mental health consultation will be documented  must be recorded in source 
documentation.  
 
Chan ge #24  
Section 7.2 Treatment(s) to be administered  
Randomized -Withdrawal Period dosing  
Investigational medicinal product treatment during the Randomized -Withdrawal Period will be 
based on treatment group assignment at randomization (see Section  5.2.3 ). 
 Subjects who are to receive bimekizumab 320mg Q4W will receive 2 bimekizumab 160mg 
injections sc Q4W.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 189 of 209  Subjects reallocated to receive bimekizumab 320mg  Q8W will alternate between receiving 
bimekizumab (2 bimekizumab 160mg injections sc) followed 4 weeks later by placebo (2 
placebo injections sc).  
 Subjects in the placebo treatment arm in the Initial Treatment Period who are ≥PASI90 at 
Week 16 and ≥PASI 75  at Week 20 or later will continue to receive placebo Q4W at 
Week  16 and later visits.  
Has been changed to:  
Randomized -Withdrawal Period dosing  
Investigational medicinal product treatment during the Randomized -Withdrawal Period will be 
based on treatment g roup assignment at randomization (see Section  5.2.3 ). 
 Subjects who are re-randomize d to receive bimekizumab 320mg Q4W will receive 2 
bimekizumab 160mg injections sc Q4W.  
 Subjects reallocated  re-randomized  to receive bimekizumab 320mg Q8W will alternate 
between receiving bimekizumab (2 bimekizumab 160mg injections sc) followed 4 weeks 
later by placebo (2 placebo injections sc).  
 Subjects re -randomize d to receive placebo will receive 2 placebo injections Q4W.  
 Subjects in the placebo treatment arm in the Initial Treatment Period who are ≥PASI90 at 
Week 16 and ≥PASI 75 at Week 20 or later will continue to receive placebo Q4W at 
Week  16 and later visits.  
 
Change #25  
Section 7.2 Treatment(s) to be administered  
Table  7-1: Dosing Scheme  
Week  
Dose Assignment  0 4 8 12 16 20 24 28 32 36 40 44 48 52 
Bimekizumab 320mg 
Q4W/Q4W  ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Bimekizumab 320mg 
Q4W/Q8W  ●● ●● ●● ●● ●● ○○ ●● ○○ ●● ○○ ●● ○○ ●● ○○ 
Placebo  ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ 
n/a=not applicable; Q4W=every 4 weeks; Q8W=every 8 weeks  
Note: A bimekizumab 160mg injection is depicted by a black circle (●). A placebo injection is depicted by an open 
circle (○).  
Note: Subjects who do not achieve a ≥PASI90 response at Week  16 and all subjects who relapse (defined not 
achieving a ≥PASI75 res ponse at Week  20 or later) during the Randomized -Withdrawal Period (up to Week 52) 
will receive open -label bimekizumab 320mg Q4W for 12 weeks (ie, escape treatment). Subjects in the placebo 
treatment arm in the Initial Treatment Period that are >PASI90 at Week 16 and >PASI 75 at Week 20 or later will 
continue to receive placebo Q4W at Week 16 and later visits.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 190 of 209 Has been changed to:  
Table  7-1: Dosing Scheme  
Week  
Dose Assignment  0 4 8 12 16 20 24 28 32 36 40 44 48 52 
Bimekizumab 320mg 
Q4W/Q4W  ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● ●● 
Bimekizumab 320mg 
Q4W/Q8W  ●● ●● ●● ●● ●● ○○ ●● ○○ ●● ○○ ●● ○○ ●● ○○ 
Bimekizumab 320mg 
Q4W/placebo  ●● ●● ●● ●● ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ 
Placebo  ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ ○○ 
n/a=not applicable; Q4W=every 4 weeks; Q8W=every 8 weeks  
Note: A bimekizumab 160mg injection is depicted by a black circle (●). A placebo injection is depicted by an open 
circle (○).  
Note: Subjects who do not achieve a ≥PASI90 response at Week  16 and all subjects who relapse (defined no t 
achieving a ≥PASI75 response at Week  20 or later) during the Randomized -Withdrawal Period (up to Week 52) 
will receive open -label bimekizumab 320mg Q4W for 12 weeks (ie, escape treatment). Subjects in the placebo 
treatment arm in the Initial Treatment Pe riod that are >PASI90 at Week 16 and >PASI 75 at Week 20 or later will 
continue to receive placebo Q4W at Week 16 and later visits.  
 
Change #26  
Section 7.8.2 Prohibited concomitant treatments (medications and therapies)  
Table  7-2: Prohibited psoriasis medications  
Drug  Washout period relative to Baseline Visit  
Topicals except for those permitted ( Section  7.8.1.1 ) 2 weeks  
Systemic retinoids  3 months  
Systemic treatment (nonbiological):  
systemic immunosuppressant agents (eg, 
methotrexate, cyclosporine,  azathioprine, 
thioguanine)  
fumaric acid esters specifically used for the 
treatment of PSO  
systemic corticosteroids  
phototherapy or photochemotherapy  1 month  
Anti-TNFs:  
adalimumab (including biosimilar)  
etanercept (including biosimilar)  
infliximab (includ ing biosimilar), golimumab, 
certolizumab pegol   
Any exposure to adalimumab  
1 month for etanercept  
3 months for infliximab (including biosimilar), 
golimumab, certolizumab pegol  
Other biologics and other systemic therapies, eg:   
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 191 of 209 Table  7-2: Prohibited psoriasis medications  
Drug  Washout period relative to Baseline Visit  
apremilast, tofacitinib  2 weeks for apremilast and tofacitinib  
alefacept, efalizumab, guselkumab  3 months for alefacept, efalizumab, and 
guselkumab  
ustekinumab, briakinumab  6 months for ustekinumab and briakinumab  
rituximab  12 months for rituximab  
Anti-IL-17 therapy:  
brodalumab  
ixekizumab  
secukinumab  3 months  
(bimekizumab is excluded per exclusion 
criteria)  
Any other antipsoriatic agent (systemic) under 
investigation (or approved after the protocol is 
approved)  3 months or 5 half -lives, whichever is greater  
Any other antipsoriatic agent (topical) under 
investigation  1 month  
IL-17=interleukin 17; PSO=psoriasis; TNF=tumor necrosis factor  
Has been changed to:  
Table  7-2: Prohibited psoriasis  PSO medications  
Drug  Washout period relative to Baseline Visit  
Topicals except for those permitted ( Section  7.8.1.1 ) 2 weeks  
Systemic retinoids  3 months  
Systemic treatment (nonbiological):  
systemic immunosuppressant agents (eg, 
methotrexate, cyclosporine, azathioprine, 
thioguanine)  
fumaric acid esters specifically used for the 
treatment of PSO  
systemic corticosteroids  
phototherapy or photochemotherapy  1 month  
Anti-TNFs:  
adalimumab (including biosimilar)  
etanercept (including biosimilar)  
infliximab (including biosimilar), golimumab, 
certolizumab pegol   
Any exposure to adalimumab  
1 month for etanercept  
3 months for infliximab (including biosimilar), 
golimumab, certolizumab pegol  
Other biologics and other systemic therapies, eg:   
apremilast, tofacitinib  2 weeks for apremilast and tofacitinib  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 192 of 209 Table  7-2: Prohibited psoriasis  PSO medications  
Drug  Washout period relative to Baseline Visit  
alefacept, efalizumab, guselkumab  3 months for alefacept, efalizumab, and 
guselkumab  
tildrakizumab, risankizumab  5 months for tildrakizumab and 
risankizumab  
ustekinumab, briakinumab  6 months for ustekinumab and briakinumab  
rituximab  12 months for rituximab  
Anti-IL-17 therapy:  
brodalumab  
ixekizumab  
secukinumab  3 months  
(bimekizumab is excluded per exclusion 
criteria)  
Any other antipsoriatic agent (systemic) under 
investigation (or approved after the protocol is 
approved)  3 months or 5 half -lives, whichever is greater  
Any other antipsoriatic agent (topical) under 
investigation  1 month  
IL-17=interleukin 17; PSO=psoriasis; TNF=tumor necrosis factor  
 
Change #27  
Section  7.10 Randomization and numbering of subjects, first and fourth paragraphs  
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The randomization schedule will be produced by the IRT vendor. The IRT wil l 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region (North America, Western 
Europe, Central/Eastern Europe, and Asia/Australia) and prior biol ogic exposure (yes/no). The 
IRT will generate individual assignments for subject kits of IMP, as appropriate, according to the 
visit schedule.  
At Week  16, subjects who received bimekizumab Q4W during the Initial Treatment Period may 
be reallocated to a ne w treatment group based on their PASI response.  
Have been changed to:  
An IRT will be used for assigning eligible subjects to a treatment regimen based on a 
predetermined production randomization and/or packaging schedule provided by UCB (or 
designee). The  randomization schedule will be produced by the IRT vendor. The IRT will 
generate individual assignments for subject kits of IMP, as appropriate, according to the visit 
schedule. Subject treatment assignment will be stratified by region (North America, Wes tern 
Europe, Central/Eastern Europe, and Asia/Australia)  and prior biologic exposure (yes/no). 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 193 of 209 The IRT will generate individual assignments for subject kits of IMP, as appropriate, according 
to the visit schedule.  
At Week  16, subjects who received bimekiz umab Q4W during the Initial Treatment Period may 
be reallocated  re-randomized  to a new treatment group based on their PASI response.  
 
Change #28  
Section 8 Study Procedures by Visit  
 Visit windows of ±3 days on either side of the scheduled dosing are permitted; however, the 
Investigator should try to keep the subjects on the original dosing schedule. The window of 
±3 days is relative to Baseline and applicable for all subsequent visits. Changes to the dosing 
schedule outside of the 3 -day window must be  discussed with the Medical Monitor.  
 The dosing window is ±7 days relative to the scheduled dosing visit.  
 For the SFU Visit (20 weeks after the last dose), the visit should occur no more than 3 days 
prior to the scheduled visit date and within 7 days after  the scheduled visit date 
(-3 days/+7  days).  
Has been changed to:  
 From the Week 1 Visit to the Week 24 Visit, visit windows of ±3 days on either side of 
the scheduled dosing are permitted; however, the Investigator should try to keep the 
subjects on the or iginal dosing schedule.  From the Week 28 Visit to the Week 52 Visit, 
visit windows are ±7  days.  Visit windows of ±3 days on either side of the scheduled 
dosing are permitted; however, the Investigator should try to keep the subjects on the 
original dosing schedule. The window of ±3  days is relative to Baseline and applicable 
for all subsequent visits.   Changes to the dosing schedule outside of the 3-day visit window 
must be discussed with the Medical Monitor.  
 The dosing window is ±7 days ±3 days relative to  the scheduled dosing visit through 
Week 24. The dosing window is ±7 days  relative to the scheduled dosing visit from Week 
28 through the end of the study.  
 For the SFU Visit (20 weeks after the last final  dose), the visit window should occur no 
more than 3  days prior to the  is ±7  days  relative to the scheduled visit date . 
 
Change #29  
Section 8.1 Screening Visit (2 to 4 weeks)  
Has been changed to:  
Section 8.1 Screening Visit (2 to 4 5 weeks)  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 194 of 209 Change #30  
Sections 8.1 Screening Visit (2 to 4 5 weeks) and 8.2.1 Baseline  
The following text has been added:  
 Patient Global Assessment of PSO  
 
Change #31  
Sections 8.2.1 Baseline Visit  
The following has been added to the bulleted list:  
 Physical examination including evaluation of signs and symptoms of active TB an d risk for 
exposure to TB  
 Patient Global Assessment of PSO  
 
Change #32  
Section 8.2.4 Week 12 (±3 days relative to Baseline)  
The following have been added to the bulleted list:  
 Physical exam including evaluation of signs and symptoms of active TB and risk f or 
exposure to TB  
 Body weight  
 Record 12 -lead ECG  
 TB questionnaire  
 PGADA  
 
Change #33  
Sections 8.2.5 Week 16 (±3 days relative to Baseline)  
The following has been deleted from the bulleted list:  
 Physical exam including evaluation of signs and symptoms of active TB and risk for 
exposure to TB  
 Body weight  
 Record 12 -lead ECG  
 TB questionnaire  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 195 of 209 Change #34  
Section 8.3.1 Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52 (±3 days relative to Baseline)  
Has been changed to:  
8.3.1  Weeks 20 and 24 (±3 days relative to Base line)  and Weeks, 28, 32, 36, 40, 44, 48, and 
52 (±3 ±7 days relative to Baseline)  
 
Change #35  
Section 8.3.1 Weeks 20, 24, 28, 32, 36, 40, 44, 48, and 52 (±3 days relative to Baseline)  
The following have been modified:  
 Tuberculosis questionnaire (Weeks 24, 36, and 52 48 only)  
 Patient Global Assessment of PSO (Weeks 24, 32, 40, and 48 only only) 
 PGADA for subjects with PsA at Baseline (Weeks 24, 32, 40, and 48 only only) 
The following have been deleted from the bulleted l ist: 
 Patient Symptom Diary (daily) (Week 24 only)  
 
Change #36  
Section 8.6 Safety Follow Up Visit (20 weeks after last dose ± -3/+7 days)  
Has been changed to:  
Section 8.6 Safety Follow Up Visit (20 weeks after last final  dose ±-3/+7 days ±7 days ) 
 
Change #37  
Section 9  ASSESSMENT OF EFFICACY  
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp -IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documente d training on how to perform these 
assessments correctly. Preferably, the same assessor should evaluate the subject at each 
assessment.  
Has been changed to:  
The PASI, BSA, IGA, scalp IGA, mNAPSI, and pp -IGA should be performed by the 
Investigator, another delegated physician, or an appropriately qualified medical professional 
(based on local requirements) who has had documented training on how to perform these 
assessments correctly. Preferably, the  The same assessor should evaluate the subject at each 
asses sment.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 196 of 209 Change #38  
Section 9.10 Patient Global Assessment of psoriasis, second and third paragraphs and last 
sentence  
The Patient Global Assessment of PSO will be performed as part of the patient symptoms diary 
from baseline through the Initial Treatment Period ; the assessment is to completed within a +3 
day completion window at each of the visits specified in Table 5 -1. 
During the Randomized -Withdrawal Period, this assessment will be completed within a +3 day 
completion window at the visits specified in T able 5 -1. 
During escape treatment, this assessment will be completed within a +3 day completion window 
at the visits specified in Table 5 -1. 
Has been changed to:  
The Patient Global Assessment of PSO will be performed as part of the patient symptoms diary 
from baseline  Screening  through the Initial Treatment Period ; the assessment is to completed 
at each of the visits specified in Table 5 -1. 
During the Randomized -Withdrawal Period, this assessment will be completed  within a +3 day 
completion window  at the v isits specified in Table 5 -1. 
During escape treatment, this assessment will be completed within a +3 day completion 
window at the visits specified in Table 5 -1. 
 
Change #39  
Section 9.11 Patient Symptom Diary responses, second paragraph  
The ePRO diary will also administer the patient global assessment of PSO as noted above 
appropriate anchor items at the end of every study week. The ePRO diary software will be 
programmed such that the subjects will be given a window of opportunity to complete the ePRO 
diarye ach evening. The data collected on the ePRO diary will be uploaded to a central server 
database and will be 21 CFR Part 11 compliant. Appropriate GCP procedures (including 
subject/site training and testing) will be performed at the study sites.  
Has been ch anged to:  
The ePRO diary will also administer the patient global assessment of PSO as noted above 
appropriate anchor items at the end of every study week. The ePRO diary software will be 
programmed such that the subjects will be given a window of opportun ity to complete the ePRO 
diary each evening . The data collected on the ePRO diary will be uploaded to a central server 
database and will be 21 CFR Part 11 compliant. Appropriate GCP procedures (including 
subject/site training and testing) will be performed at the study sites.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 197 of 209 Change #40  
Section 9.12  PASE questionnaire  
Standardized responses are based on 5 categories relating to agreement (strongly agree [1], agree 
[2], no idea [3], disagree [4], and strongly disagree [5]). The total maximum score is 75 poin ts 
(symptom score: 35 points and function score: 40 points).  
Has been changed to:  
Standardized responses are based on 5 categories relating to agreement ( strongly agree [ 1 5], 
agree [ 2 4], no idea [3],  disagree [ 4 2], and strongly disagree [ 5 1]). The total maximum score 
is 75 points (symptom score: 35 points and function score: 40 points).  
 
Change #41  
Section 12.1.4  Pregnancy, second bullet and fourth paragraph  
 The subject should immediately stop the intake of the IMP or be down -titrated as ins tructed 
at the PEOT visit.  
A pregnancy becomes an SAE in the following circumstances: miscarriage, abortion (elective or 
spontaneous), unintended pregnancy after hormonal contraceptive failure (if the hormonal 
contraceptive was correctly used), ectopic pre gnancy, fetal demise, or any congenital 
anomaly/birth defect of the baby. Those SAEs must be additionally reported using the 
Investigator SAE Report Form.  
Have been changed to:  
 The subject should immediately stop the intake of the IMP or be down -titrated as 
instructed at the PEOT visit . 
A pregnancy becomes an SAE in the following circumstances: miscarriage,  abortion (elective 
or spontaneous elective  abortion when medically indicated (e.g. when pregnancy is 
endangering life or health of woman or when fetus will be born with severe abnormalities ), 
unintended pregnancy after hormonal contraceptive failure (if the hormonal contraceptive was 
correctly used), ectopic pregnancy, fetal demise, or any congenital anomaly/birth defect of the 
baby. Those SAEs must be a dditionally reported using the Investigator SAE Report Form.  
 
Change #42  
Section 12.2 Laboratory measurements  
Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Basophils  Calcium  pH 
Eosinophils  Chloride  Albumin (protein)  
Lymphocytes  Magnesium  Glucose  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 198 of 209 Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Atypical lymphocytes  Potassium  Blood  
Monocytes  Sodium  Leukocyte esterase  
Neutrophils  Glucose  Nitrite  
Hematocrit  BUN  Urine dipstick for pregnancy testingb 
Hemoglobin  Creatinine  Urine drug screend 
MCH  ALP   
MCHC  AST   
MCV  ALT   
Platelet count  GGT   
RBC count  Total bilirubin   
WBC count  LDH   
 Serum pregnancy testingb  
Has been changed to:  
Table  12-2: Laboratory measurements  
Hematology  Chemistry  Urinalysis dipsticka 
Basophils  Calcium  pH 
Eosinophils  Chloride  Albumin (protein)  
Lymphocytes  Magnesium  Glucose  
Atypical lymphocytes  Potassium  Blood  
Monocytes  Sodium  Leukocyte esterase  
Neutrophils  Glucose  Nitrite  
Hematocrit  BUN  Urine dipstick for pregnancy testingb 
Hemoglobin  Creatinine  Urine drug screend 
MCH  ALP   
MCHC  AST   
MCV  ALT   
Platelet count  GGT   
RBC count  Total bilirubin   
WBC count  LDH   
 Serum pregnancy testingb  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 199 of 209  
Change #43  
Section 12.2.1  Evaluation of PDILI  
Rechallenge with a substance potentially causing drug -induced liver injury is dangerous, may be 
fatal, and must not occur.  
Has been changed to:  
Rechallenge with a substance potentially causing drug -induced liver injury is dangerous, 
may be fatal, and must not occur.  
 
Change #44  
Section 12.2.1.2.1  IMP restart/rechallenge (if applicable)  
Rechallenge w ith a substance potentially causing drug -induced liver injury is dangerous, may be 
fatal, and must not occur.  
Has been changed to:  
Section 12.2.1.2.1  IMP restart/rechallenge (if applicable)  
Rechallenge with a substance potentially causing drug -induced liv er injury is dangerous, 
may be fatal, and must not occur.  Rechallenge with IMP can occur only if ALL of the 
following requirements are met:  
 The results of additional testing and monitoring described in Section 12.2.1.3 and 
Section  12.2.1.4 confirm a nondru g-related cause for the abnormal hepatic laboratory 
parameters and any associated symptoms (ie, a subsequent alternative diagnosis fully 
explains the hepatic findings).  
 The subject has shown clear therapeutic benefit from the IMP.  
 Subject’s ALT or AST ele vations do not exceed ≥5xULN.  
 Subject’s total bilirubin is <2xULN.  
 Subject has no signs or symptoms of hypersensitivity or hepatitis.  
 The rechallenge is approved by the UCB responsible physician, DMC, and a 
hepatologist. The hepatologist must be external to UCB but may be a member of the 
DMC. It is recommended that the hepatologist be a local hepatology expert or the 
hepatologist treating the subject.  
 Subject agrees to the Investigator -recommended monitoring plan.  
 
Change #45  
Section 12.3.1 Assessment and management of TB and TB risk factors  
b. High risk of acquiring TB infection:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 200 of 209  Known exposure  to another person with active TB infection within the 3 months prior to 
Screening.  
Has been changed to:  
b. High risk of acquiring TB infection:  
 Known close  exposure  to another person with active TB infection within the 3 months 
prior to Screening.  
 
Change #46  
Section 12.3.1.1 Tuberculosis assessment by IGRA  
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB GOLD is 
recommended) will be performed as described in Table  5-1 for all subjects.  
Has been changed to:  
During conduct of the study, the TB assessment by IGRA (QuantiFERON TB GOLD  test is 
recommended) will be performed as described in Table  5-1 for all subjects.  
 
Change #47  
Section 12.3.1.3 Tuberculosis questionnaire, last paragraph  
Subjects with a latent or active TB infection must be withdrawn from the study.  
Has been deleted:  
Subject s with a latent or active TB infection must be withdrawn from the study.  
 
Change #48  
Section 12.3.1.4 Tuberculosis management, second paragraph  
During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation. Evidence of 
LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confi rmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
indicates that TB infection or exposure may have occurred. Evidence of active TB includes, in 
addition to the aforementioned tests, signs and symptoms of organ involvemen t. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB or LTB infection should be withdrawn from the study and receive 
appropriate TB or prophylaxis therapy.  
Has been changed to:  
During the study, subjects who develop evidence of LTB infection or active TB must 
immediately stop further administration of IMP and will be referred to an appropriate TB 
specialist (pulmonologist or infectious disease specialist) for further evaluation.  Evidence of 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 201 of 209 LTB infection is defined as subject’s IGRA test converts to positive or indeterminate (and 
confirmed indeterminate on repeat), or the subject’s questionnaire or history and physical 
indicates that TB infection or exposure may have occurred. Ev idence of active TB includes, in 
addition to the aforementioned tests, signs and symptoms of organ involvement. In either 
situation, the subject should be carefully assessed by a TB specialist for active TB. Subjects 
diagnosed with active TB or LTB infecti on should be withdrawn from the study and receive 
appropriate TB or prophylaxis therapy.  
 
Change #49  
Section 12.3.2 Pregnancy testing  
A negative urine pregnancy test result should be obtained immediately prior to each 
administration of IMP and at all subse quent postdosing visits.  
.Has been changed to:  
A negative urine pregnancy test result should be obtained immediately prior to each 
administration of IMP and at all subsequent postdosing visits at the visits specified in 
Table  5-1. 
 
Change #50  
Section 13.3. 1.1 Electronic Health Record extraction pilot  
It is anticipated that a selection of data points (Demography, Medical History, Concomitant 
Medications, and potentially Vital Signs) will be collected via the subjects’ Electronic 
Healthcare Record (EHR) at sp ecific sites as part of a small EHR Pilot. Retrieve Form for Data 
Capture (RFD) will be used to extract the selected data points from the EHR and imported into 
the EDC system. An archive of selected data points, at the time of extraction, will be stored at  
the sites.  
Has been deleted:  
Section 13.3.1.1 Electronic Health Record extraction pilot  
It is anticipated that a selection of data points (Demography, Medical History, Concomitant 
Medications, and potentially Vital Signs) will be collected via the subjects’ Electronic 
Healthcare Record (EHR) at specific sites as part of a small EHR Pilot. Retrieve Form for 
Data Capture (RFD) will be used to extract the selected data points from the EHR and 
imported into the EDC system. An archive of selected data po ints, at the time of extraction, 
will be stored at the sites.  
 
Change #51  
Section 14.1 Definition of analysis sets  
The Full Analysis Set (FAS) will consist of all randomized subjects that received at least 1 dose 
of the IMP and have a valid measurement of the co -primary efficacy variables at Baseline.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 202 of 209 Has been changed to:  
The Full Analysis Set (FAS) will consist of all randomized subjects that received at least 1 dose 
of the IMP and have a valid measurement for each  of the co -primary efficacy variables at 
Baseline.  
 
Change #52  
Section 14.2 General statistical considerations  
Figure  14-1: Sequence of testing  
 
Has been changed to:  
Figure  14-1: Sequence of testing  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 203 of 209  
 
Change #53  
Section 14.4 Subgroup analyses  
Subgroup analyses will be performed on the primary and secondary efficacy variables that are 
part of the fixed sequence testing procedure described in Section 14.3. The following variables 
for subgroup analyses will be defined: age, gender, disease duration, region, weight, body mass 
index (BMI), prior sys temic chemotherapy or photochemotherapy, prior biologic exposure, prior 
systemic therapy of any kind, Baseline disease severity, and antibody positivity. These 
summaries will be based on imputed data (NRI) and will include descriptive statistics only.  
Has been changed to:  
Subgroup analyses will be performed on the primary and secondary efficacy variables that are 
part of the fixed sequence testing procedure described in Section 14.3. The following variables 
for subgroup analyses will be defined: age, gende r, disease duration, region, weight, body mass 
index  (BMI) , prior systemic chemotherapy or photochemotherapy  phototherapy , prior 
biologic exposure, prior systemic therapy of any kind, Baseline disease severity, and antibody 
positivity. These summaries will  be based on imputed data (NRI) and will include descriptive 
statistics only.  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 204 of 209 Change #54  
Section 14.5.2 Pharmacokinetic/pharmacodynamic analyses  
Pharmacokinetic variables will be analyzed for all subjects in the PK -PPS. Bimekizumab plasma 
concentrations w ill be summarized for each treatment at each scheduled visit.  
The relationship between efficacy response (PASI/IGA) and bimekizumab plasma concentration 
will be explored via graphical and a model based (PK -PD) approach quantify the time course of 
dose/expo sure response. In addition, the relationship between safety and exposure will also be 
explored. The data will be combined with that from other Bimekizumab trials in psoriasis for a 
pooled, cross trial analysis. The details of this analysis will be describe d in a data analysis plan, 
and the analysis itself will be reported separately from the Clinical Study Report (CSR). 
Candidate biomarkers may include, but are not limited to: IL -17A/IL -17F pathway signaling and 
PSO biology (eg, IL -17A, IL -17F, IL -23, IL -6, TNF, DC -STAMP, and circulating osteoclast 
precursors). The details of the model and the approach will be specified in a data analysis plan.  
Pharmacodynamic variables will be analyzed for all subjects in the PD -PPS.  
Has been changed to:  
Section 14.5.2 Pha rmacokinetic /pharmacodynamic  analyses  
Pharmacokinetic variables will be analyzed for all subjects in the PK -PPS. Bimekizumab plasma 
concentrations will be summarized for each treatment at each scheduled visit.  
The relationship between efficacy response (PASI/IGA) and bimekizumab plasma 
concentration will be explored via graphical and a model based (PK -PD) approach to 
quantify the time course of dose/exposure response. In addition, the relationship between 
safety and exposure will also be explored. The da ta will be combined with that from other 
Bimekizumab trials in psoriasis for a pooled, cross trial analysis. The details of this analysis 
will be described in a data analysis plan, and the analysis itself will be reported separately 
from the Clinical Study  Report (CSR). Candidate biomarkers may include, but are not 
limited to: IL -17A/IL -17F pathway signaling and PSO biology (eg, IL -17A, IL -17F, IL -23, 
IL-6, TNF, DC -STAMP, and circulating osteoclast precursors). The details of the model 
and the approach will  be specified in a data analysis plan.  
Pharmacodynamic variables will be analyzed for all subjects in the PD -PPS.  
 
Change #55  
Section 14.6 Handling of protocol deviations  
Important protocol deviations are deviations from the protocol which potentially coul d have a 
meaningful impact on study conduct, or on the primary efficacy, key safety, or PK/PD outcomes 
for an individual subject.  
Has been changed to:  
Important protocol deviations are deviations from the protocol which potentially could have a 
meaningful  impact on study conduct, or on the primary efficacy, key safety, or PK /PD 
outcomes  for an individual subject.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 205 of 209 Change #56  
Section 17 References  
The following reference has been added:  
Husni ME, Qureshi AA, Keonig AS, Pedersen R, Robertson D. Utility of the  PASE 
questionnaire, psoriatic arthritis (PsA) prevalenece and PsA improvement with anti -TNF 
therapy: results from the PRISTINE trial. J Dermatolog Treat. 2014;25(1):90 -5. 
 
18.3 Protocol Amendment 3  
Rationale for the amendment  
The purpose of this amendment was to update the secondary and “other” efficacy variables to be 
consistent with the wording in the statistical analysis plan (SAP). The secondary and “other” 
efficacy variables for the scalp IGA response, and the “other” efficacy variable for the IGA 
response  were updated to clarify that the response required “at least a 2 -category improvement 
from Baseline,” as it is described in the SAP.  
For the Patient Symptom Diary, the secondary and “other” efficacy variables were updated from 
“change from Baseline” to “r esponse” on the items of itch, pain, and scaling in order to align the 
protocol with the planned responder analyses described in the SAP which define clinically 
meaningful thresholds of change for defining treatment response, rather than change from 
Baseli ne. The hierarchy figure (Figure 14.1) was also updated to reflect this change. There is no 
change to the frequency of diary assessments or how the diary assessments are performed.  
The name and contact information of the Clinical Trial Biostatistician was  also changed.  
Change #1  
Clinical Trial Biostatistician  
Name:   
Address:  8010 Arco Corporate Drive, Raleigh, NC 27617  
Phone:   
Fax:  
Have been changed to:  
Name:   
Address:  208 Bath Road, Slough, SL1 3WE, UK  
Phone:   
Fax:  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 206 of 209 Change #2  
Section 4.2.1  Secondary efficacy variables  
The following 2 bullets:  
 Change from Baseline in the Patient Symptom Diary responses for itch, pain, and scaling at 
Week  16 
 Scalp IGA response (Clear or Almost Clear) at Week 16 for subjects with scalp PSO at 
Baseline  
Have been changed to:  
 Change from Baseline in the  Patient Symptom Diary responses for itch, pain, and scaling at 
Week  16 
 Scalp IGA response (Clear or Almost Clear with at least a 2 -category improvement from 
Baseline ) at Week 16 for subjects with scalp PSO at Baseline  
Change #3  
Section 4.3.1  Other efficacy variable(s)  
The following 2 bullets:  
 IGA response (Clear)  
 Change from Baseline in the Patient Symptom Diary responses  
 Scalp -specific Investigator’s Global Assessment (scalp IGA) response (Clear or Almost 
Clear) for subjects with scalp PSO at Baseline  
Have been changed to:  
 IGA response (Clear with at least a 2 -category improvement from Baseline )  
 Change from Baseline in the  Patient Symptom Diary responses  
 Scalp -specific Investigator’s Global Assessment (scalp IGA) response (Clear or Almost 
Clear with at least a 2 -category improvement relative to Baseline ) for subjects with scalp 
PSO at Baseline  
Change # 4 
Section 9.11  Patient  Symptom Diary responses  
A third paragraph has been added:  
The Patient Symptom Diary responses for itch, pain, and scaling at Week 16  will be 
computed based on the responder definition as well as the absolute and percent change 
from Baseline. Each of the P atient Symptom Diary response scores included in the 
statistical testing procedure (itch, pain, and scaling) will be characterized in terms of the 
cumulative percent of subjects demonstrating a pre -specified point improvement at 
Week16. The threshold for t he Patient Symptom Diary response score of itch, pain, and 
scaling is 2.39, 1.98, and 2.86, respectively. The responder analysis will be limited to the 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 207 of 209 subjects with a Baseline Patient Symptom Diary response score at or above the applicable 
threshold score  (ie, at least 2.39, 1.98, and 2.86 for itch, pain, and scaling, respectively).  
Change # 5 
Figure 14 -1: Sequence of testing  
 
BL=Baseline; IGA=Investigator’s Global Assessment; PASI=Psoriasis Area Severity Index, PSD=patient symptom 
diary; PSO=psoriasis; PSSI=Psoriasis Scalp Severity Index; Q4W=every 4 weeks; Q8W=every 8 weeks.  
Has been changed to:  
 
BL=Baseline;  IGA=Investigator’s Global Assessment; PASI=Psoriasis Area Severity Index, PSD=patient symptom 
diary; PSO=psoriasis; PSSI=Psoriasis Scalp Severit y Index;  Q4W=every 4 weeks; Q8W=every 8 weeks.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 208 of 209 19 DECLARATION AND SIGN ATURE OF INVESTIGATO R 
I confirm that I have carefully read and understood this protocol and agree to conduct this 
clinical study as outlined in this protocol, according to current Good Clin ical Practice and local 
laws and requirements.  
I will ensure that all subinvestigators and other staff members read and understand all aspects of 
this protocol.  
I have received and read all study -related information provided to me.  
The objectives and conte nt of this protocol as well as the results deriving from it will be treated 
confidentially, and will not be made available to third parties without prior authorization by 
UCB.  
All rights of publication of the results reside with UCB, unless other agreement s were made in a 
separate contract.  
Investigator:  
 
   
Printed name    Date/Signature  
 
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
UCB   21 May 2019  
Clinical Study Protocol  Bimekizumab  PS0013  
   
Confidential  Page 209 of 209 20 SPONSOR DECLARATION  
I confirm that I have carefully read and understand this protocol and agree to conduct this 
clinical study as outlined in this protocol and according  to current Good Clinical Practice.  
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 
Approval Signatures
Name: ps0013-protocol-amend-3
Version: 1 . 0
Document Number: CLIN-000134878
Title: PS0013 Protocol Amendment 3
Approved Date: 23 May 2019
Document Approvals
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 22-May-2019 20:10:38 GMT+0000
Approval
Verdict: ApprovedName: 
Capacity: Clinical
Date of Signature: 23-May-2019 05:32:06 GMT+0000
Approval
Verdict: ApprovedName:
Capacity: Clinical
Date of Signature: 23-May-2019 08:25:11 GMT+0000
REDACTED COPY 
This document cannot be used to support any marketing authorization application and any extensions or variations thereof. 